EP3200775A2 - Polythérapies - Google Patents
PolythérapiesInfo
- Publication number
- EP3200775A2 EP3200775A2 EP15782164.6A EP15782164A EP3200775A2 EP 3200775 A2 EP3200775 A2 EP 3200775A2 EP 15782164 A EP15782164 A EP 15782164A EP 3200775 A2 EP3200775 A2 EP 3200775A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- inhibitor
- alkyl
- combination
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002648 combination therapy Methods 0.000 title abstract description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 317
- 239000003112 inhibitor Substances 0.000 claims description 253
- 201000011510 cancer Diseases 0.000 claims description 231
- 239000002955 immunomodulating agent Substances 0.000 claims description 113
- 229940121354 immunomodulator Drugs 0.000 claims description 113
- 238000000034 method Methods 0.000 claims description 95
- 229960003301 nivolumab Drugs 0.000 claims description 93
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 85
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 81
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 81
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 80
- 229960002621 pembrolizumab Drugs 0.000 claims description 75
- -1 CEACAM Proteins 0.000 claims description 72
- 230000002584 immunomodulator Effects 0.000 claims description 69
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 69
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 68
- 239000003814 drug Substances 0.000 claims description 66
- 229940124597 therapeutic agent Drugs 0.000 claims description 58
- 239000003795 chemical substances by application Substances 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
- 241000282414 Homo sapiens Species 0.000 claims description 51
- 239000000427 antigen Substances 0.000 claims description 51
- 102000036639 antigens Human genes 0.000 claims description 50
- 108091007433 antigens Proteins 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 49
- UFPFGVNKHCLJJO-SSKFGXFMSA-N (2s)-n-[(1s)-1-cyclohexyl-2-[(2s)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C=2SC=C(N=2)C(=O)C=2C=CC(F)=CC=2)CCCCC1 UFPFGVNKHCLJJO-SSKFGXFMSA-N 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 48
- 208000035475 disorder Diseases 0.000 claims description 46
- 229940043355 kinase inhibitor Drugs 0.000 claims description 41
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 36
- 108091007065 BIRCs Proteins 0.000 claims description 34
- 230000000139 costimulatory effect Effects 0.000 claims description 33
- 102000017578 LAG3 Human genes 0.000 claims description 30
- 101150030213 Lag3 gene Proteins 0.000 claims description 30
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 29
- 108091008794 FGF receptors Proteins 0.000 claims description 29
- 201000001441 melanoma Diseases 0.000 claims description 29
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 28
- 102000003964 Histone deacetylase Human genes 0.000 claims description 26
- 108090000353 Histone deacetylase Proteins 0.000 claims description 26
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 26
- 229940122016 Pim kinase inhibitor Drugs 0.000 claims description 26
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 26
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 26
- 230000035772 mutation Effects 0.000 claims description 26
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 24
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 24
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 23
- 102100032257 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 23
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 23
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 23
- 239000012190 activator Substances 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 23
- 201000005202 lung cancer Diseases 0.000 claims description 23
- 208000020816 lung neoplasm Diseases 0.000 claims description 23
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 22
- 206010009944 Colon cancer Diseases 0.000 claims description 21
- 206010066476 Haematological malignancy Diseases 0.000 claims description 21
- 229940113306 Ligase inhibitor Drugs 0.000 claims description 21
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 21
- 239000000436 ligase inhibitor Substances 0.000 claims description 21
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims description 21
- 206010006187 Breast cancer Diseases 0.000 claims description 20
- 208000026310 Breast neoplasm Diseases 0.000 claims description 20
- 206010025323 Lymphomas Diseases 0.000 claims description 20
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 20
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 20
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 20
- 206010017758 gastric cancer Diseases 0.000 claims description 20
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 20
- 201000011549 stomach cancer Diseases 0.000 claims description 20
- 102100024263 CD160 antigen Human genes 0.000 claims description 18
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 18
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 18
- 239000000556 agonist Substances 0.000 claims description 18
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 16
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 16
- VRQXRVAKPDCRCI-ZNMIVQPWSA-N n-[4-[(1r,3s,5s)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide Chemical compound C1[C@H](C)C[C@H](N)C[C@@H]1C1=CC=NC=C1NC(=O)C1=CC=C(F)C(C=2C(=CC=CC=2F)F)=N1 VRQXRVAKPDCRCI-ZNMIVQPWSA-N 0.000 claims description 16
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 14
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 14
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 14
- 206010060862 Prostate cancer Diseases 0.000 claims description 14
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 14
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 13
- 230000001079 digestive effect Effects 0.000 claims description 13
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 13
- 201000002528 pancreatic cancer Diseases 0.000 claims description 13
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 13
- CLRSLRWKONPSRQ-IIPSPAQQSA-N C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)C[C@@H]2CC[C@H](CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 Chemical compound C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)C[C@@H]2CC[C@H](CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 CLRSLRWKONPSRQ-IIPSPAQQSA-N 0.000 claims description 12
- 208000034578 Multiple myelomas Diseases 0.000 claims description 12
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 12
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 12
- 208000032839 leukemia Diseases 0.000 claims description 12
- 208000025113 myeloid leukemia Diseases 0.000 claims description 12
- 229960005184 panobinostat Drugs 0.000 claims description 12
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 11
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 11
- 201000010536 head and neck cancer Diseases 0.000 claims description 11
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 11
- 229950010773 pidilizumab Drugs 0.000 claims description 11
- 230000006870 function Effects 0.000 claims description 10
- CLRSLRWKONPSRQ-CPOWQTMSSA-N (1s)-1-(4-chlorophenyl)-6-methoxy-2-[4-[methyl-[[4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]methyl]amino]phenyl]-7-propan-2-yloxy-1,4-dihydroisoquinolin-3-one Chemical compound C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)CC2CCC(CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 CLRSLRWKONPSRQ-CPOWQTMSSA-N 0.000 claims description 9
- XIFFUJNWCYQIBQ-UHFFFAOYSA-N 8-(2,6-difluoro-3,5-dimethoxyphenyl)-n-[5-[(dimethylamino)methyl]-1h-imidazol-2-yl]quinoxaline-5-carboxamide Chemical compound COC1=CC(OC)=C(F)C(C=2C3=NC=CN=C3C(C(=O)NC=3NC=C(CN(C)C)N=3)=CC=2)=C1F XIFFUJNWCYQIBQ-UHFFFAOYSA-N 0.000 claims description 9
- 102100038078 CD276 antigen Human genes 0.000 claims description 9
- 101710185679 CD276 antigen Proteins 0.000 claims description 9
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 9
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 9
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 9
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 9
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 9
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 9
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 9
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 9
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 9
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 9
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 9
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 9
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 9
- 102100027207 CD27 antigen Human genes 0.000 claims description 8
- 101150013553 CD40 gene Proteins 0.000 claims description 8
- 102100035793 CD83 antigen Human genes 0.000 claims description 8
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 8
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 8
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 8
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 8
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 8
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 8
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 8
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 8
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 8
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 8
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 8
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 108010087819 Fc receptors Proteins 0.000 claims description 7
- 102000009109 Fc receptors Human genes 0.000 claims description 7
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 7
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 7
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 7
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 7
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 7
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 7
- 230000002489 hematologic effect Effects 0.000 claims description 7
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 7
- 229940125565 BMS-986016 Drugs 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 239000012636 effector Substances 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 102000042838 JAK family Human genes 0.000 claims description 5
- 108091082332 JAK family Proteins 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 5
- 230000013595 glycosylation Effects 0.000 claims description 5
- 238000006206 glycosylation reaction Methods 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 230000003915 cell function Effects 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 102200087780 rs77375493 Human genes 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 229950009791 durvalumab Drugs 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 238000011275 oncology therapy Methods 0.000 claims description 3
- 210000003800 pharynx Anatomy 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 230000004083 survival effect Effects 0.000 claims description 3
- 201000003957 thoracic cancer Diseases 0.000 claims description 3
- 230000035899 viability Effects 0.000 claims description 3
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 2
- 210000003443 bladder cell Anatomy 0.000 claims description 2
- 210000004958 brain cell Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- ZPIVTGDIMHFXKE-ZNMIVQPWSA-N n-[4-[(1r,3s,5s)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-3-fluoropyridine-2-carboxamide Chemical compound C1[C@H](C)C[C@H](N)C[C@@H]1C1=CC=NC=C1NC(=O)C1=NC(C=2C(=CC=CC=2F)F)=CC=C1F ZPIVTGDIMHFXKE-ZNMIVQPWSA-N 0.000 claims description 2
- 210000003061 neural cell Anatomy 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 210000004498 neuroglial cell Anatomy 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 10
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 7
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 6
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims 5
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 5
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 5
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 94
- 125000003118 aryl group Chemical group 0.000 description 85
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 80
- 102000008096 B7-H1 Antigen Human genes 0.000 description 78
- 125000000753 cycloalkyl group Chemical group 0.000 description 70
- 125000001424 substituent group Chemical group 0.000 description 59
- 125000005843 halogen group Chemical group 0.000 description 57
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 55
- 125000001072 heteroaryl group Chemical group 0.000 description 53
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 51
- 125000000217 alkyl group Chemical group 0.000 description 51
- 210000001744 T-lymphocyte Anatomy 0.000 description 48
- 102000001301 EGF receptor Human genes 0.000 description 33
- 108060006698 EGF receptor Proteins 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 33
- 125000003710 aryl alkyl group Chemical group 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 30
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 30
- 229910052739 hydrogen Inorganic materials 0.000 description 30
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 29
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 28
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 28
- 150000001413 amino acids Chemical class 0.000 description 27
- 125000005311 halosulfanyl group Chemical group 0.000 description 27
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 26
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 25
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical group CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 24
- 239000001257 hydrogen Substances 0.000 description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 24
- 238000011282 treatment Methods 0.000 description 24
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 23
- 229960001602 ceritinib Drugs 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 229910052717 sulfur Inorganic materials 0.000 description 23
- 230000004927 fusion Effects 0.000 description 22
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 21
- 229910052799 carbon Inorganic materials 0.000 description 21
- 229910052736 halogen Inorganic materials 0.000 description 21
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 20
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 20
- 239000012271 PD-L1 inhibitor Substances 0.000 description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 20
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 19
- 150000002367 halogens Chemical class 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 125000000623 heterocyclic group Chemical group 0.000 description 18
- 230000008685 targeting Effects 0.000 description 17
- 125000004093 cyano group Chemical group *C#N 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 15
- 229940125431 BRAF inhibitor Drugs 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 125000000539 amino acid group Chemical group 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 14
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 14
- 229940124647 MEK inhibitor Drugs 0.000 description 14
- 239000012828 PI3K inhibitor Substances 0.000 description 14
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 14
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 14
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 13
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 13
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical group C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 description 13
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 13
- 229940118364 Bcr-Abl inhibitor Drugs 0.000 description 13
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 13
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 13
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 12
- 102000040430 polynucleotide Human genes 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 11
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 125000000732 arylene group Chemical group 0.000 description 9
- 125000002993 cycloalkylene group Chemical group 0.000 description 9
- 125000005549 heteroarylene group Chemical group 0.000 description 9
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 208000005017 glioblastoma Diseases 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000005945 translocation Effects 0.000 description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 7
- 125000001931 aliphatic group Chemical group 0.000 description 7
- 125000004966 cyanoalkyl group Chemical group 0.000 description 7
- 125000001188 haloalkyl group Chemical group 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 7
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical group C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 6
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 6
- 206010029260 Neuroblastoma Diseases 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 125000004663 dialkyl amino group Chemical group 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229960005386 ipilimumab Drugs 0.000 description 6
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical group C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 6
- 230000008707 rearrangement Effects 0.000 description 6
- 102200048955 rs121434569 Human genes 0.000 description 6
- 108010078373 tisagenlecleucel Proteins 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101150023956 ALK gene Proteins 0.000 description 5
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 5
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 5
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 5
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 5
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 5
- 229940125563 LAG3 inhibitor Drugs 0.000 description 5
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 238000011374 additional therapy Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 229960005061 crizotinib Drugs 0.000 description 5
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 102000048362 human PDCD1 Human genes 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 4
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 4
- 241000282836 Camelus dromedarius Species 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 4
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 125000004103 aminoalkyl group Chemical group 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical group OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 4
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical group COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical group C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 108091006082 receptor inhibitors Proteins 0.000 description 4
- 239000010948 rhodium Substances 0.000 description 4
- 229950003687 ribociclib Drugs 0.000 description 4
- 102200048928 rs121434568 Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 201000002510 thyroid cancer Diseases 0.000 description 4
- 238000013414 tumor xenograft model Methods 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical group C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 3
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
- 102100032818 Integrin alpha-4 Human genes 0.000 description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 description 3
- 102100022339 Integrin alpha-L Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 102100030704 Interleukin-21 Human genes 0.000 description 3
- 206010069755 K-ras gene mutation Diseases 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 239000012272 PD-L2 inhibitor Substances 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 102100029197 SLAM family member 6 Human genes 0.000 description 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 229950010482 alpelisib Drugs 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 229950003628 buparlisib Drugs 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 235000020937 fasting conditions Nutrition 0.000 description 3
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 3
- 102000048776 human CD274 Human genes 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 108010074108 interleukin-21 Proteins 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 3
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229940121654 pd-l2 inhibitor Drugs 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 125000005415 substituted alkoxy group Chemical group 0.000 description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 244000303258 Annona diversifolia Species 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 2
- 229960005532 CC-1065 Drugs 0.000 description 2
- 102100038077 CD226 antigen Human genes 0.000 description 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 2
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 2
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 2
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000688216 Homo sapiens Intestinal-type alkaline phosphatase Proteins 0.000 description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 101000616014 Homo sapiens Magnesium transporter protein 1 Proteins 0.000 description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
- 101000633782 Homo sapiens SLAM family member 8 Proteins 0.000 description 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102100025323 Integrin alpha-1 Human genes 0.000 description 2
- 102100039904 Integrin alpha-D Human genes 0.000 description 2
- 102100022341 Integrin alpha-E Human genes 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 229910052765 Lutetium Inorganic materials 0.000 description 2
- 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 2
- 102000011769 Member 9 Tumor Necrosis Factor Receptor Superfamily Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100236865 Mus musculus Mdm2 gene Proteins 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229910052777 Praseodymium Inorganic materials 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102100029214 SLAM family member 8 Human genes 0.000 description 2
- 102100027744 Semaphorin-4D Human genes 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 238000010317 ablation therapy Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052767 actinium Inorganic materials 0.000 description 2
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 229910052789 astatine Inorganic materials 0.000 description 2
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000053119 human ALPI Human genes 0.000 description 2
- 102000054751 human RUNX1T1 Human genes 0.000 description 2
- 229940116978 human epidermal growth factor Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 1
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 101150032367 BIRC8 gene Proteins 0.000 description 1
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 1
- 102100021676 Baculoviral IAP repeat-containing protein 1 Human genes 0.000 description 1
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 1
- 102100027515 Baculoviral IAP repeat-containing protein 6 Human genes 0.000 description 1
- 101710178008 Baculoviral IAP repeat-containing protein 6 Proteins 0.000 description 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 1
- 101710177963 Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 1
- 102100027517 Baculoviral IAP repeat-containing protein 8 Human genes 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710139831 CD82 antigen Proteins 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100452644 Drosophila melanogaster Ilp2 gene Proteins 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 1
- 101710203446 Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 description 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010043766 IRX 2 Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101100236305 Mus musculus Ly9 gene Proteins 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 108091008877 NK cell receptors Proteins 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 108010006696 Neuronal Apoptosis-Inhibitory Protein Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 229910004749 OS(O)2 Inorganic materials 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 101000935814 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Periplasmic beta-glucosidase Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010062314 Signaling Lymphocytic Activation Molecule Family Proteins 0.000 description 1
- 102000010841 Signaling Lymphocytic Activation Molecule Family Human genes 0.000 description 1
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229940123155 T cell inhibitor Drugs 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 244000247617 Teramnus labialis var. labialis Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 229940122429 Tubulin inhibitor Drugs 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124675 anti-cancer drug Drugs 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 229940044684 anti-microtubule agent Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000012893 effector ligand Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 201000006974 gastroesophageal cancer Diseases 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003259 immunoinhibitory effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HAJKHJOABGFIGP-UHFFFAOYSA-N indolizidine Chemical compound C1CCCN2CCCC21 HAJKHJOABGFIGP-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 208000014277 lung inflammatory myofibroblastic tumor Diseases 0.000 description 1
- 201000001037 lung lymphoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 238000012083 mass cytometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- LJPZHJUSICYOIX-UHFFFAOYSA-N quinolizidine Chemical compound C1CCCC2CCCCN21 LJPZHJUSICYOIX-UHFFFAOYSA-N 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 208000015608 reproductive system cancer Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229940120975 revlimid Drugs 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 102200055464 rs113488022 Human genes 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- TXHPORRYUKITDP-UHFFFAOYSA-N sulfamoylsulfamic acid Chemical compound NS(=O)(=O)NS(O)(=O)=O TXHPORRYUKITDP-UHFFFAOYSA-N 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940069905 tasigna Drugs 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940034915 thalomid Drugs 0.000 description 1
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940052129 zykadia Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- T cells The ability of T cells to mediate an immune response against an antigen requires two distinct signaling interactions (Viglietta, V. et al. (2007) Neurotherapeutics 4:666-675; Korman, A. J. et al. (2007) Adv. Immunol. 90:297-339).
- APC antigen-presenting cells
- TCR T cell receptor
- the immune system is tightly controlled by a network of costimulatory and co-inhibitory ligands and receptors. These molecules provide the second signal for T cell activation and provide a balanced network of positive and negative signals to maximize immune responses against infection, while limiting immunity to self (Wang, L. et al. (Epub Mar. 7, 2011) J. Exp. Med. 208(3):577-92; Lepenies, B. et al. (2008) Endocrine, Metabolic & Immune Disorders- Drug Targets 8:279-288).
- costimulatory signals include the binding between the B7.1 (CD80) and B7.2 (CD86) ligands of the APC and the CD28 and CTLA-4 receptors of the CD4 + T-lymphocyte (Sharpe, A. H. et al. (2002) Nature Rev. Immunol. 2:116-126; Lindley, P. S. et al. (2009) Immunol. Rev. 229:307-321). Binding of B7.1 or B7.2 to CD28 stimulates T cell activation, whereas binding of B7.1 or B7.2 to CTLA-4 inhibits such activation (Dong, C. et al. (2003) Immunolog. Res.28(1):39-48; Greenwald, R. J. et al. (2005) Ann. Rev. Immunol.23:515- 548). CD28 is constitutively expressed on the surface of T cells (Gross, J., et al. (1992) J.
- B7 Superfamily a group of related B7 molecules, also known as the "B7 Superfamily" (Coyle, A. J. et al. (2001) Nature Immunol.2(3):203-209; Sharpe, A. H. et al. (2002) Nature Rev. Immunol.2:116-126; Collins, M. et al. (2005) Genome Biol.6:223.1- 223.7; Korman, A. J. et al. (2007) Adv. Immunol.90:297-339).
- B7 Superfamily Several members of the B7 Superfamily are known, including B7.1 (CD80), B7.2 (CD86), the inducible co-stimulator ligand (ICOS-L), the programmed death-1 ligand (PD-L1; B7-H1), the programmed death-2 ligand (PD-L2; B7-DC), B7-H3, B7-H4 and B7-H6 (Collins, M. et al. (2005) Genome Biol.6:223.1- 223.7).
- B7.1 CD80
- B7.2 the inducible co-stimulator ligand
- PD-L1 programmed death-1 ligand
- PD-L2 programmed death-2 ligand
- B7-DC B7-H3, B7-H4 and B7-H6
- the Programmed Death 1 (PD-1) protein is an inhibitory member of the extended CD28/CTLA-4 family of T cell regulators (Okazaki et al. (2002) Curr Opin Immunol 14:
- CD28 CD28
- CTLA-4 CTLA-4
- ICOS BTLA
- PD-1 is suggested to exist as a monomer, lacking the unpaired cysteine residue characteristic of other CD28 family members. PD-1 is expressed on activated B cells, T cells, and monocytes.
- the PD-1 gene encodes a 55 kDa type I transmembrane protein (Agata et al. (1996) Int Immunol.8:765-72). Although structurally similar to CTLA-4, PD-1 lacks the MYPPY motif (SEQ ID NO: 1) that is important for B7-1 and B7-2 binding.
- SEQ ID NO: 1 Two ligands for PD-1 have been identified, PD-L1 (B7-H1) and PD-L2 (B7-DC), that have been shown to downregulate T cell activation upon binding to PD-1 (Freeman et al. (2000) J. Exp. Med.192:1027-34; Carter et al. (2002) Eur. J. Immunol.32:634-43).
- Both PD-L1 and PD-L2 are B7 homologs that bind to PD- 1, but do not bind to other CD28 family members.
- PD-L1 is abundant in a variety of human cancers (Dong et al. (2002) Nat. Med.8:787-9).
- PD-1 is known as an immunoinhibitory protein that negatively regulates TCR signals (Ishida, Y. et al. (1992) EMBO J.11:3887-3895; Blank, C. et al. (Epub 2006 Dec.29) Immunol. Immunother.56(5):739-745).
- the interaction between PD-1 and PD-L1 can act as an immune checkpoint, which can lead to, e.g., a decrease in tumor infiltrating lymphocytes, a decrease in T- cell receptor mediated proliferation, and/or immune evasion by cancerous cells (Dong et al. (2003) J. Mol. Med.81:281-7; Blank et al. (2005) Cancer Immunol.
- the present invention provides, at least in part, methods and compositions comprising an immunomodulator (e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule) in combination with a second therapeutic agent chosen from one or more of the agents listed in Table 1.
- an immunomodulator e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule
- an inhibitor of an immune checkpoint molecule e.g., one or more inhibitors of PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3, and/or -5) or CTLA-4) can be combined with a second therapeutic agent chosen from one or more agents listed in Table 1 (e.g., one or more of: 1) an IAP inhibitor; 2) a TOR kinase inhibitor; 3) a HDM2 ligase inhibitor; 4) a PIM kinase inhibitor; 5) a HER3 kinase inhibitor; 6) a Histone Deacetylase (HDAC) inhibitor; 7) a Janus kinase inhibitor; 8) an FGF receptor inhibitor; 9) an EGF receptor inhibitor; 10) a c-MET inhibitor; 11) an ALK inhibitor; 12) a CDK4/6-inhibitor; 13) a PI3K inhibitor; 14) a BRAF inhibitor; 15)
- the combinations described herein can provide a beneficial effect, e.g., in the treatment of a cancer, such as an enhanced anti-cancer effect, reduced toxicity and/or reduced side effects.
- the immunomodulator, the second therapeutic agent, or both can be administered at a lower dosage than would be required to achieve the same therapeutic effect compared to a monotherapy dose.
- compositions and methods for treating proliferative disorders, including cancer, using the aforesaid combination therapies are disclosed.
- the invention features a method of treating (e.g., inhibiting, reducing, ameliorating, or preventing) a proliferative condition or disorder (e.g., a cancer) in a subject.
- the method includes administering to the subject an immunomodulator (e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule) and a second therapeutic agent, e.g., a second therapeutic agent chosen from one or more of the agents listed in Table 1, thereby treating the proliferative condition or disorder (e.g., the cancer).
- the immunomodulator is an inhibitor of an immune checkpoint molecule (e.g., an inhibitor of PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3, and/or -5) or CTLA-4, or any combination thereof).
- the second therapeutic agent is chosen from one or more of the agents listed in Table 1, e.g., one or more of: 1) an IAP inhibitor; 2) a TOR kinase inhibitor; 3) a HDM2 ligase inhibitor; 4) a PIM kinase inhibitor; 5) a HER3 kinase inhibitor; 6) a Histone Deacetylase (HDAC) inhibitor; 7) a Janus kinase inhibitor; 8) an FGF receptor inhibitor); 9) an EGF receptor inhibitor; 10) a c-MET inhibitor; 11) an ALK inhibitor; 12) a CDK4/6-inhibitor; 13) a PI3K inhibitor; 14) a BRAF inhibitor; 15) a CAR T cell (e.g., a CAR T cell targeting CD19); 16) a MEK inhibitor, or 17) a BCR-ABL inhibitor).
- HDAC Histone Deacetylase
- the combination of the immunomodulator and the second agent can be administered together in a single composition or administered separately in two or more different compositions, e.g., one or more compositions or dosage forms as described herein.
- the administration of the immunomodulator and the second agent can be in any order.
- the immunomodulator can be administered concurrently with, prior to, or subsequent to, the second agent.
- the invention features a method of reducing an activity (e.g., growth, survival, or viability, or all), of a proliferative (e.g., a cancer) cell.
- the method includes contacting the cell with an immunomodulator (e.g., one or more of: an activator of a
- the immunomodulator is an inhibitor of an immune checkpoint molecule (e.g., an inhibitor of PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3, and/or -5) or CTLA-4, or any combination thereof).
- an immune checkpoint molecule e.g., an inhibitor of PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3, and/or -5) or CTLA-4, or any combination thereof.
- the second therapeutic agent is chosen from one or more of the agents listed in Table 1, e.g., one or more: 1) an IAP inhibitor; 2) a TOR kinase inhibitor; 3) a HDM2 ligase inhibitor; 4) a PIM kinase inhibitor; 5) a HER3 kinase inhibitor; 6) a Histone Deacetylase (HDAC) inhibitor; 7) a Janus kinase inhibitor; 8) an FGF receptor inhibitor); 9) an EGF receptor inhibitor; 10) a c-MET inhibitor; 11) an ALK inhibitor; 12) a CDK4/6-inhibitor; 13) a PI3K inhibitor; 14) a BRAF inhibitor; 15) a CAR T cell (e.g., a CAR T cell targeting CD19); 16) a MEK inhibitor, or 17) a BCR-ABL inhibitor).
- HDAC Histone Deacetylase
- the methods described herein can be used in vitro.
- in vitro hPBMC-based assays can be used to screen for combination signals of
- the methods described herein can be used in vivo, e.g., in an animal subject or model or as part of a therapeutic protocol.
- the contacting of the cell with the immunomodulator and the second agent can be in any order.
- the cell is contacted with the immunomodulator concurrently, prior to, or subsequent to, the second agent.
- the method described herein is used to measure tumor lymphocyte infiltration (TLI) in vitro or in vivo, as disclosed, e.g., in Frederick, D.T. et al. (2013) Clinical Cancer Research 19:1225-31.
- TLI tumor lymphocyte infiltration
- the method includes contacting the cell with an immunomodulator (e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule) and/or a second therapeutic agent, e.g., a second therapeutic agent chosen from one or more of the agents listed in Table 1, in an animal model.
- an immunomodulator e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule
- a second therapeutic agent e.g., a second therapeutic agent chosen from one or more of the agents listed in Table 1
- the animal model has a mutation that inhibits or activates IAP, EGF receptor, cMET, ALK, CDK4/6, PI3K, BRAF, FGF receptor, MEK, and/or BCR-ABL.
- an animal model is a mouse model implanted with MC38 murine colon carcinoma.
- an animal model is a mouse model with an inactivated p110 ⁇ isoform of PI3 kinase (e.g., p110 ⁇ D910A ) as disclosed, e.g., in Ali, K., et al., (2014) Nature 510:407-411.
- PI3 kinase e.g., p110 ⁇ D910A
- an immune phenotype is determined by measuring one or more of expression, activation, signalling, flow cytometry, mRNA analysis, cytokine levels and/or immunohistochemisty. In some embodiments, the immune phenotype is determined
- the immune phenotype is determined in situ, e.g, in tumor cells.
- one or more of the following parameters is characterized to determine an immune phenotype: checkpoint induction; level of M1
- the invention features a composition (e.g., one or more compositions, formulations or dosage formulations) or a pharmaceutical combination, comprising an immunomodulator (e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule) and a second therapeutic agent, e.g., a second therapeutic agent chosen from one or more of the agents listed in Table 1.
- an immunomodulator e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule
- a second therapeutic agent e.g., a second therapeutic agent chosen from one or more of the agents listed in Table 1.
- the immunomodulator is an inhibitor of an immune checkpoint molecule (e.g., an inhibitor of PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3 and/or -5) or CTLA-4, or any combination thereof).
- an immune checkpoint molecule e.g., an inhibitor of PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3 and/or -5) or CTLA-4, or any combination thereof.
- the second therapeutic agent is chosen from one or more of the agents listed in Table 1, e.g., one or more of: 1) an IAP inhibitor; 2) a TOR kinase inhibitor; 3) a HDM2 ligase inhibitor; 4) a PIM kinase inhibitor; 5) a HER3 kinase inhibitor; 6) a Histone Deacetylase (HDAC) inhibitor; 7) a Janus kinase inhibitor; 8) an FGF receptor inhibitor); 9) an EGF receptor inhibitor; 10) a c-MET inhibitor; 11) an ALK inhibitor; 12) a CDK4/6-inhibitor; 13) a PI3K inhibitor; 14) a BRAF inhibitor; 15) a CAR T cell (e.g., a CAR T cell targeting CD19); 16) a MEK inhibitor, or 17) a BCR-ABL inhibitor).
- the composition comprises a pharmaceutically acceptable carrier.
- the immunomodulator and the second agent can be present
- compositions comprising the immunomodulator and the second agent can be administered via the same administration route or via different administration routes.
- the immunomodulator and the second agent can be administered via the same administration route or via different administration routes.
- pharmaceutical combination comprises the immunomodulator and the second agent separately or together.
- the composition, formulation or pharmaceutical combination is for use as a medicine, e.g., for the treatment of a proliferative disease (e.g., a cancer as described herein).
- a proliferative disease e.g., a cancer as described herein.
- the immunomodulator and the second agent are administered concurrently, e.g., independently at the same time or within an overlapping time interval, or separately within time intervals. In certain embodiment, the time interval allows the
- the immunomodulator and the second agent to be jointly active.
- the second agent to be jointly active.
- composition, formulation or pharmaceutical combination includes an amount which is jointly therapeutically effective for the treatment of a proliferative disease, e.g., a cancer as described herein.
- the invention features a use of a composition (e.g., one or more compositions, formulations or dosage formulations) or a pharmaceutical combination, comprising an immunomodulator (e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule) and a second therapeutic agent, e.g., a second therapeutic agent chosen from one or more of the agents listed in Table 1, for the manufacture of a medicament for treating a proliferative disease, e.g., a cancer.
- an immunomodulator e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule
- a second therapeutic agent e.g., a second therapeutic agent chosen from one or more of the agents listed in Table 1, for the manufacture of a medicament for treating
- the immunomodulator is an inhibitor of an immune checkpoint molecule (e.g., an inhibitor of PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3 and/or -5) or CTLA-4, or any combination thereof).
- an immune checkpoint molecule e.g., an inhibitor of PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3 and/or -5) or CTLA-4, or any combination thereof.
- the second therapeutic agent is chosen from one or more of the agents listed in Table 1, e.g., one or more of: 1) an IAP inhibitor; 2) a TOR kinase inhibitor; 3) a HDM2 ligase inhibitor; 4) a PIM kinase inhibitor; 5) a HER3 kinase inhibitor; 6) a Histone Deacetylase (HDAC) inhibitor; 7) a Janus kinase inhibitor; 8) an FGF receptor inhibitor); 9) an EGF receptor inhibitor; 10) a c-MET inhibitor; 11) an ALK inhibitor; 12) a CDK4/6-inhibitor; 13) a PI3K inhibitor; 14) a BRAF inhibitor; 15) a CAR T cell (e.g., a CAR T cell targeting CD19); 16) a MEK inhibitor, or 17) a BCR-ABL inhibitor).
- HDAC Histone Deacetylase
- Kits e.g., therapeutic kits, that include the immunomodulator (e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule as described herein) and the second therapeutic agent, e.g., a second therapeutic agent chosen from one or more of the agents listed in Table 1, and instructions for use, are also disclosed. Additional features or embodiments of the methods, compositions, dosage formulations, and kits described herein include one or more of the following: In certain embodiments, the immunomodulator is an activator of a costimulatory molecule.
- the agonist of the costimulatory molecule is chosen from an agonist (e.g., an agonistic antibody or antigen-binding fragment thereof, or a soluble fusion) of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7- H3 or CD83 ligand, or any combination thereof.
- an agonist e.g., an agonistic antibody or antigen-binding fragment thereof, or a soluble fusion
- OX40 e.g., an agonistic antibody or antigen-binding fragment thereof, or a soluble fusion
- CD2 e.g., an agonistic antibody or antigen-binding fragment thereof, or a soluble fusion
- ICAM-1 e.g., I
- the immunomodulator is an inhibitor of an immune checkpoint molecule.
- the immunomodulator is an inhibitor of PD-1, PD-L1, PD-L2, CTLA-4, TIM-3, LAG-3, CEACAM (e.g., CEACAM-1, -3 and/or -5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and/or TGFR beta.
- the inhibitor of an immune checkpoint molecule inhibits PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3 and/or -5) or CTLA-4, or any combination thereof.
- Inhibition of an inhibitory molecule can be performed at the DNA, RNA or protein level.
- an inhibitory nucleic acid e.g., a dsRNA, siRNA or shRNA
- the inhibitor of an inhibitory signal is, a polypeptide e.g., a soluble ligand (e.g., PD-1-Ig or CTLA-4 Ig).
- the inhibitor of the inhibitory signal is an antibody or antigen-binding fragment thereof, that binds to the inhibitory molecule; e.g., an antibody or fragment thereof (also referred to herein as“an antibody molecule”) that binds to PD-1, PD-L1, PD-L2, CTLA-4, TIM-3, LAG- 3, CEACAM (e.g., CEACAM-1, -3 and/or -5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and/or TGFR beta, or a combination thereof.
- an antibody or fragment thereof also referred to herein as“an antibody molecule”
- CEACAM e.g., CEACAM-1, -3 and/or -5
- VISTA e.g., CEACAM-1, -3 and/or -5
- BTLA TIGIT
- LAIR1 CD160
- 2B4 and/or TGFR beta
- the antibody molecule is a full antibody or fragment thereof (e.g., a Fab, F(ab') 2 , Fv, or a single chain Fv fragment (scFv)).
- the antibody molecule has a heavy chain constant region (Fc) chosen from, e.g., the heavy chain constant regions of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE; particularly, chosen from, e.g., the heavy chain constant regions of IgG1, IgG2, IgG3, and IgG4, more particularly, the heavy chain constant region of IgG1 or IgG4 (e.g., human IgG1 or IgG4).
- Fc heavy chain constant region
- the heavy chain constant region is human IgG1 or human IgG4.
- the constant region is altered, e.g., mutated, to modify the properties of the antibody molecule (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function).
- the antibody molecule is in the form of a bispecific or multispecific antibody molecule.
- the bispecific antibody molecule has a first binding specificity to PD-1 or PD-L1 and a second binding specifity, e.g., a second binding specificity to TIM-3, LAG-3, or PD-L2.
- the bispecific antibody molecule binds to PD-1 or PD-L1 and TIM-3.
- the bispecific antibody molecule binds to PD-1 or PD-L1 and LAG-3.
- the bispecific antibody molecule binds to PD-1 or PD-L1 and CEACAM (e.g., CEACAM-1, -3 and/or -5).
- CEACAM e.g., CEACAM-1, -3 and/or -5
- the bispecific antibody molecule binds to PD-1 or PD-L1 and CEACAM-1. In still another embodiment, the bispecific antibody molecule binds to PD-1 or PD-L1 and CEACAM-3. In yet another embodiment, the bispecific antibody molecule binds to PD-1 or PD-L1 and CEACAM-1. In another embodiment, the bispecific antibody molecule binds to PD-1 or PD- L1. In yet another embodiment, the bispecific antibody molecule binds to PD-1 and PD-L2. In another embodiment, the bispecific antibody molecule binds to TIM-3 and LAG-3.
- the bispecific antibody molecule binds to CEACAM (e.g., CEACAM-1, -3 and/or - 5) and LAG-3. In another embodiment, the bispecific antibody molecule binds to CEACAM (e.g., CEACAM-1, -3 and/or -5) and TIM-3. Any combination of the aforesaid molecules can be made in a multispecific antibody molecule, e.g., a trispecific antibody that includes a first binding specificity to PD-1 or PD-1, and a second and third binding specifities to two or more of: TIM-3, CEACAM (e.g., CEACAM-1, -3 and/or -5), LAG-3, or PD-L2.
- a multispecific antibody molecule e.g., a trispecific antibody that includes a first binding specificity to PD-1 or PD-1, and a second and third binding specifities to two or more of: TIM-3, CEACAM (e.g., CEACAM-1,
- the immunomodulator is an inhibitor of PD-1, e.g., human PD-1.
- the immunomodulator is an inhibitor of PD-L1, e.g., human PD-L1.
- the inhibitor of PD-1 or PD-L1 is an antibody molecule to PD-1 or PD-L1.
- the PD-1 or PD-L1 inhibitor can be administered alone, or in combination with other immunomodulators, e.g., in combination with an inhibitor of LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3 and/or -5) or CTLA-4.
- the inhibitor of PD-1 or PD-L1, e.g., the anti-PD-1 or PD-L1 antibody molecule is administered in combination with a LAG-3 inhibitor, e.g., an anti-LAG-3 antibody molecule.
- the inhibitor of PD-1 or PD-L1, e.g., the anti-PD-1 or PD-L1 antibody molecule is administered in combination with a TIM-3 inhibitor, e.g., an anti-TIM-3 antibody molecule.
- the inhibitor of PD-1 or PD-L1, e.g., the anti-PD-1 antibody molecule is administered in combination with a LAG-3 inhibitor, e.g., an anti-LAG-3 antibody molecule, and a TIM-3 inhibitor, e.g., an anti-TIM-3 antibody molecule.
- the inhibitor of PD-1 or PD-L1, e.g., the anti-PD-1 or PD-L1 antibody molecule is administered in combination with a CEACAM (e.g., CEACAM-1, -3 and/or -5) inhibitor, e.g., an anti-CEACAM antibody molecule.
- a CEACAM e.g., CEACAM-1, -3 and/or -5 inhibitor
- the inhibitor of PD-1 or PD-L1, e.g., the anti-PD-1 or PD-L1 antibody molecule is administered in combination with a CEACAM-1 inhibitor, e.g., an anti-CEACAM-1 antibody molecule.
- the inhibitor of PD-1 or PD- L1, e.g., the anti-PD-1 or PD-L1 antibody molecule is administered in combination with a CEACAM-3 inhibitor, e.g., an anti-CEACAM-3 antibody molecule.
- the inhibitor of PD-1 or PD-L1 is administered in combination with a CEACAM-5 inhibitor, e.g., an anti-CEACAM-5 antibody molecule.
- a CEACAM-5 inhibitor e.g., an anti-CEACAM-5 antibody molecule.
- Other combinations of immunomodulators with a PD-1 inhibitor e.g., one or more of PD-L2, CTLA-4, TIM-3, LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and/or TGFR
- Any of the antibody molecules known in the art or disclosed herein can be used in the aforesaid combinations of inhibitors of checkpoint molecule.
- the PD-1 inhibitor is an anti-PD-1 antibody chosen from Nivolumab, Pembrolizumab or Pidilizumab.
- the anti-PD-1 antibody is Nivolumab.
- Alternative names for Nivolumab include MDX- 1106, MDX-1106-04, ONO-4538, or BMS-936558.
- the anti-PD-1 antibody is Nivolumab (CAS Registry Number: 946414-94-4).
- Nivolumab is a fully human IgG4 monoclonal antibody which specifically blocks PD- 1.
- Nivolumab (clone 5C4) and other human monoclonal antibodies that specifically bind to PD- 1 are disclosed in US 8,008,449 and WO2006/121168.
- the anti-PD-1 antibody is Pembrolizumab.
- Pembrolizumab (Trade name KEYTRUDA formerly Lambrolizumab, also known as Merck 3745, MK-3475 or SCH- 900475) is a humanized IgG4 monoclonal antibody that binds to PD-1.
- Pembrolizumab is disclosed, e.g., in Hamid, O. et al. (2013) New England Journal of Medicine 369 (2): 134–44, WO2009/114335, and US 8,354,509.
- the anti-PD-1 antibody is Pidilizumab.
- Pidilizumab CT-011; Cure Tech
- CT-011 Cure Tech
- IgG1k monoclonal antibody that binds to PD-1.
- Pidilizumab and other humanized anti-PD-1 monoclonal antibodies are disclosed in WO2009/101611.
- Other anti- PD-1 antibodies are disclosed in US 8,609,089, US 2010028330, and/or US
- anti-PD-1 antibodies include AMP 514 (Amplimmune).
- the PD-1 inhibitor is an immunoadhesin (e.g., an immunoadhesin comprising an extracellular or PD-1 binding portion of PD-Ll or PD-L2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence)).
- the PD-1 inhibitor is AMP-224.
- the PD-Ll inhibitor is anti-PD-Ll antibody.
- the anti-PD-Ll inhibitor is chosen from YW243.55.S70, MPDL3280A, MEDI-4736, MSB- 0010718C, or MDX-1105.
- the PD-L1 inhibitor is MDX-1105.
- MDX-1105 also known as BMS-936559, is an anti-PD-Ll antibody described in WO2007/005874.
- the PD-L1 inhibitor is YW243.55.S70.
- the YW243.55.S70 antibody is an anti-PD-Ll described in WO 2010/077634 (heavy and light chain variable region sequences shown in SEQ ID Nos.20 and 21, respectively, of WO 2010/077634).
- the PD-L1 inhibitor is MDPL3280A (Genentech / Roche).
- MDPL3280A is a human Fc optimized IgG1 monoclonal antibody that binds to PD-L1.
- MDPL3280A and other human monoclonal antibodies to PD-L1 are disclosed in U.S. Patent No.: 7,943,743 and U.S Publication No.: 20120039906.
- the PD-L2 inhibitor is AMP-224.
- AMP-224 is a PD-L2 Fc fusion soluble receptor that blocks the interaction between PD-1 and B7-H1 (B7-DCIg; Amplimmune; e.g., disclosed in WO2010/027827 and WO2011/066342).
- the LAG-3 inhibitor is an anti-LAG-3 antibody molecule. In one embodiment, the LAG-3 inhibitor is BMS-986016, disclosed in more detail herein below.
- the TIM-3 inhibitor is an anti-TIM-3 antibody molecule, e.g., an anti-TIM-3 antibody molecule as described herein.
- One or more of the aforesaid inhibitors of immune checkpoint molecules can be used in combination with one or more of the second agents disclosed in Table 1, as more specifically exemplified below.
- the second agent is chosen from one or more of:
- anti-HER3 monoclonal antibody or antigen binding fragment thereof that comprises a VH of SEQ ID NO: 141 and VL of SEQ ID NO: 140, as described in U.S.8,735,551;
- the inhibitor of PD-1 is Nivolumab (CAS Registry No: 946414-94-4) disclosed in e.g., US 8,008,449, and having a sequence disclosed herein, e.g., a heavy chain sequence of SEQ ID NO: 2 and a light chain sequence of SEQ ID NO: 3 (or a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to the sequence specified).
- the inhibitor of PD-1 is Pembrolizumab disclosed in, e.g., US 8,354,509 and WO 2009/114335, and having a sequence disclosed herein, e.g., a heavy cahin sequence of SEQ ID NO: 4 and a light chain sequence of SEQ ID NO: 5 (or a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to the sequence specified).
- the inhibitor of PD-L1 is MSB0010718C (also referred to as A09-246-2) disclosed in, e.g., WO 2013/0179174, and having a sequence disclosed herein, e.g., a heavy cahin sequence of SEQ ID NO: 6 and a light chain sequence of SEQ ID NO: 7 (or a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to the sequence specified).
- the PD-1 inhibitor e.g., the anti-PD-1 antibody (e.g., the anti-PD-1 antibody (e.g., the anti-PD-1 antibody).
- Nivolumab is used in a method or composition described herein.
- the PD-1 inhibitor e.g., the anti-PD-1 antibody (e.g., Nivolumab or Pembrolizumab); or the PD-L1 inhibitor, e.g., the anti-PD-L1 antibody (e.g., MSB0010718C) (alone or in combination with other immunomodulators) is used in combination with one or more of the agents described herein, e.g., listed in Table 1, or disclosed in a publication listed in Table 1, e.g., one or more of: 1) an Inhibitor of Apoptosis (IAP) inhibitor; 2) an inhibitor of a Target of Rapamycin (TOR) kinase; 3) an inhibitor of a human homolog of mouse double minute 2 E3 ubiquitin ligase (HDM2); 4) a PIM kinase inhibitor; 5) an inhibitor of Human epidermal growth factor 3 (HER3) kinase;
- one or more of the aforesaid combinations is used to treat a disorder, e.g., a disorder described herein (e.g., a disorder disclosed in Table 1).
- one or more of the aforesaid combinations is used to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the inhibitor of the immune checkpoint molecule is used in combination with an IAP inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- an IAP inhibitor is used in combination with an IAP inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- a cancer described herein e.g., a cancer disclosed in Table 1
- the IAP inhibitor is disclosed herein, e.g., in Table 1.
- the IAP inhibitor is LCL161 as disclosed herein, or in a publication recited in Table 1.
- the IAP inhibitor is disclosed, e.g., in U.S. Patent No.8,546,336.
- LCL161 has the structure provided in Table 1, or as disclosed in the publication recited in Table 1.
- the inhibitor of the immune checkpoint molecule (e.g., one of Nivolumab, Pembrolizumab or MSB0010718C) is used in combination with LCL161 to treat a cancer or disorder described herein, e.g., in Table 1, e.g., a solid tumor, e.g., a breast cancer, colon cancer, or a pancreatic cancer; or a hematological malignancy, e.g., multiple myeloma or a hematopoeisis disorder.
- a cancer or disorder described herein e.g., in Table 1, e.g., a solid tumor, e.g., a breast cancer, colon cancer, or a pancreatic cancer; or a hematological malignancy, e.g., multiple myeloma or a hematopoeisis disorder.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with LCL161, wherein LCL161 is (S)-N-((S)-1-cyclohexyl-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2- oxoethyl)-2-(methylamino)propanamide.
- LCL161 is administered at a dose (e.g., oral dose) of about 10-3000 mg, e.g., about 20-2400 mg, about 50-1800 mg, about 100-1500 mg, about 200-1200 mg, about 300-900 mg, e.g., about 600 mg, about 900 mg, about 1200 mg, about 1500 mg, about 1800 mg, about 2100 mg, or about 2400 mg.
- LCL161 is administered once a week or once every two weeks.
- LCL161 is administered prior to administration of the immune checkpoint inhibitor (e.g., the anti-PD-1 antibody).
- the immune checkpoint inhibitor e.g., the anti-PD-1 antibody
- LCL161 can be administered one, two, three, four or five days or more before the anti-PD-1 antibody is administered.
- LCL161 is administred concurrently or substantially concurrently (e.g., on the same day) with the anti-PD-1 antibody.
- LCL161 is administered after administration of the immune checkpoint inhibitor (e.g., the anti- PD-1 antibody).
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a TOR kinase inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the TOR kinase inhibitor is disclosed herein, e.g., in Table 1.
- the TOR kinase inhibitor is Rad-001 as disclosed herein, or in a publication recited in Table 1. In certain embodiments, the TOR kinase inhibitor is disclosed, e.g., in International Patent Publication No.2014/085318. In one embodiment, Rad-001 has the structure provided in Table 1, or as disclosed in the publication recited in Table 1.
- the inhibitor of the immune checkpoint molecule (e.g., one of Nivolumab, Pembrolizumab or MSB0010718C) is used in combination with Rad-001 to treat a cancer or disorder described herein, e.g., in Table 1, e.g., a solid tumor, e.g., a sarcoma, a lung cancer (e.g., a non-small cell lung cancer (NSCLC) (e.g., a NSCLC with squamous and/or non-squamous histology)), a melanoma (e.g., an advanced melanoma), a digestive/gastrointestinal cancer, a gastric cancer, a neurologic cancer, a prostate cancer, a bladder cancer, a breast cancer; or a hematological malignancy, e.g., a lymphoma or leukemia.
- a solid tumor e.g., a sarcoma
- a lung cancer e
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with Rad-001, wherein Rad- 001 is ((1R, 9S, 12S, 15R, 16E, 18R, 19R, 21R, 23S, 24E, 26E, 28E, 30S, 32S, 35R)-1,18- dihydroxy-12- ⁇ (1R)-2-[(1S, 3R, 4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1- methylethyl ⁇ -19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza- tricyclo[30.3.1.04,9] hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone).
- the inhibitor of the immune checkpoint molecule is used in combination with a HDM2 ligase inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- a cancer e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the HDM2 ligase inhibitor is disclosed herein, e.g., in Table 1.
- the HDM2 ligase inhibitor is CGM097 as disclosed herein, or in a publication recited in Table 1.
- the HDM2 ligase inhibitor is disclosed, e.g., in International Patent Publication No.2011/076786.
- CGM097 has the structure provided herein, e.g., in Table 1, or as disclosed in the publication recited in Table 1.
- the inhibitor of the immune checkpoint molecule e.g., one of Nivolumab, Pembrolizumab or MSB0010718C
- CGM097 is used in combination with CGM097 to treat a cancer or disorder described herein, e.g., in Table 1, e.g., a solid tumor.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with CGM097, wherein CGM097 is (S)-1-(4-chlorophenyl)-7-isopropoxy-6-methoxy-2-(4- ⁇ methyl-[4-(4-methyl-3-oxo- piperazin-1-yl)-trans-cyclohexylmethyl]-amino ⁇ phenyl)-1,4-dihydro-2H-isoquinolin-3one.
- the inhibitor of the immune checkpoint molecule is used in combination with a PIM kinase inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the PIM kinase inhibitor is LGH447 (also known as PIM447) disclosed herein, e.g., in Table 1.
- the PIM kinase inhibitor is disclosed in a publication recited in Table 1.
- the PIM kinase inhibitor is disclosed, e.g., in International Patent Publication No.2010/026124, European Patent Application No. EP2344474, and U.S.
- the PIM kinase inhibitor has the structure provided in Table 1, or as disclosed in the publication recited in Table 1.
- the inhibitor of the immune checkpoint molecule e.g., one of Nivolumab,
- Pembrolizumab or MSB0010718C is used in combination with the PIM kinase inhibitor to treat a cancer or disorder described herein, e.g., in Table 1, e.g., hematological malignancy, e.g., multiple myeloma, myelodysplastic syndrome, myeloid leukemia, or non-Hodgkin's lymphoma.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with LGH447, wherein LGH447 is N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)- 5-fluoropicolinamide.
- the inhibitor of the immune checkpoint molecule is used in combination with a HER3 kinase inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the HER3 kinase inhibitor is disclosed herein, e.g., in Table 1.
- the HER3 kinase inhibitor is LJM716 as disclosed herein, or in a publication recited in Table 1.
- the HER3 kinase inhibitor is disclosed, e.g., in International Patent Publication No.2012/022814 and U.S. Patent No.8,735,551.
- LJM716 has the structure provided in Table 1, or as disclosed in the publication recited in Table 1.
- the anti-HER3 monoclonal antibody or antigen binding fragment thereof comprises a VH of SEQ ID NO: 141 and VL of SEQ ID NO: 140, as described in U.S.
- the inhibitor of the immune checkpoint molecule (e.g., one of Nivolumab, Pembrolizumab or MSB0010718C) is used in combination with LJM716 to treat a cancer or disorder described herein, e.g., in Table 1, e.g., a solid tumor, e.g. a gastric cancer, an esophageal cancer, a breast cancer, a head and neck cancer, a stomach cancer, or a
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a HDAC inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- a cancer e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the HDAC inhibitor is disclosed herein, e.g., in Table 1.
- the HDAC inhibitor is LBH589 as disclosed herein, or in a publication recited in Table 1.
- the HDAC inhibitor is disclosed, e.g., in International Patent Publication Nos. 2014/072493 and 2002/022577 and European Patent Application No. EP1870399.
- LBH589 has the structure provided in Table 1, or as disclosed in the publication recited in Table 1.
- the inhibitor of the immune checkpoint molecule e.g., one of Nivolumab, Pembrolizumab or MSB0010718C
- a cancer or disorder described herein e.g., in Table 1, e.g., a solid tumor,e.g., a bone cancer, a small cell lung cancer, a respiratory/thoracic cancer a prostate cancer, a non-small cell lung cancer (NSCLC), a nerologic cancer, a gastric cancer, a melanoma, a breast cancer, a pancreatic cancer, a colorectal cancer, a renal cancer, or a head and neck cancer, or a liver cancer; or a hematological malignancy, e.g., multiple myeloma, a hematopoeisis disorder, myelodysplastic syndrome
- NSCLC non-small cell lung cancer
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with LBH589, wherein LBH589 is (E)-N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl) acrylamide.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a Janus kinase inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the Janus kinase inhibitor is disclosed herein, e.g., in Table 1.
- the Janus kinase inhibitor is INC424 as disclosed herein, or in a publication recited in Table 1.
- the Janus kinase inhibitor is disclosed, e.g., in International Patent Publication Nos.2007/070514 and 2014/018632, European Patent Application No. EP2474545, and U.S. Patent No.7,598,257.
- INC424 has the structure provided herein, e.g., in Table 1, or as disclosed in the publication recited in Table 1.
- the inhibitor of the immune checkpoint molecule (e.g., one of Nivolumab, Pembrolizumab or MSB0010718C) is used in combination with INC424 to treat a cancer or disorder described herein, e.g., in Table 1, e.g., a solid tumor,e.g., a prostate cancer, a lung cancer, a breast cancer, a pancreatic cancer, a colorectal cancer; or a hematological malignancy, e.g., multiple myeloma, lymphoma (e.g., non-Hodgkin lymphoma), or leukemia (e.g., myeloid leukemia, lymphocytic leukemia).
- the cancer has, or is identified as having, a JAK mutation.
- the JAK mutation is a JAK2 V617F mutation.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with INC424, wherein INC424 is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo-[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1- yl]propanenitrile.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with an FGF receptor inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the FGF receptor inhibitor is disclosed herein, e.g., in Table 1.
- the FGF receptor inhibitor is BUW078 or BGJ398 as disclosed herein, or in a publication recited in Table 1.
- the FGF receptor inhibitor e.g., BUW078 or BGJ398, has the structure (compound or generic structure) provided herein, e.g., in Table 1, or as disclosed in the publication recited in Table 1.
- Pembrolizumab or MSB0010718C is used in combination with BUW078 or BGJ398 to treat a cancer described herein, e.g., in Table 1, e.g., a solid tumor, e.g., a digestive/gastrointestinal cancer; or a hematological cancer.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with BUW078, wherein BUW078 is 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- dimethylaminomethyl-1H-imidazol-2-yl)-amide.
- any of the aforesaid combinations can further include one or more of the second agents described herein below, e.g., one or more of the additional compounds shown in Table 1 (e.g., one or more of: an EGF receptor inhibitor, a c-MET inhibitor, an ALK inhibitor, a CDK4/6 inhibitor, a PI3K inhibitor, a BRAF inhibitor, a CAR T cell inhibitor, a MEK inhibitor or a BCR-ABL inhibitor as described herein).
- the additional compounds shown in Table 1 e.g., one or more of: an EGF receptor inhibitor, a c-MET inhibitor, an ALK inhibitor, a CDK4/6 inhibitor, a PI3K inhibitor, a BRAF inhibitor, a CAR T cell inhibitor, a MEK inhibitor or a BCR-ABL inhibitor as described herein.
- the PD-1 inhibitor e.g., the anti-PD-1 antibody (e.g., Nivolumab or Pembrolizumab); or the PD-L1 inhibitor, e.g., the anti-PD-L1 antibody (e.g., MSB0010718C), (alone or in combination with other immunomodulators) is used in combination with an EGF receptor inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the EGF receptor inhibitor is disclosed herein, e.g., in Table 1.
- the EGF receptor inhibitor is EGF816, or as provided herein (e.g., a publication recited in Table 1).
- the EGF receptor inhibitor e.g., EGF816, has the structure (compound or generic structure) provided herein, e.g., in Table 1, or as disclosed in the publication recited in Table 1.
- Pembrolizumab or MSB0010718C is used in combination with EGF816 to treat a cancer described herein, e.g., in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a lymphoma, or a neuroblastoma.
- a cancer described herein e.g., in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a lymphoma, or a neuroblastoma.
- NSCLC non-small cell lung cancer
- the cancer is NSCLC and is characterized by one or more of:
- the cancer is NSCLC wherein the NSCLC is characterized by harbouring an EGFR exon 20 insertion, an EGFR exon 19 deletion, EGFR L858R mutation, EGFR T790M, or any combination thereof.
- the combination is for use in the treatment of NSCLC, wherein the NSCLC is characterized by harboring an EGFR exon 20 insertion, an EGFR exon 19 deletion, EGFR L858R mutation, EGFR T790M, or any combination thereof.
- the NSCLC is characterized by harboring L858R and T790M mutations of EGFR.
- the NSCLC is characterized by harboring an EGFR exon 20 insertion and T790M mutations of EGFR.
- the NSCLC is
- the NSCLC is characterized by harboring an EGFR exon 19 deletion and T790M mutations of EGFR.
- the NSCLC is characterized by harboring EGFR mutation selected from the group consisting of an exon 20 insertion, an exon 19 deletion, L858R mutation, T790M mutation, and any combination thereof.
- the lymphoma e.g., an anaplastic large-cell lymphoma or non- Hodgkin lymphoma
- the lymphoma has, or is identified as having, an ALK translocation, e.g., an EML4-ALK fusion.
- EGF816 is administered at an oral dose of about 50 to 500 mg, e.g., about 100 mg to 400 mg, about 150 mg to 350 mg, or about 200 mg to 300 mg, e.g., about 100 mg, 150 mg or 200 mg.
- the dosing schedule can vary from e.g., every other day to daily, twice or three times a day.
- EGF816 is administered at an oral dose from about 100 to 200 mg, e.g., about 150 mg, once a day.
- EGF816 isadministered at a dose of 75, 100, 150, 225, 150, 200, 225, 300 or 350 mg. These doses may be administered once daily.
- EGF816 may be administered at a dose of 100 or 150 mg once daily.
- Nivolumab is administered in an amount from about 1 mg/kg to 5 mg/kg, e.g., 3 mg/kg, and may be administered over a period of 60 minutes, ca. once a week to once every 2, 3 or 4 weeks.
- the PD-1 inhibitor e.g., the anti-PD-1 antibody (e.g., Nivolumab or Pembrolizumab); or the PD-L1 inhibitor, e.g., the anti-PD-L1 antibody (e.g., MSB0010718C), (alone or in combination with other immunomodulators) is used in combination with a c-MET inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the c-MET inhibitor is disclosed herein, e.g., in Table 1.
- the c-MET inhibitor is INC280 (formerly known as INCB28060) as disclosed herein, or in a publication recited in Table 1.
- the c-MET inhibitor e.g., INC280, has the structure (compound or generic structure) provided herein, e.g., in Table 1, or as disclosed in the publication recited in Table 1.
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with INC280 to treat a cancer described in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), glioblastoma multiforme (GBM), a renal cancer, a liver cancer (e.g., a hepatocellular carcinoma) or a gastric cancer.
- the cancer has, or is identified as having, a c-MET mutation (e.g., a c-MET mutation or a c-MET amplification).
- INC280 is administered at an oral dose of about 100 to 1000 mg, e.g., about 200 mg to 900 mg, about 300 mg to 800 mg, or about 400 mg to 700 mg, e.g., about 400 mg, 500 mg or 600 mg.
- the dosing schedule can vary from e.g., every other day to daily, twice or three times a day.
- INC280 is administered at an oral dose from about 400 to 600 mg twice a day.
- the PD-1 inhibitor e.g., the anti-PD-1 antibody (e.g., Nivolumab or Pembrolizumab); or the PD-L1 inhibitor, e.g., the anti-PD-L1 antibody (e.g., MSB0010718C), (alone or in combination with other immunomodulators) is used in combination with an Alk inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the Alk inhibitor is disclosed herein, e.g., in Table 1.
- the Alk inhibitor is LDK378 (also known as ceritinib (Zykadia®), e.g., as described herein or in a publication recited in Table 1.
- the Alk inhibitor e.g., LDK378, has the structure (compound or generic structure) provided herein, e.g., in Table 1, or as disclosed in the publication recited in Table 1.
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with LDK378 to treat a cancer described in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a lymphoma (e.g., an anaplastic large-cell lymphoma or non-Hodgkin lymphoma), an inflammatory myofibroblastic tumor (IMT), or a neuroblastoma.
- the NSCLC is a stage IIIB or IV NSCLC, or a relapsed locally advanced or metastic NSCLC.
- the cancer e.g., the lung cancer, lymphoma, inflammatory myofibroblastic tumor, or neuroblastoma
- the ALK fusion has, or is identified as having, an ALK rearrangement or translocation, e.g., an ALK fusion.
- the ALK fusion is an EML4-ALK fusion, e.g., an EML4-ALK fusion described herein.
- the ALK fusion is an ALK-ROS1 fusion.
- the cancer has progressed on, or is resistant or tolerant to, a ROS1 inhibitor, or an ALK inhibitor, e.g., an ALK inhibitor other than LDK378.
- the cancer has progressed on, or is resistant or tolerant to, crizotinib.
- the subject is an ALK-na ⁇ ve patient, e.g., a human patient.
- the subject is a patient, e.g., a human patient, that has been pre- treated with an ALK inhibitor.
- the subject is a patient, e.g., a human patient, that has been pretreated with LDK378.
- LDK378 and Nivolumab are administered to an ALK-na ⁇ ve patient. In another embodiment, LDK378 and Nivolumab are administered to a patient that has been pretreated with an ALK inhibitor. In yet another embodiment, LDK378 and Nivolumab are administered to a patient that has been pretreated with LDK378.
- LDK378 is administered at an oral dose of about 100 to 1000 mg, e.g., about 150 mg to 900 mg, about 200 mg to 800 mg, about 300 mg to 700 mg, or about 400 mg to 600 mg, e.g., about 150 mg, 300 mg, 450 mg, 600 mg or 750 mg. In certain embodiment, LDK378 is administered at an oral dose of about 750 mg or lower, e.g., about 600 mg or lower, e.g., about 450 mg or lower. In certain embodiments, LDK378 is administered with food. In other embodiments, the dose is under fasting condition. The dosing schedule can vary from e.g., every other day to daily, twice or three times a day. In one embodiment,
- LDK378 is administered daily. In one embodiment, LDK378 is administered at an oral dose from about 150 mg to 750 mg daily, either with food or in a fasting condition. In one embodiment, LDK378 is administered at an oral dose of about 750 mg daily, in a fasting condition. In one embodiment, LDK378 is administered at an oral dose of about 750 mg daily, via capsule or tablet. In another embodiment, LDK378 is administered at an oral dose of about 600 mg daily, via capsule or tablet. In one embodiment, LDK378 is administered at an oral dose of about 450 mg daily, via capsule or tablet.
- LDK378 is administered at a dose of about 450 mg and nivolumab is administered at a dose of about 3 mg/kg. In another embodiment, the LDK378 dose is 600 mg and the nivolumab dose is 3 mg/kg. In one embodiment, LDK378 is administered with a low fat meal.
- the PD-1 inhibitor e.g., the anti-PD-1 antibody (e.g., Nivolumab or Pembrolizumab); or the PD-L1 inhibitor, e.g., the anti-PD-L1 antibody (e.g., MSB0010718C), (alone or in combination with other immunomodulators) is used in combination with a CDK4/6 inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the CDK4/6 inhibitor is disclosed herein, e.g., in Table 1.
- LEE011 also knows as Ribociclib®, e.g., as described herein or in a publication recited in Table 1.
- the CDK4/6 inhibitor e.g., LEE011
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with LEE011 to treat a cancer described in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a neurologic cancer, melanoma or a breast cancer, or a hematological malignancy, e.g., lymphoma.
- a cancer described in Table 1 e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a neurologic cancer, melanoma or a breast cancer, or a hematological malignancy, e.g., lymphoma.
- NSCLC non-small cell lung cancer
- the PD-1 inhibitor e.g., the anti-PD-1 antibody (e.g., Nivolumab or Pembrolizumab); or the PD-L1 inhibitor, e.g., the anti-PD-L1 antibody (e.g., MSB0010718C), (alone or in combination with other immunomodulators) is used in combination with a PI3K- inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the PI3K inhibitor is disclosed herein, e.g., in Table 1.
- the PI3K inhibitor is BKM120 or BYL719, e.g., disclosed herein or in a publication recited in Table 1.
- the PI3K-inhibitor e.g., BKM120 or BYL719, has the structure
- Nivolumab compound or generic structure provided herein, e.g., in Table 1, or as disclosed in the publication recited in Table 1.
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with BKM120 or BYL719 to treat a cancer or disorder described herein, e.g., in Table 1.
- the cancer or disorder is chosen from, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a prostate cancer, an endocrine cancer, an ovarian cancer, a melanoma, a bladder cancer, a female reproductive system cancer, a digestive/gastrointestinal cancer, a colorectal cancer, glioblastoma multiforme (GBM), a head and neck cancer, a gastric cancer, a pancreatic cancer or a breast cancer; or a hematological malignancy, e.g., leukemia, non-Hodgkin lymphoma; or a hematopoiesis disorder.
- a solid tumor e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a prostate cancer, an endocrine cancer, an ovarian cancer, a melanoma, a bladder cancer, a female reproductive system cancer
- the PD-1 inhibitor e.g., the anti-PD-1 antibody (e.g., Nivolumab or Pembrolizumab); or the PD-L1 inhibitor, e.g., the anti-PD-L1 antibody (e.g., MSB0010718C), (alone or in combination with other immunomodulators) is used in combination with a BRAF inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the BRAF inhibitor is disclosed herein, e.g., in Table 1.
- the BRAF inhibitor is LGX818, e.g., as described herein or in a publication recited in Table 1.
- the BRAF inhibitor e.g., LGX818, has the structure (compound or generic structure) provided herein, e.g., in Table 1, or as disclosed in the publication recited in Table 1.
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with LGX818 to treat a cancer described in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a melanoma, e.g., advanced melanoma, a thyroid cancer, e.g, papillary thyroid cancer, or a colorectal cancer.
- a cancer described in Table 1 e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a melanoma, e.g., advanced melanoma, a thyroid cancer, e.g,
- the cancer has, or is identified as having, a BRAF mutation (e.g., a BRAF V600E mutation), a BRAF wildtype, a KRAS wildtype or an activating KRAS mutation.
- a BRAF mutation e.g., a BRAF V600E mutation
- BRAF wildtype e.g., a BRAF V600E mutation
- KRAS wildtype e.g., a KRAS wildtype
- an activating KRAS mutation e.g., a BRAF V600E mutation
- the cancer may be at an early, intermediate or late stage.
- the PD-1 inhibitor e.g., the anti-PD-1 antibody (e.g., Nivolumab or Pembrolizumab); or the PD-L1 inhibitor, e.g., the anti-PD-L1 antibody (e.g., MSB0010718C), (alone or in combination with other immunomodulators) is used in combination with a CAR T cell targeting CD19 to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the CAR T cell targeting CD19 is disclosed in Table 1, e.g., CTL019, or in a publication recited in Table 1.
- the CAR T cell targeting CD19 e.g., CTL019
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with CTL019 to treat a cancer described in Table 1, e.g., a solid tumor, or a hematological malignancy, e.g., a lymphocytic leukemia or a non-Hodgkin lymphoma.
- the CAR T cell targeting CD19 has the USAN designation
- CTL019 is made by a gene modification of T cells is mediated by stable insertion via transduction with a self-inactivating, replicationdeficient Lentiviral (LV) vector containing the CTL019 transgene under the control of the EF-1 alpha promoter.
- LV Lentiviral
- CTL019 is a mixture of transgene positive and negative T cells that are delivered to the subject on the basis of percent transgene positive T cells.
- the PD-1 inhibitor e.g., the anti-PD-1 antibody (e.g., Nivolumab or Pembrolizumab); or the PD-L1 inhibitor, e.g., the anti-PD-L1 antibody (e.g., MSB0010718C), (alone or in combination with other immunomodulators) is used in combination with a MEK inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the MEK inhibitor is disclosed herein, e.g., in Table 1.
- the MEK inhibitor is MEK162, e.g., disclosed herein or in a publication recited in Table 1.
- the MEK inhibitor e.g., MEK162
- the structure e.g., in Table 1, or as disclosed in the publication recited in Table 1.
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in
- the cancer or disorder treated with the combination is chosen from a melanoma, a colorectal cancer, a non-small cell lung cancer, an ovarian cancer, a breast cancer, a prostate cancer, a pancreatic cancer, a hematological malignancy or a renal cell carcinoma, a multisystem genetic disorder, a digestive/gastrointestinal cancer, a gastric cancer, or a colorectal cancer; or rheumatoid arthritis.
- the cancer has, or is identified as having, a KRAS mutation.
- the PD-1 inhibitor e.g., the anti-PD-1 antibody (e.g., Nivolumab or Pembrolizumab); or the PD-L1 inhibitor, e.g., the anti-PD-L1 antibody (e.g., MSB0010718C), (alone or in combination with other immunomodulators) is used in combination with a BCR- ABL inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the BCR-ABL inhibitor is disclosed herein, e.g., in Table 1.
- the BCR-ABL inhibitor is AMN-107 (also known as Nilotinib, trade name
- AMN- 107 has the structure (compound or generic structure) provided herein, e.g., in Table 1, or as disclosed in the publication recited in Table 1.
- Pembrolizumab or MSB0010718C is used in combination with AMN-107 to treat a cancer or disorder described in Table 1, e.g., a solid tumor, e.g., a neurologic cancer, a melanoma, a digestive/gastrointestinal cancer, a colorectal cancer, a head and neck cancer; or a hematological malignancy, e.g., chronic myelogenous leukemia (CML), a lymphocytic leukemia, a myeloid leukemia; Parkinson's disease; or pulmonary hypertension.
- CML chronic myelogenous leukemia
- a lymphocytic leukemia a myeloid leukemia
- Parkinson's disease or pulmonary hypertension.
- the proliferative disorder or condition includes but is not limited to, a solid tumor, a soft tissue tumor (e.g., a hematological cancer, leukemia, lymphoma, or myeloma), and a metastatic lesion of any of the aforesaid cancers.
- the cancer is a solid tumor.
- solid tumors include malignancies, e.g., sarcomas, adenocarcinomas, and carcinomas, of the various organ systems, such as those affecting the lung, breast, ovarian, lymphoid, gastrointestinal (e.g., colon), anal, genitals and genitourinary tract (e.g., renal, urothelial, bladder cells, prostate), pharynx, CNS (e.g., brain, neural or glial cells), head and neck, skin (e.g., melanoma), and pancreas, as well as adenocarcinomas which include
- malignancies such as colon cancers, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell lung cancer, cancer of the small intestine and cancer of the esophagus.
- the cancer may be at an early, intermediate, late stage or metastatic cancer.
- the cancer is chosen from a cancer disclosed in Table 1.
- the cancer can be chosen from a solid tumor, e.g., a lung cancer (e.g., a non-small cell lung cancer (NSCLC) (e.g., a NSCLC with squamous and/or non-squamous histology)), a colorectal cancer, a melanoma (e.g., an advanced melanoma), a head and neck cancer (e.g., head and neck squamous cell carcinoma (HNSCC), a digestive/gastrointestinal cancer, a gastric cancer, a neurologic cancer, a glioblastoma (e.g., glioblastoma multiforme), an ovarian cancer, a renal cancer, a liver cancer, a pancreatic cancer, a prostate cancer, a liver cancer; a breast cancer, an anal cancer, a gastro-esophageal cancer, a thyroid cancer, a cervical cancer;
- hematological cancer e.g., chosen from a Hogdkin lymphoma, a non-Hodgkin lymphoma, a lymphocytic leukemia, or a myeloid leukemia.
- the cancer is a colon cancer, e.g., a colon cancer that expresses an IAP, e.g., a human IAP.
- the human IAP family includes, e.g., NAIP, XIAP, cIAP1, cIAP2, ILP2, BRUCE, surviving, and livin.
- the cancer is a non-small cell lung cancer (NSCLC), e.g., an ALK+ NSCLC.
- NSCLC non-small cell lung cancer
- the term“ALK+ non-small cell lung cancer” or“ALK+ NSCLC” refers to an NSCLC that has an activated (e.g., constitutively activated) anaplastic lymphoma kinase activity or has a rearrangement or translocation of an Anaplastic Lymphoma Kinase (ALK) gene.
- ALK Anaplastic Lymphoma Kinase
- patients with ALK+ NSCLC are generally younger, have light (e.g., ⁇ 10 pack years) or no smoking history, present with lower Eastern Cooperative Oncology Group performance status, or may have more aggressive disease and, therefore, experience earlier disease progression (Shaw et al. J Clin Oncol.2009; 27(26):4247-4253; Sasaki et al. Eur J Cancer.2010; 46(10):1773-1780; Shaw et al. N Engl J Med.2013;368(25):2385-2394; Socinski et al. J Clin Oncol.2012; 30(17):2055- 2062 ; Yang et al. J Thorac Oncol.2012;7(1):90–97).
- the cancer e.g., an NSCLC
- the rearrangement or translocation of the ALK gene leads to a fusion (e.g., fusion upstream of the ALK promoter region).
- the fusion results in constitutive activation of the kinase activity.
- the fusion is an EML4-ALK fusion.
- EML4-ALK fusion proteins include, but are not limited to, E13;A20 (V1), E20;A20 (V2), E6a/b;A20 (V3a/b), E14;A20 (V4), E2a/b;A20 (V5a/b), E13b;A20 (V6), E14;A20(V7), E15;A20(“V4”), or E18;A20 (V5) (Choi et al. Cancer Res.2008; 68(13):4971-6; Horn et al. J Clin Oncol.2009; 27(26):4232- 5; Koivunen et al. Clin Cancer Res.2008; 14(13):4275-83; Soda et al. Nature.2007;
- the ALK gene is fused to a non-EML4 partner.
- the fusion is a KIF5B-ALK fusion.
- the fusion is a TFG- ALK fusion. Exemplary KIF5B-ALK and TFG-ALK fusions are described, e.g., in Takeuchi et al. Clin Cancer Res.2009; 15(9):3143-9, Rikova et al. Cell.2007; 131(6):1190-203.
- ALK gene rearrangements or translocations, or cancer cells that has an ALK gene rearrangement or translocation can be detected, e.g., using fluorescence in situ hybridization (FISH), e.g., with an ALK break apart probe.
- FISH fluorescence in situ hybridization
- the subject is a mammal, e.g., a primate, preferably a higher primate, e.g., a human (e.g., a patient having, or at risk of having, a disorder described herein).
- the subject is in need of enhancing an immune response.
- the subject has, or is at risk of, having a disorder described herein, e.g., a cancer as described herein.
- the subject is, or is at risk of being,
- the subject is undergoing or has undergone a
- chemotherapeutic treatment and/or radiation therapy Alternatively, or in combination, the subject is, or is at risk of being, immunocompromised as a result of an infection.
- the subject e.g., a subject having a lung cancer (e.g., a non-small cell lung cancer), a lymphoma (e.g., an anaplastic large-cell lymphoma or non-Hodgkin lymphoma), an inflammatory myofibroblastic tumor, or a neuroblastoma) is being treated, or has been treated, with another ALK inhibitor and/or a ROS1 inhibitor, e.g., crizotinib.
- crizotinib can be administered at a daily oral dose of 750 mg or lower, e.g., 600 mg or lower, e.g., 450 mg or lower.
- the subject or cancer e.g., a lung cancer (e.g., a non-small cell lung cancer), a lymphoma (e.g., an anaplastic large-cell lymphoma or non-Hodgkin lymphoma), an inflammatory myofibroblastic tumor, or a neuroblastoma) has progressed on, or is resistant or tolerant to, another ALK inhibitor and/or a ROS1 inhibitor, e.g., crizotinib.
- a lung cancer e.g., a non-small cell lung cancer
- a lymphoma e.g., an anaplastic large-cell lymphoma or non-Hodgkin lymphoma
- an inflammatory myofibroblastic tumor e.g., a neuroblastoma
- a neuroblastoma e.g., crizotinib.
- the subject or cancer e.g., a lung cancer (e.g., a non-small cell lung cancer), a lymphoma (e.g., an anaplastic large-cell lymphoma or non-Hodgkin lymphoma), an inflammatory myofibroblastic tumor, or a neuroblastoma) is at risk of progression on, or developing resistance or tolerance to, another ALK inhibitor and/or a ROS1 inhibitor, e.g., crizotinib.
- a lung cancer e.g., a non-small cell lung cancer
- a lymphoma e.g., an anaplastic large-cell lymphoma or non-Hodgkin lymphoma
- an inflammatory myofibroblastic tumor e.g., a neuroblastoma
- a neuroblastoma e.g., crizotinib.
- the subject or cancer is resistant or tolerant, or is at risk of developing resistance or tolerance, to a tyrosine kinase inhibitor (TKI), e.g., an EGFR tyrosine kinase inhibitor.
- TKI tyrosine kinase inhibitor
- the subject or cancer has no detectable EGFR mutation, KRAS mutation, or both.
- the subject has previously been treated with PD-1.
- the subject has or is identified as having a tumor that has one or more of high PD-L1 level or expression and/or Tumor Infiltrating Lymphocyte (TIL)+.
- TIL Tumor Infiltrating Lymphocyte
- the subject has or is identified as having a tumor that has high PD-L1 level or expression and TIL+.
- the methods described herein further describe identifying a subject based on having a tumor that has one or more of high PD-L1 level or expression and/or TIL+.
- the methods described herein further describe identifying a subject based on having a tumor that has high PD-L1 level or expression and TIL+.
- tumors that are TIL+ are positive for CD8 and IFN ⁇ .
- the subject has or is identified as having a high percentage of cells that are positive for one or more of PD-L1, CD8, and/or IFN ⁇ . In certain embodiments, the subject has or is identified as having a high percentage of cells that are positive for all of PD-L1, CD8, and IFN ⁇ .
- the methods described herein further describe identifying a subject based on having a high percentage of cells that are positive for one or more of PD-L1, CD8, and/or IFN ⁇ . In certain embodiments, the methods described herein further describe identifying a subject based on having a high percentage of cells that are positive for all of PD-L1, CD8, and IFN ⁇ .
- the subject has or is identified as having one or more of PD-L1, CD8, and/or IFN ⁇ , and one or more of a lung cancer, e.g., squamous cell lung cancer or lung adenocarcinoma; a head and neck cancer; a squamous cell cervical cancer; a stomach cancer; a thyroid cancer; and/or a melanoma.
- a lung cancer e.g., squamous cell lung cancer or lung adenocarcinoma
- a head and neck cancer e.g., squamous cell lung cancer or lung adenocarcinoma
- a head and neck cancer e.g., squamous cell lung cancer or lung adenocarcinoma
- a head and neck cancer e.g., squamous cell cervical cancer or lung adenocarcinoma
- a stomach cancer e.g., a squamous cell cervical cancer
- a thyroid cancer
- the methods described herein further describe identifying a subject based on having one or more of PD-L1, CD8, and/or IFN ⁇ , and one or more of a lung cancer, e.g., squamous cell lung cancer or lung adenocarcinoma; a head and neck cancer; a squamous cell cervical cancer; a stomach cancer; a thyroid cancer;
- a lung cancer e.g., squamous cell lung cancer or lung adenocarcinoma
- a head and neck cancer e.g., squamous cell lung cancer or lung adenocarcinoma
- a head and neck cancer e.g., squamous cell lung cancer or lung adenocarcinoma
- a head and neck cancer e.g., squamous cell lung cancer or lung adenocarcinoma
- a head and neck cancer e.g., squamous cell cervical cancer or adenocarcinoma
- Dosages and therapeutic regimens of the agents described herein can be determined by a skilled artisan.
- the anti-PD-1 antibody molecule is administered by injection (e.g., subcutaneously or intravenously) at a dose of about 1 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg.
- the dosing schedule can vary from e.g., once a week to once every 2, 3, or 4 weeks.
- the anti-PD-1 antibody molecule is administered at a dose from about 10 to 20 mg/kg every other week.
- the anti-PD-1 antibody molecule e.g., Nivolumab
- the anti-PD-1 antibody molecule e.g., Nivolumab
- Nivolumab is administered in an amount from about 1 mg/kg to 5 mg/kg, e.g., 3 mg/kg, and may be administered over a period of 60 minutes, ca. once a week to once every 2, 3 or 4 weeks.
- the combination therapies described herein can be administered to the subject systemically (e.g., orally, parenterally, subcutaneously, intravenously, rectally, intramuscularly, intraperitoneally, intranasally, transdermally, or by inhalation or intracavitary installation), topically, or by application to mucous membranes, such as the nose, throat and bronchial tubes.
- the anti-PD-1 antibody molecule is administered intravenously.
- one or more of the agents listed in Table 1, e.g., an IAP inhibitor or LCL161 is administered orally.
- the anti-PD-1 antibody molecule is administered, e.g., intravenously, at least one, two, three, four, five, six, or seven days, e.g., three days, after an agent listed in Table 1, e.g., an IAP inhibitor or LCL161, is administered, e.g., orally.
- the anti-PD-1 antibody molecule is administered, e.g., intravenously, at least one, two, three, four, five, six, or seven days, e.g., three days, before an agent listed in Table 1, e.g., an IAP inhibitor or LCL161, is administered, e.g., orally.
- the anti-PD-1 antibody molecule is administered, e.g., intravenously, on the same day, as the one or more agents listed in Table 1, e.g., an IAP inhibitor or LCL161, is administered, e.g., orally.
- the administration of the anti-PD-1 antibody molecule and one or more of the agents listed in Table 1, e.g., an IAP inhibitor or LCL161 results in an enhanced reduction of a solid tumor, e.g., colon cancer, , relative to administration of each of these agents as a monotherapy.
- the concentration of an agent listed in Table 1, e.g., an IAP inhibitor or LCL161, that is required to achieve inhibition, e.g., growth inhibition is lower than the therapeutic dose of the agent as a monotherapy, e.g., 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, or 80-90% lower.
- the concentration of the anti-PD-1 antibody molecule that is required to achieve inhibition, e.g., growth inhibition, is lower than the therapeutic dose of the anti-PD-1 antibody molecule as a monotherapy, e.g., 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, or 80-90% lower.
- the methods and compositions described herein can be used in combination with further agents or therapeutic modalities.
- the combination therapies can be administered simultaneously or sequentially in any order. Any combination and sequence of the anti-PD-1 or PD-L1 antibody molecules and other therapeutic agents, procedures or modalities (e.g., as described herein) can be used.
- the combination therapies can be administered during periods of active disorder, or during a period of remission or less active disease.
- the combination therapies can be administered before the other treatment, concurrently with the treatment, post-treatment, or during remission of the disorder.
- the methods and compositions described herein are administered in combination with one or more of other antibody molecules, chemotherapy, other anti-cancer therapy (e.g., targeted anti-cancer therapies, gene therapy, viral therapy, RNA therapy bone marrow transplantation, nanotherapy, or oncolytic drugs), cytotoxic agents, immune-based therapies (e.g., cytokines or cell-based immune therapies), surgical procedures (e.g., lumpectomy or mastectomy) or radiation procedures, or a combination of any of the foregoing.
- the additional therapy may be in the form of adjuvant or neoadjuvant therapy.
- the additional therapy is an enzymatic inhibitor (e.g., a small molecule enzymatic inhibitor) or a metastatic inhibitor.
- exemplary cytotoxic agents that can be administered in combination with include antimicrotubule agents, topoisomerase inhibitors, anti-metabolites, mitotic inhibitors, alkylating agents, anthracyclines, vinca alkaloids, intercalating agents, agents capable of interfering with a signal transduction pathway, agents that promote apoptosis, proteosome inhibitors, and radiation (e.g., local or whole body irradiation (e.g., gamma irradiation).
- the additional therapy is surgery or radiation, or a combination thereof.
- the additional therapy is a therapy targeting an mTOR pathway, an HSP90 inhibitor, or a tubulin inhibitor.
- the methods and compositions described herein can be administered in combination with one or more of: a vaccine, e.g., a therapeutic cancer vaccine; or other forms of cellular immunotherapy.
- the combination therapy is used in combination with one, two or all of oxaliplatin, leucovorin or 5-FU (e.g., a FOLFOX co-treatment).
- combination further includes a VEGF inhibitor (e.g., a VEGF inhibitor as disclosed herein).
- the cancer treated with the combination is chosen from a melanoma, a colorectal cancer, a non-small cell lung cancer, an ovarian cancer, a breast cancer, a prostate cancer, a pancreatic cancer, a hematological malignancy or a renal cell carcinoma.
- the cancer may be at an early, intermediate or late stage.
- the combination therapy is administered with a tyrosine kinase inhibitor (e.g., axitinib) to treat renal cell carcinoma and other solid tumors.
- a tyrosine kinase inhibitor e.g., axitinib
- the combination therapy is administered with a 4-1BB receptor targeting agent (e.g., an antibody that stimulates signaling through 4-1BB (CD-137), e.g., PF- 2566).
- a 4-1BB receptor targeting agent e.g., an antibody that stimulates signaling through 4-1BB (CD-137), e.g., PF- 2566.
- the combination therapy is administered in combination with a tyrosine kinase inhibitor (e.g., axitinib) and a 4-1BB receptor targeting agent.
- FIG. 1 shows a graphical representation of flow cytometry of PD-L1 surface expression in EBC-1 cells in vitro with or without INC280 treatment.
- EBC-1 cells are non-small cell lung cancer cells with a cMET amplification.
- Figure 2 shows a graphical representation of PD-L1 mRNA expression in Hs.746.T cells in a tumor xenograft model with or without INC280 treatment.
- Hs.746.T cells are gastric cancer cells with a c-MET amplification and a c-MET mutation.
- FIG. 3 shows a graphical representation of PD-L1 mRNA expression in H3122 cells in vitro with or without LDK378.
- H3122 cells are non-small cell lung cancer (NSCLC) cells with an ALK translocation.
- NSCLC non-small cell lung cancer
- Figure 4 shows a graphical representation of PD-L1 mRNA expression in LOXIMV1 cells (BRAF mutant melanoma cells) in a tumor xenograft model with or without LGX818 treatment.
- Figure 5 shows a graphical representation of PD-L1 mRNA expression in HEYA8 cells (KRAS mutant ovarian cancer cells) in a tumor xenograft model with or without MEK162 treatment.
- Figure 6 shows a graphical representation of PD-L1 mRNA expression in UKE-1 cells (JAK2 V617F mutant myeloproliferative neoplasm cells) in a tumor xenograft model with or without INC424 treatment.
- Figure 7A shows a graphical representation of IFN- ⁇ production in unstimulated PBMCs or stimulated PBMCs treated with different concentrations of LCL161 or DMSO control.
- Figure 7B shows a graphical representation of IL-10 production in unstimulated PBMCs or stimulated PBMCs treated with different concentrations of LCL161 or DMSO control.
- Figure 8A shows a graphical representation of FACS analysis of CD4+ T cells from unstimulated PBMCs or PMBCs stimulated in the presence of different concentrations of LCL161 or DMSO control.
- Figure 8B shows a graphical representation of FACS analysis of CD8+ T cells from unstimulated PBMCs or PMBCs stimulated in the presence of different concentrations of LCL161 or DMSO control.
- Figure 9 shows a graphical representation of CyTOF mass cytometry of unstimulated PBMCs or stimulated PBMCs treated with LCL161 or DMSO control.
- Figure 10A shows a graphical representation of expression signatures related to T cells from mice implanted with MC38 cells. The mice were treated with LCL161, anti-mouse PD-1, or both. In the control group, mice were dosed with vehicle and isotype (mIgG1).
- Figure 10B shows a graphical representation of expression signatures related to dendritic cells from mice implanted with MC38 cells. The mice were treated with LCL161, anti-mouse PD-1, or both. In the control group, mice were dosed with vehicle and isotype (mIgG1).
- Figure 10C shows a graphical representation of expression signatures related to macrophages from mice implanted with MC38 cells.
- the mice were treated with LCL161, anti- mouse PD-1, or both.
- mice were dosed with vehicle and isotype (mIgG1).
- Figure 10D shows a graphical representation of chemokine expression signatures from mice implanted with MC38 cells.
- the mice were treated with LCL161, anti-mouse PD-1, or both.
- mice were dosed with vehicle and isotype (mIgG1).
- Figure 11A shows an exemplary treatment schedule and a graphical representation of tumor volumes in mice implanted with MC38 cells.
- the mice were treated with LCL161, anti- mouse PD-1, or both.
- anti-mouse PD-1 was administered three days after LCL161 was administered.
- mice were dosed with vehicle and isotype (mIgG1).
- Figure 11B shows another exemplary treatment schedule and a graphical representation of tumor volumes in mice implanted with MC38 cells.
- the mice were treated with LCL161, anti-mouse PD-1, or both.
- LCL161 and anti-mouse PD-1 were administered concurrently.
- mice were dosed with vehicle and isotype (mIgG1).
- Figure 12 is a representation of the sequence of drug administration for patients enrolled in the Phase II trial that will be treated with EGF816 and Nivolumab. BRIEF DESCRIPTION OF THE TABLE
- Table 1 is a summary of selected therapeutic agents that can be administered in combination with the immunomodulators (e.g., one or more of: an activator of a costimulatory molecule and/or an inhibitor of an immune checkpoint molecule) described herein.
- Table 1 provides from left to right the following: the Name and/or Designation of the second therapeutic agent, the Compound structure, a Patent publication disclosing the Compound, Exemplary Indications/Uses, and Generic structure.
- Table 2 shows the trial objectives and related endpoints in a phase II, multicenter, open- label study of EGF816 in combination with nivolumab in adult patients with EGFR mutated non- small cell lung cancer.
- Table 3 shows the dose and treatment schedule in a phase II, multicenter, open-label study of EGF816 in combination with nivolumab in adult patients with EGFR mutated non-small cell lung cancer.
- compositions which comprise an immunomodulator (e.g., one or more of: an activator of a costimulatory molecule and/or an inhibitor of an immune checkpoint molecule) in combination with a second therapeutic agent chosen from one or more of the agents listed in Table 1.
- an immunomodulator e.g., one or more of: an activator of a costimulatory molecule and/or an inhibitor of an immune checkpoint molecule
- a second therapeutic agent chosen from one or more of the agents listed in Table 1.
- Immune therapy alone can be effective in a number of indications (e.g., melanoma). However, for most patients, it is not a cure.
- an inhibitor of an immune checkpoint molecule e.g., one or more of inhibitors to PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3 and/or -5) or CTLA-4) can be combined with a second therapeutic agent chosen from one or more of the agents listed in Table 1 (e.g., chosen from one or more of: 1) an IAP inhibitor; 2) a TOR kinase inhibitor; 3) a HDM2 ligase inhibitor; 4) a PIM kinase inhibitor; 5) a HER3 kinase inhibitor; 6) a Histone Deacetylase (HDAC) inhibitor; 7) a Janus kinase inhibitor; 8) an FGF receptor inhibitor; 9) an EGF receptor inhibitor; 10) a c-MET inhibitor; 11) an ALK inhibitor; 12) a CDK4/6-inhibitor; 13) a PI3K inhibitor; 14) a BRAF
- the combinations described herein can provide a beneficial effect, e.g., in the treatment of a cancer, such as an enhanced anti-cancer effect, reduced toxicity and/or reduced side effects.
- the immunomodulator, the second therapeutic agent, or both can be administered at a lower dosage than would be required to achieve the same therapeutic effect compared to a monotherapy dose.
- inhibitortion includes a reduction in a certain parameter, e.g., an activity, of a given molecule, e.g., an immune checkpoint inhibitor.
- a certain parameter e.g., an activity, of a given molecule
- an immune checkpoint inhibitor e.g., an enzyme that catalyzes the production of a protein
- inhibition of an activity e.g., an activity of, e.g., PD-1, PD-L1, c-MET, ALK, CDK4/6, PI3K, BRAF, FGFR, MET or BCR-ABL, of at least 5%, 10%, 20%, 30%, 40% or more is included by this term.
- the term“Programmed Death 1” or“PD-1” include isoforms, mammalian, e.g., human PD-1, species homologs of human PD-1, and analogs comprising at least one common epitope with PD-1.
- the amino acid sequence of PD-1, e.g., human PD-1 is known in the art, e.g., Shinohara T et al. (1994) Genomics 23(3):704-6; Finger LR, et al. Gene (1997) 197(1-2):177-87.
- or“PD-Ligand 1” or“PD-L1” include isoforms, mammalian, e.g., human PD-1, species homologs of human PD-L1, and analogs comprising at least one common epitope with PD-L1.
- the amino acid sequence of PD-L1, e.g., human PD-L1 is known in the art
- “Lymphocyte Activation Gene-3” or“LAG-3” include all isoforms
- LAG-3 mammalian, e.g., human LAG-3, species homologs of human LAG-3, and analogs comprising at least one common epitope with LAG-3.
- the amino acid and nucleotide sequences of LAG-3, e.g., human LAG-3, is known in the art, e.g., Triebel et al. (1990) J. Exp. Med.171:1393-1405.
- TIM-3 refers to a transmembrane receptor protein that is expressed on Th1 (T helper 1) cells. TIM-3 has a role in regulating immunity and tolerance in vivo (see Hastings et al., Eur J Immunol.2009 Sep;39(9):2492-501).
- CEACAM Carcinoembryonic Antigen-related Cell Adhesion Molecule
- CEACAM includes all family members (e.g., CEACAM-1, CEACAM-3, or CEACAM-5), isoforms, mammalian, e.g., human CEACAM, species homologs of human CEACAM, and analogs comprising at least one common epitope with CEACAM.
- CEACAM e.g., human CEACAM
- the articles “a” and “an” refer to one or to more than one (e.g., to at least one) of the grammatical object of the article.
- “About” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given value or range of values.
- compositions and methods of the present invention encompass polypeptides and nucleic acids having the sequences specified, or sequences substantially identical or similar thereto, e.g., sequences at least 85%, 90%, 95% identical or higher to the sequence specified.
- substantially identical is used herein to refer to a first amino acid that contains a sufficient or minimum number of amino acid residues that are i) identical to, or ii) conservative substitutions of aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structural domain and/or common functional activity.
- amino acid sequences that contain a common structural domain having at least about 85%, 90%.91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, e.g., a sequence provided herein.
- nucleotide sequence in the context of nucleotide sequence, the term "substantially identical" is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity.
- “functional variant” refers polypeptides that have a substantially identical amino acid sequence to the naturally-occurring sequence, or are encoded by a substantially identical nucleotide sequence, and are capable of having one or more activities of the naturally-occurring sequence.
- the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
- the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence.
- the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
- amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”
- the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
- the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
- the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol.48:444-453 ) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
- the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.
- a particularly preferred set of parameters are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
- the percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- nucleic acid and protein sequences described herein can be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and
- BLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol.215:403-10.
- Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res.25:3389-3402.
- the default parameters of the respective programs e.g., XBLAST and
- NBLAST NBLAST
- hybridizes under low stringency, medium stringency, high stringency, or very high stringency conditions describes conditions for hybridization and washing.
- Guidance for performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6, which is incorporated by reference. Aqueous and nonaqueous methods are described in that reference and either can be used.
- Specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by two washes in 0.2X SSC, 0.1% SDS at least at 50°C (the temperature of the washes can be increased to 55°C for low stringency conditions); 2) medium stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C; 3) high stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C; and preferably 4) very high stringency hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C. Very high stringency conditions (4) are the preferred conditions and the ones that should be used unless otherwise specified.
- molecules of the present invention may have additional conservative or non-essential amino acid substitutions, which do not have a substantial effect on their functions.
- amino acid is intended to embrace all molecules, whether natural or synthetic, which include both an amino functionality and an acid functionality and capable of being included in a polymer of naturally-occurring amino acids.
- exemplary amino acids include naturally-occurring amino acids; analogs, derivatives and congeners thereof; amino acid analogs having variant side chains; and all stereoisomers of any of any of the foregoing.
- amino acid includes both the D- or L- optical isomers and peptidomimetics.
- a "conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
- amino acids with basic side chains e.g., lysine, arginine, histidine
- acidic side chains e.g., aspartic acid, glutamic acid
- uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
- nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
- beta-branched side chains e.g., threonine, valine, isoleucine
- aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine
- polymers of amino acids of any length may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non- amino acids.
- the terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.
- the polypeptide can be isolated from natural sources, can be a produced by recombinant techniques from a eukaryotic or prokaryotic host, or can be a product of synthetic procedures.
- nucleic acid refers to any organic acid sequence.
- nucleotide sequence refers to any organic acid sequence.
- polynucleotide sequence and “polynucleotide” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof.
- the polynucleotide may be either single-stranded or double-stranded, and if single-stranded may be the coding strand or non-coding (antisense) strand.
- a polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs.
- the sequence of nucleotides may be interrupted by non-nucleotide components.
- a polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.
- the nucleic acid may be a recombinant polynucleotide, or a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in a nonnatural arrangement.
- isolated refers to material that is removed from its original or native environment (e.g., the natural environment if it is naturally occurring).
- a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated by human intervention from some or all of the co-existing materials in the natural system, is isolated.
- Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of the environment in which it is found in nature.
- the antibody molecule binds to a mammalian, e.g., human, checkpoint molecule, e.g., PD-1, PD-L1, LAG-3, CEACAM (e.g., CEACAM-1, -3 and/or -5) or TIM-3.
- checkpoint molecule e.g., PD-1, PD-L1, LAG-3, CEACAM (e.g., CEACAM-1, -3 and/or -5) or TIM-3.
- the antibody molecule binds specifically to an epitope, e.g., linear or conformational epitope, (e.g., an epitope as described herein) on PD-1, PD-L1, LAG-3,
- CEACAM e.g., CEACAM-1, -3 and/or -5) or TIM-3.
- antibody molecule refers to a protein comprising at least one immunoglobulin variable domain sequence.
- the term antibody molecule includes, for example, full-length, mature antibodies and antigen-binding fragments of an antibody.
- an antibody molecule can include a heavy (H) chain variable domain sequence (abbreviated herein as VH), and a light (L) chain variable domain sequence (abbreviated herein as VL).
- an antibody molecule in another example, includes two heavy (H) chain variable domain sequences and two light (L) chain variable domain sequence, thereby forming two antigen binding sites, such as Fab, Fab’, F(ab’) 2 , Fc, Fd, Fd’, Fv, single chain antibodies (scFv for example), single variable domain antibodies, diabodies (Dab) (bivalent and bispecific), and chimeric (e.g., humanized) antibodies, which may be produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies. These functional antibody fragments retain the ability to selectively bind with their respective antigen or receptor.
- Antibodies and antibody fragments can be from any class of antibodies including, but not limited to, IgG, IgA, IgM, IgD, and IgE, and from any subclass (e.g., IgG1, IgG2, IgG3, and IgG4) of antibodies.
- the antibodies of the present invention can be monoclonal or polyclonal.
- the antibody can also be a human, humanized, CDR-grafted, or in vitro generated antibody.
- the antibody can have a heavy chain constant region chosen from, e.g., IgG1, IgG2, IgG3, or IgG4.
- the antibody can also have a light chain chosen from, e.g., kappa or lambda.
- antigen-binding fragments include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a diabody (dAb) fragment, which consists of a VH domain; (vi) a camelid or camelized variable domain; (vii) a single chain Fv (scFv), see e.g., Bird et al.
- a Fab fragment a monovalent fragment consisting of the VL, VH, CL and CH1 domains
- a F(ab')2 fragment a bivalent fragment comprising two Fab fragments linked by a
- antibody includes intact molecules as well as functional fragments thereof. Constant regions of the antibodies can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody
- glycosylation the number of cysteine residues, effector cell function, or complement function.
- Antibody molecules can also be single domain antibodies.
- Single domain antibodies can include antibodies whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies.
- Single domain antibodies may be any of the art, or any future single domain antibodies.
- Single domain antibodies may be derived from any species including, but not limited to mouse, human, camel, llama, fish, shark, goat, rabbit, and bovine.
- a single domain antibody is a naturally occurring single domain antibody known as heavy chain antibody devoid of light chains. Such single domain antibodies are disclosed in WO 9404678, for example.
- variable domain derived from a heavy chain antibody naturally devoid of light chain is known herein as a VHH or nanobody to distinguish it from the conventional VH of four chain immunoglobulins.
- a VHH molecule can be derived from antibodies raised in Camelidae species, for example in camel, llama, dromedary, alpaca and guanaco. Other species besides Camelidae may produce heavy chain antibodies naturally devoid of light chain; such VHHs are within the scope of the invention.
- the VH and VL regions can be subdivided into regions of hypervariability, termed “complementarity determining regions" (CDR), interspersed with regions that are more conserved, termed "framework regions" (FR or FW).
- CDR complementarity determining regions
- CDR complementarity determining region
- HCDR1, HCDR2, HCDR3 three CDRs in each heavy chain variable region
- LCDR1, LCDR2, LCDR3 three CDRs in each light chain variable region
- the precise amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme). As used herein, the CDRs defined according the “Chothia” number scheme are also sometimes referred to as“hypervariable loops.”
- the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3); and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3).
- the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3); and the amino acid residues in VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3).
- an“immunoglobulin variable domain sequence” refers to an amino acid sequence which can form the structure of an immunoglobulin variable domain.
- the sequence may include all or part of the amino acid sequence of a naturally-occurring variable domain.
- the sequence may or may not include one, two, or more N- or C-terminal amino acids, or may include other alterations that are compatible with formation of the protein structure.
- antigen-binding site refers to the part of an antibody molecule that comprises determinants that form an interface that binds to the PD-1 polypeptide, or an epitope thereof.
- the antigen-binding site typically includes one or more loops (of at least four amino acids or amino acid mimics) that form an interface that binds to the PD-1 polypeptide.
- the antigen-binding site of an antibody molecule includes at least one or two CDRs and/or hypervariable loops, or more typically at least three, four, five or six CDRs and/or hypervariable loops.
- monoclonal antibody or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition.
- a monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.
- a monoclonal antibody can be made by hybridoma technology or by methods that do not use hybridoma technology (e.g., recombinant methods).
- An“effectively human” protein is a protein that does not evoke a neutralizing antibody response, e.g., the human anti-murine antibody (HAMA) response.
- HAMA can be problematic in a number of circumstances, e.g., if the antibody molecule is administered repeatedly, e.g., in treatment of a chronic or recurrent disease condition.
- a HAMA response can make repeated antibody administration potentially ineffective because of an increased antibody clearance from the serum (see, e.g., Saleh et al., Cancer Immunol. Immunother., 32:180-190 (1990)) and also because of potential allergic reactions (see, e.g., LoBuglio et al., Hybridoma, 5:5117-5123 (1986)).
- the antibody molecule can be a polyclonal or a monoclonal antibody.
- the antibody can be recombinantly produced, e.g., produced by phage display or by combinatorial methods.
- Phage display and combinatorial methods for generating antibodies are known in the art (as described in, e.g., Ladner et al. U.S. Patent No.5,223,409; Kang et al. International Publication No. WO 92/18619; Dower et al. International Publication No. WO 91/17271; Winter et al. International Publication WO 92/20791; Markland et al. International Publication No. WO 92/15679; Breitling et al. International Publication WO 93/01288; McCafferty et al.
- the antibody is a fully human antibody (e.g., an antibody made in a mouse which has been genetically engineered to produce an antibody from a human
- a non-human antibody e.g., a rodent (mouse or rat), goat, primate (e.g., monkey), camel antibody.
- the non-human antibody is a rodent (mouse or rat antibody).
- Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al.
- An antibody can be one in which the variable region, or a portion thereof, e.g., the CDRs, are generated in a non-human organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and humanized antibodies are within the invention. Antibodies generated in a non-human organism, e.g., a rat or mouse, and then modified, e.g., in the variable framework or constant region, to decrease antigenicity in a human are within the invention.
- Chimeric antibodies can be produced by recombinant DNA techniques known in the art (see Robinson et al., International Patent Publication PCT/US86/02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., International Application WO 86/01533; Cabilly et al. U.S. Patent No.4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988 Science 240:1041-1043); Liu et al.
- a humanized or CDR-grafted antibody will have at least one or two but generally all three recipient CDRs (of heavy and or light immuoglobulin chains) replaced with a donor CDR.
- the antibody may be replaced with at least a portion of a non-human CDR or only some of the CDRs may be replaced with non-human CDRs. It is only necessary to replace the number of CDRs required for binding of the humanized antibody to PD-1.
- the donor will be a rodent antibody, e.g., a rat or mouse antibody
- the recipient will be a human framework or a human consensus framework.
- the immunoglobulin providing the CDRs is called the "donor” and the immunoglobulin providing the framework is called the “acceptor.”
- the donor immunoglobulin is a non-human (e.g., rodent).
- the acceptor framework is a naturally-occurring (e.g., a human) framework or a consensus framework, or a sequence about 85% or higher, preferably 90%, 95%, 99% or higher identical thereto.
- Consensus sequence refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence.
- a “consensus framework” refers to the framework region in the consensus immunoglobulin sequence.
- An antibody can be humanized by methods known in the art (see e.g., Morrison, S. L., 1985, Science 229:1202-1207, by Oi et al., 1986, BioTechniques 4:214, and by Queen et al. US 5,585,089, US 5,693,761 and US 5,693,762, the contents of all of which are hereby incorporated by reference).
- Humanized or CDR-grafted antibodies can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDRs of an immunoglobulin chain can be replaced. See e.g., U.S.
- Patent 5,225,539 Jones et al.1986 Nature 321:552-525; Verhoeyan et al.1988 Science 239:1534; Beidler et al.1988 J. Immunol.141:4053-4060; Winter US 5,225,539, the contents of all of which are hereby expressly incorporated by reference. Winter describes a CDR-grafting method which may be used to prepare the humanized antibodies of the present invention (UK Patent Application GB 2188638A, filed on March 26, 1987; Winter US
- humanized antibodies in which specific amino acids have been substituted, deleted or added. Criteria for selecting amino acids from the donor are described in US 5,585,089, e.g., columns 12-16 of US 5,585,089, e.g., columns 12-16 of US 5,585,089, the contents of which are hereby incorporated by reference. Other techniques for humanizing antibodies are described in Padlan et al. EP 519596 A1, published on December 23, 1992.
- the antibody molecule can be a single chain antibody.
- a single-chain antibody (scFV) may be engineered (see, for example, Colcher, D. et al. (1999) Ann N Y Acad Sci 880:263-80; and Reiter, Y. (1996) Clin Cancer Res 2:245-52).
- the single chain antibody can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target protein.
- the antibody molecule has a heavy chain constant region chosen from, e.g., the heavy chain constant regions of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE; particularly, chosen from, e.g., the (e.g., human) heavy chain constant regions of IgG1, IgG2, IgG3, and IgG4.
- the antibody molecule has a light chain constant region chosen from, e.g., the (e.g., human) light chain constant regions of kappa or lambda.
- the constant region can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, and/or complement function).
- the antibody has: effector function; and can fix complement.
- the antibody does not; recruit effector cells; or fix complement.
- the antibody has reduced or no ability to bind an Fc receptor. For example, it is a isotype or subtype, fragment or other mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.
- Antibodies with altered function e.g. altered affinity for an effector ligand, such as FcR on a cell, or the C1 component of complement can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see e.g., EP 388,151 A1, U.S. Pat. No. 5,624,821 and U.S. Pat. No.5,648,260, the contents of all of which are hereby incorporated by reference). Similar type of alterations could be described which if applied to the murine, or other species immunoglobulin would reduce or eliminate these functions.
- an antibody molecule can be derivatized or linked to another functional molecule (e.g., another peptide or protein).
- a "derivatized" antibody molecule is one that has been modified. Methods of derivatization include but are not limited to the addition of a fluorescent moiety, a radionucleotide, a toxin, an enzyme or an affinity ligand such as biotin. Accordingly, the antibody molecules of the invention are intended to include derivatized and otherwise modified forms of the antibodies described herein, including immunoadhesion molecules.
- an antibody molecule can be functionally linked (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate association of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).
- another antibody e.g., a bispecific antibody or a diabody
- detectable agent e.g., a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate association of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).
- One type of derivatized antibody molecule is produced by crosslinking two or more antibodies (of the same type or of different types, e.g., to create bispecific antibodies).
- Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional (e.g., disuccinimidyl suberate).
- an appropriate spacer e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester
- homobifunctional e.g., disuccinimidyl suberate
- An antibody molecules may be conjugated to another molecular entity, typically a label or a therapeutic (e.g., a cytotoxic or cytostatic) agent or moiety.
- Radioactive isotopes can be used in diagnostic or therapeutic applications. Radioactive isotopes that can be coupled to the anti- PSMA antibodies include, but are not limited to ⁇ -, ⁇ -, or ⁇ -emitters, or ⁇ -and ⁇ -emitters.
- radioactive isotopes include, but are not limited to iodine ( 131 I or 125 I), yttrium ( 90 Y), lutetium ( 177 Lu), actinium ( 225 Ac), praseodymium, astatine ( 211 At), rhenium ( 186 Re), bismuth ( 212 Bi or 213 Bi), indium ( 111 In), technetium ( 99 mTc), phosphorus ( 32 P), rhodium ( 188 Rh), sulfur ( 35 S) , carbon ( 14 C), tritium ( 3 H), chromium ( 51 Cr), chlorine ( 36 Cl), cobalt ( 57 Co or 58 Co), iron ( 59 Fe), selenium ( 75 Se), or gallium ( 67 Ga).
- Radioisotopes useful as therapeutic agents include yttrium ( 90 Y), lutetium ( 177 Lu), actinium ( 225 Ac), praseodymium, astatine ( 211 At), rhenium ( 186 Re), bismuth ( 212 Bi or 213 Bi), and rhodium ( 188 Rh).
- Radioisotopes useful as labels include iodine ( 131 I or 125 I), indium ( 111 In), technetium ( 99 mTc), phosphorus ( 32 P), carbon ( 14 C), and tritium ( 3 H), or one or more of the therapeutic isotopes listed above.
- the invention provides radiolabeled antibody molecules and methods of labeling the same.
- a method of labeling an antibody molecule is disclosed. The method includes contacting an antibody molecule, with a chelating agent, to thereby produce a conjugated antibody.
- the conjugated antibody is radiolabeled with a radioisotope, e.g.,
- the antibody molecule can be conjugated to a therapeutic agent.
- therapeutically active radioisotopes have already been mentioned.
- examples of other therapeutic agents include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin,
- daunorubicin dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1- dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, maytansinoids, e.g., maytansinol (see U.S. Pat. No.5,208,020), CC-1065 (see U.S. Pat. Nos. 5,475,092, 5,585,499, 5,846, 545) and analogs or homologs thereof.
- Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, CC-1065, melphalan, carmustine (BSNU) and lomustine (CCNU),
- antimetabolites e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine
- alkylating agents e.g., mechlorethamine, thioepa chlorambucil, CC-1065, melphalan, carmustine (BSNU) and lomustine (CCNU)
- cyclothosphamide busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis- dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclinies (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine, vinblastine, taxol and maytansinoids).
- DDP dichlorodiamine platinum
- anthracyclinies e.g., daunorubicin (formerly daunomycin) and doxorubicin
- antibiotics e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)
- the combination therapies can include an immunomodulator (e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule) and a second therapeutic agent, e.g., a second therapeutic agent chosen from one or more of the agents listed in Table 1.
- an immunomodulator e.g., one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule
- a second therapeutic agent e.g., a second therapeutic agent chosen from one or more of the agents listed in Table 1.
- the therapy or the therapeutic agents must be administered at the same time and/or formulated for delivery together (e.g., in the same composition), although these methods and compositions are within the scope described herein.
- the immunomodulator and the second therapeutic agent can be administered concurrently with, prior to, or subsequent to, one or more other additional therapies or therapeutic agents.
- the agents in the combination can be administered in any order. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent.
- the additional therapeutic agent utilized in this combination may be administered together in a single composition or administered separately in different compositions. In general, it is expected that additional therapeutic agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
- a combination includes a formulation of the immunomodulator and the second therapeutic agent, with or without instructions for combined use or to
- the combined compounds can be manufactured and/or formulated by the same or different manufacturers.
- the combination partners may thus be entirely separate pharmaceutical dosage forms or pharmaceutical compositions that are also sold independently of each other.
- instructions for their combined use are provided: (i) prior to release to physicians (e.g. in the case of a“kit of part” comprising the compound of the disclosure and the other therapeutic agent); (ii) by the physicians themselves (or under the guidance of a physician) shortly before administration; (iii) the patient themselves by a physician or medical staff.
- the combination therapies disclosed herein can include an inhibitor of an inhibitory molecule of an immune checkpoint molecule.
- immune checkpoints refers to a group of molecules on the cell surface of CD4 and CD8 T cells. These molecules can effectively serve as “brakes” to down-modulate or inhibit an anti-tumor immune response. Inhibition of an inhibitory molecule can be performed by inhibition at the DNA, RNA or protein level.
- an inhibitory nucleic acid e.g., a dsRNA, siRNA or shRNA
- the inhibitor of an inhibitory signal is, a polypeptide e.g., a soluble ligand, or an antibody or antigen-binding fragment thereof, that binds to the inhibitory molecule.
- Immune checkpoint molecules useful in the methods and compositions of the present invention include, but are not limited to, Programmed Death 1 (PD-1), PD-1, PD-L1, PD-L2, Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), TIM-3, CEACAM (e.g., CEACAM-1,
- CEACAM-3 and/or CEACAM-5 LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H1, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, TGFR (e.g., TGFR beta).
- TGFR e.g., TGFR beta
- the immunomodulator is an inhibitor of an immune checkpoint molecule (e.g., an inhibitor of PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3 and/or -5) or CTLA- 4, or any combination thereof).
- an immune checkpoint molecule e.g., an inhibitor of PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3 and/or -5) or CTLA- 4, or any combination thereof.
- the PD-1 inhibitor is an anti-PD-1 antibody chosen from
- Nivolumab Pembrolizumab or Pidilizumab.
- the anti-PD-1 antibody is Nivolumab.
- Alternative names for Nivolumab include MDX-1106, MDX-1106-04, ONO-4538, or BMS-936558.
- the anti-PD-1 antibody is Nivolumab (CAS Registry Number: 946414-94-4).
- Nivolumab is a fully human IgG4 monoclonal antibody which specifically blocks PD- 1.
- Nivolumab (clone 5C4) and other human monoclonal antibodies that specifically bind to PD- 1 are disclosed in US 8,008,449 and WO2006/121168.
- the inhibitor of PD- 1 is Nivolumab, and having a sequence disclosed herein (or a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to the sequence specified).
- the heavy and light chain amino acid sequences of Nivolumab are as follows: Heavy chain (SEQ ID NO: 2)
- the anti-PD-1 antibody is Pembrolizumab.
- Pembrolizumab (also referred to as Lambrolizumab, MK-3475, MK03475, SCH-900475 or KEYTRUDA®; Merck) is a humanized IgG4 monoclonal antibody that binds to PD-1. Pembrolizumab and other humanized anti-PD-1 antibodies are disclosed in Hamid, O. et al. (2013) New England Journal of Medicine 369 (2): 134–44, US 8,354,509 and WO2009/114335.
- the inhibitor of PD-1 is Pembrolizumab disclosed in, e.g., US 8,354,509 and WO 2009/114335, and having a sequence disclosed herein (or a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to the sequence specified).
- the heavy and light chain amino acid sequences of Pembrolizumab are as follows: Heavy chain (SEQ ID NO: 4)
- RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350
- the anti-PD-1 antibody is Pidilizumab.
- Pidilizumab (CT-011; Cure Tech) is a humanized IgG1k monoclonal antibody that binds to PD-1.
- Pidilizumab and other humanized anti-PD-1 monoclonal antibodies are disclosed in WO2009/101611.
- anti-PD-1 antibodies include AMP 514 (Amplimmune), among others, e.g., anti- PD-1 antibodies disclosed in US 8,609,089, US 2010028330, and/or US 20120114649.
- exemplary PD-L1 or PD-L2 Inhibitors include AMP 514 (Amplimmune), among others, e.g., anti- PD-1 antibodies disclosed in US 8,609,089, US 2010028330, and/or US 20120114649.
- the PD-L1 inhibitor is an antibody molecule. In some embodiments, the PD-L1 inhibitor is an antibody molecule.
- the anti-PD-Ll inhibitor is chosen from YW243.55.S70, MPDL3280A, MEDI- 4736, MSB-0010718C, or MDX-1105.
- the anti-PD-L1 antibody is MSB0010718C.
- MSB0010718C also referred to as A09-246-2; Merck Serono
- A09-246-2 Merck Serono
- Pembrolizumab and other humanized anti-PD-L1 antibodies are disclosed in
- the heavy and light chain amino acid sequences of MSB0010718C include at least the following: Heavy chain variable region (SEQ ID NO: 24 as disclosed in WO2013/079174) (SEQ ID NO: 6) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS
- the PD-L1 inhibitor is YW243.55.S70.
- the YW243.55.S70 antibody is an anti-PD-Ll described in WO 2010/077634 (heavy and light chain variable region sequences shown in SEQ ID Nos.20 and 21, respectively, of WO 2010/077634), and having a sequence disclosed therein (or a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to the sequence specified).
- the PD-L1 inhibitor is MDX-1105.
- MDX-1105 also known as BMS-936559, is an anti-PD-Ll antibody described in WO2007/005874, and having a sequence disclosed therein (or a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to the sequence specified).
- the PD-L1 inhibitor is MDPL3280A (Genentech / Roche).
- MDPL3280A is a human Fc optimized IgG1 monoclonal antibody that binds to PD-L1.
- MDPL3280A and other human monoclonal antibodies to PD-L1 are disclosed in U.S. Patent No.: 7,943,743 and U.S Publication No.: 20120039906.
- the PD-L2 inhibitor is AMP-224.
- AMP-224 is a PD-L2 Fc fusion soluble receptor that blocks the interaction between PD-1 and B7-H1 (B7-DCIg; Amplimmune; e.g., disclosed in WO2010/027827 and WO2011/066342).
- a combination described herein includes a TIM-3 inhibitor.
- the combination is used to treat a cancer, e.g., a cancer described herein, e.g., a solid tumor or a hematologic malignancy.
- Exemplary anti-TIM-3 antibodies are disclosed in U.S. Patent No.: 8,552,156, WO 2011/155607, EP 2581113 and U.S Publication No.: 2014/044728.
- Exemplary LAG-3 Inhibitors are disclosed in U.S. Patent No.: 8,552,156, WO 2011/155607, EP 2581113 and U.S Publication No.: 2014/044728.
- Exemplary LAG-3 Inhibitors are disclosed in U.S. Patent No.: 8,552,156, WO 2011/155607, EP 2581113 and U.S Publication No.: 2014/044728.
- a combination described herein includes a LAG-3 inhibitor.
- the combination is used to treat a cancer, e.g., a cancer described herein, e.g., a solid tumor or a hematologic malignancy.
- the anti-LAG-3 antibody is BMS-986016.
- BMS-986016 also referred to as BMS986016; Bristol-Myers Squibb
- BMS-986016 and other humanized anti-LAG-3 antibodies are disclosed in US 2011/0150892, WO2010/019570, and WO2014/008218.
- a combination described herein includes a CTLA-4 inhibitor.
- the combination is used to treat a cancer, e.g., a cancer described herein, e.g., a solid tumor or a hematologic malignancy.
- Exemplary anti-CTLA-4 antibodies include Tremelimumab (IgG2 monoclonal antibody available from Pfizer, formerly known as ticilimumab, CP-675,206); and Ipilimumab (CTLA-4 antibody, also known as MDX-010, CAS No.477202-00-9).
- Tremelimumab IgG2 monoclonal antibody available from Pfizer, formerly known as ticilimumab, CP-675,206
- Ipilimumab CLA-4 antibody, also known as MDX-010, CAS No.477202-00-9
- the combination includes an anti-PD-1 antibody molecule, e.g., as described herein, and an anti-CTLA-4 antibody, e.g., ipilimumab.
- an anti-CTLA-4 antibody e.g., ipilimumab.
- exemplary doses that can be use include a dose of anti-PD-1 antibody molecule of about 1 to 10 mg/kg, e.g., 3 mg/kg, and a dose of an anti-CTLA-4 antibody, e.g., ipilimumab, of about 3 mg/kg.
- the anti-PD-1 antibody molecule is administered after treatment, e.g., after treatment of a melanoma, with an anti-CTLA-4 antibody (e.g., ipilimumab) with or without a BRAF inhibitor (e.g., vemurafenib or dabrafenib).
- an anti-CTLA-4 antibody e.g., ipilimumab
- BRAF inhibitor e.g., vemurafenib or dabrafenib.
- the inhibitor is a soluble ligand (e.g., a CTLA-4-Ig), or an antibody or antibody fragment that binds to PD-L1, PD-L2 or CTLA-4.
- a soluble ligand e.g., a CTLA-4-Ig
- an antibody or antibody fragment that binds to PD-L1, PD-L2 or CTLA-4.
- the anti-PD-1 antibody molecule can be administered in combination with an anti-CTLA-4 antibody, e.g., ipilimumab, for example, to treat a cancer (e.g., a cancer chosen from: a melanoma, e.g., a metastatic melanoma; a lung cancer, e.g., a non-small cell lung carcinoma; or a prostate cancer).
- a cancer e.g., a cancer chosen from: a melanoma, e.g., a metastatic melanoma; a lung cancer, e.g., a non-small cell lung carcinoma; or a prostate cancer.
- the anti-PD-1 molecules described herein are administered in combination with one or more other inhibitors of PD-1, PD-L1 and/or PD-L2, e.g., as described herein.
- the antagonist may be an antibody, an antigen binding fragment thereof, an
- immunoadhesin a fusion protein, or oligopeptide.
- the anti-PD-1 or PD-L1 antibody molecule is administered in combination with an anti-LAG-3 antibody or an antigen-binding fragment thereof. In another embodiment, the anti-PD-1 or PD-L1 antibody molecule is administered in combination with an anti-TIM-3 antibody or antigen-binding fragment thereof. In yet other embodiments, the anti- PD-1 or PD-L1 antibody molecule is administered in combination with an anti-LAG-3 antibody and an anti-TIM-3 antibody, or antigen-binding fragments thereof.
- the combination of antibodies recited herein can be administered separately, e.g., as separate antibodies, or linked, e.g., as a bispecific or trispecific antibody molecule.
- a bispecific antibody that includes an anti-PD-1 or PD-L1 antibody molecule and an anti-TIM-3 or anti-LAG-3 antibody, or antigen-binding fragment thereof, is administered.
- the combination of antibodies recited herein is used to treat a cancer, e.g., a cancer as described herein (e.g., a solid tumor).
- a cancer e.g., a cancer as described herein (e.g., a solid tumor).
- the efficacy of the aforesaid combinations can be tested in animal models known in the art. For example, the animal models to test the synergistic effect of anti- PD-1 and anti-LAG-3 are described, e.g., in Woo et al. (2012) Cancer Res.72(4):917-27).
- the anti-PD-1 or PD-L1 antibody molecule is administered in combination with an inhibitor of CEACAM (e.g., CEACAM-1, -3 and/or -5).
- an inhibitor of CEACAM e.g., CEACAM-1, -3 and/or -5.
- the inhibitor of CEACAM is an anti-CEACAM antibody molecule.
- CEACAM carcinoembryonic antigen cell adhesion molecules
- CEACAM-1 and CEACAM-5 are believed to mediate, at least in part, inhibition of an anti-tumor immune response (see e.g., Markel et al. J Immunol. 2002 Mar 15;168(6):2803-10; Markel et al. J Immunol.2006 Nov 1;177(9):6062-71; Markel et al. Immunology.2009 Feb;126(2):186-200; Markel et al.
- CEACAM-1 has been described as a heterophilic ligand for TIM-3 and as playing a role in TIM-3-mediated T cell tolerance and exhaustion (see e.g., WO 2014/022332; Huang, et al. (2014) Nature doi:10.1038/nature13848).
- co-blockade of CEACAM-1 and TIM-3 has been shown to enhance an anti-tumor immune response in xenograft colorectal cancer models (see e.g., WO 2014/022332; Huang, et al. (2014), supra).
- co- blockade of CEACAM-1 and PD-1 reduce T cell tolerance as described, e.g., in WO
- CEACAM inhibitors can be used with the other immunomodulators described herein (e.g., anti-PD-1 and/or anti-TIM-3 inhibitors) to enhance an immune response against a cancer, e.g., a melanoma, a lung cancer (e.g., NSCLC), a bladder cancer, a colon cancer an ovarian cancer, and other cancers as described herein.
- a cancer e.g., a melanoma
- a lung cancer e.g., NSCLC
- bladder cancer e.g., a colon cancer an ovarian cancer
- other cancers as described herein.
- the anti-PD-1 antibody molecule is administered in combination with a CEACAM inhibitor (e.g., CEACAM-1, CEACAM-3, and/or CEACAM-5 inhibitor).
- a CEACAM inhibitor e.g., CEACAM-1, CEACAM-3, and/or CEACAM-5 inhibitor.
- the inhibitor of CEACAM is an anti-CEACAM antibody molecule.
- the anti-PD-1 antibody molecule is administered in combination with a CEACAM-1 inhibitor, e.g., an anti- CEACAM-1 antibody molecule.
- the anti-PD-1 antibody molecule is administered in combination with a CEACAM- 3 inhibitor, e.g., an anti- CEACAM-3 antibody molecule.
- the anti-PD-1 antibody molecule is administered in combination with a CEACAM-5 inhibitor, e.g., an anti- CEACAM-5 antibody molecule.
- a CEACAM-5 inhibitor e.g., an anti- CEACAM-5 antibody molecule.
- Exemplary anti-CEACAM-1 antibodies are described in WO 2010/125571, WO 2013/082366 and WO 2014/022332, e.g., a monoclonal antibody 34B1, 26H7, and 5F4; or a recombinant form thereof, as described in, e.g., US 2004/0047858, US 7,132,255 and WO 99/052552.
- the anti-CEACAM antibody binds to CEACAM-5 as described in, e.g., Zheng et al. PLoS One.2010 Sep 2;5(9). pii: e12529
- the combination therapies disclosed herein include a modulator of a costimulatory molecule.
- the costimulatory modulator, e.g., agonist, of a costimulatory molecule is chosen from an agonist (e.g., an agonistic antibody or antigen-binding fragment thereof, or soluble fusion) of an MHC class I molecule, a TNF receptor protein, an Immunoglobulin-like proteins, a cytokine receptor, an integrin, a signaling lymphocytic activation molecules (SLAM proteins), an activating NK cell receptor, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp
- CD226 SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM
- the combination therapies disclosed herein include a costimulatory molecule, e.g., an agonist associated with a positive signal that includes a costimulatory domain of CD28, CD27, ICOS and GITR.
- a costimulatory molecule e.g., an agonist associated with a positive signal that includes a costimulatory domain of CD28, CD27, ICOS and GITR.
- a combination described herein includes a GITR agonist.
- the combination is used to treat a cancer, e.g., a cancer described herein, e.g., a solid tumor or a hematologic malignancy.
- Exemplary GITR agonists include, e.g., GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies), such as, a GITR fusion protein described in U.S. Patent No.: 6,111,090, European Patent No.: 0920505B1, U.S Patent No.: 8,586,023, PCT Publication Nos.: WO 2010/003118 and 2011/090754, or an anti-GITR antibody described, e.g., in U.S. Patent No.: 7,025,962, European Patent No.: 1947183B1, U.S. Patent No.: 7,812,135, U.S. Patent No.: 8,388,967, U.S.
- anti-GITR antibodies e.g., bivalent anti-GITR antibodies
- the GITR agonist is used in combination with a PD-1 inhibitor, e.g., as described in WO2015/026684.
- the GITR agonist is used in combination with a TLR agonist, e.g., as described in WO2004060319, and International Publication No.: WO2014012479. Additional Combinations
- the combination therapies include a modified T-cell, e.g., in combination with an adoptive T-cell immunotherapy using chimeric antigen receptor (CAR) T cells (e.g., as described by John LB, et al. (2013) Clin. Cancer Res.19(20): 5636-46).
- CAR chimeric antigen receptor
- the combination therapies disclosed herein can also include a cytokine, e.g., interleukin-21 or interleukin-2.
- a cytokine e.g., interleukin-21 or interleukin-2.
- the combination described herein is used to treat a cancer, e.g., a cancer as described herein (e.g., a solid tumor or melanoma).
- immunomodulators that can be used in the combination therapies include, but are not limited to, e.g., afutuzumab (available from Roche®); pegfilgrastim (Neulasta®);
- lenalidomide CC-5013, Revlimid®
- Thalomid® thalidomide
- actimid CC4047
- cytokines e.g., IL-21 or IRX-2 (mixture of human cytokines including interleukin 1, interleukin 2, and interferon ⁇ , CAS 951209-71-5, available from IRX Therapeutics).
- the combination therapies can be administered to a subject in conjunction with (e.g., before, simultaneously or following) one or more of: bone marrow transplantation, T cell ablative therapy using chemotherapy agents such as, fludarabine, external- beam radiation therapy (XRT), cyclophosphamide, and/or antibodies such as OKT3 or
- the anti-PD-1 or PD-L1 antibody molecules are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan.
- B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan.
- subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation.
- subjects receive the anti-PD-1 or PD-L1 antibody molecules.
- the anti-PD-1 or PD-L1 antibody molecules are administered before or following surgery.
- Another example of a further combination therapy includes decarbazine for the treatment of melanoma.
- decarbazine for the treatment of melanoma.
- the combined use of PD-1 blockade and chemotherapy is believed to be facilitated by cell death, that is a consequence of the cytotoxic action of most chemotherapeutic compounds, which can result in increased levels of tumor antigen in the antigen presentation pathway.
- Other combination therapies that may result in synergy with PD-1 blockade through cell death are radiation, surgery, and hormone deprivation. Each of these protocols creates a source of tumor antigen in the host.
- Angiogenesis inhibitors may also be combined with PD-1 blockade. Inhibition of angiogenesis leads to tumor cell death which may feed tumor antigen into host antigen presentation pathways.
- Combination therapies can also be used in combination with bispecific antibodies.
- Bispecific antibodies can be used to target two separate antigens.
- anti-Fc receptor/anti tumor antigen e.g., Her-2/neu
- bispecific antibodies have been used to target macrophages to sites of tumor. This targeting may more effectively activate tumor specific responses.
- the T cell arm of these responses would by augmented by the use of PD-1 blockade.
- antigen may be delivered directly to DCs by the use of bispecific antibodies which bind to tumor antigen and a dendritic cell specific cell surface marker.
- Tumors evade host immune surveillance by a large variety of mechanisms. Many of these mechanisms may be overcome by the inactivation of proteins which are expressed by the tumors and which are immunosuppressive. These include among others TGF-beta (Kehrl, J. et al. (1986) J. Exp. Med.163: 1037-1050), IL-10 (Howard, M. & O'Garra, A. (1992) Immunology Today 13: 198-200), and Fas ligand (Hahne, M. et al. (1996) Science 274: 1363-1365).
- Antibodies or antigen-binding fragments thereof to each of these entities may be used in combination with anti-PD-1 to counteract the effects of the immunosuppressive agent and favor tumor immune responses by the host.
- Anti-CD40 antibodies are able to substitute effectively for T cell helper activity (Ridge, J. et al. (1998) Nature 393: 474-478) and can be used in conjunction with PD-1 antibodies (Ito, N. et al. (2000) Immunobiology 201 (5) 527-40).
- Antibodies to T cell costimulatory molecules such as CTLA-4 (e.g., U.S. Pat. No.5,811,097), OX-40 (Weinberg, A. et al.
- PD-1 blockade can be combined with other forms of immunotherapy such as cytokine treatment (e.g., interferons, GM-CSF, G-CSF, IL-2, IL-21), or bispecific antibody therapy, which provides for enhanced presentation of tumor antigens (see e.g., Holliger (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak (1994) Structure 2:1121- 1123).
- cytokine treatment e.g., interferons, GM-CSF, G-CSF, IL-2, IL-21
- bispecific antibody therapy which provides for enhanced presentation of tumor antigens
- the combination therapies disclosed herein can be further combined with an immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines (He et al. (2004) J. Immunol.173:4919-28).
- an immunogenic agent such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines (He et al. (2004) J. Immunol.173:4919-28).
- tumor vaccines include peptides of melanoma antigens, such as peptides of gp100, MAGE antigens, Trp-2, MART1 and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.
- PD-1 blockade can be combined with a vaccination protocol.
- Many experimental strategies for vaccination against tumors have been devised (see Rosenberg, S., 2000,
- a vaccine is prepared using autologous or allogeneic tumor cells. These cellular vaccines have been shown to be most effective when the tumor cells are transduced to express GM-CSF. GM-CSF has been shown to be a potent activator of antigen presentation for tumor vaccination (Dranoff et al.
- PD-1 blockade can be used in conjunction with a collection of recombinant proteins and/or peptides expressed in a tumor in order to generate an immune response to these proteins.
- proteins are normally viewed by the immune system as self antigens and are therefore tolerant to them.
- the tumor antigen may also include the protein telomerase, which is required for the synthesis of telomeres of chromosomes and which is expressed in more than 85% of human cancers and in only a limited number of somatic tissues (Kim, N et al. (1994) Science 266: 2011-2013). (These somatic tissues may be protected from immune attack by various means).
- Tumor antigen may also be "neo-antigens" expressed in cancer cells because of somatic mutations that alter protein sequence or create fusion proteins between two unrelated sequences (ie. bcr-abl in the Philadelphia chromosome), or idiotype from B cell tumors.
- tumor vaccines may include the proteins from viruses implicated in human cancers such a Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV).
- HPV Human Papilloma Viruses
- HBV Hepatitis Viruses
- KHSV Kaposi's Herpes Sarcoma Virus
- Another form of tumor specific antigen which may be used in conjunction with PD-1 blockade is purified heat shock proteins (HSP) isolated from the tumor tissue itself. These heat shock proteins contain fragments of proteins from the tumor cells and these HSPs are highly efficient at delivery to antigen presenting cells for eliciting tumor immunity (Suot, R & Srivastava, P (1995) Science 269:1585-1588; Tamura, Y. et al. (1997) Science 278:117-120).
- HSP heat shock proteins
- DC Dendritic cells
- DC's can be produced ex vivo and loaded with various protein and peptide antigens as well as tumor cell extracts (Nestle, F. et al. (1998) Nature Medicine 4: 328-332). DCs may also be transduced by genetic means to express these tumor antigens as well. DCs have also been fused directly to tumor cells for the purposes of immunization (Kugler, A. et al. (2000) Nature Medicine 6:332-336). As a method of vaccination, DC immunization may be effectively combined with PD-1 blockade to activate more potent anti-tumor responses. Second Therapeutic Agents
- the second therapeutic agent can be chosen from one or more of: 1) an IAP inhibitor; 2) a TOR kinase inhibitor; 3) a HDM2 ligase inhibitor; 4) a PIM kinase inhibitor; 5) a HER3 kinase inhibitor; 6) a Histone Deacetylase (HDAC) inhibitor; 7) a Janus kinase inhibitor; 8) an FGF receptor inhibitor; 9) an EGF receptor inhibitor; 10) a c-MET inhibitor; 11) an ALK inhibitor; 12) a CDK4/6-inhibitor; 13) a PI3K inhibitor; 14) a BRAF inhibitor; 15) a CAR T cell (e.g., a CAR T cell targeting CD19); 16) a MEK inhibitor; or 17) a BCR-ABL inhibitor; e.g., chosen from one or more of the agents listed in Table 1.
- an inhibitor of the immune checkpoint molecule is used in a method or composition described herein.
- an inhibitor of the immune checkpoint molecule described herein e.g., the PD-1 inhibitor, e.g., the anti-PD-1 antibody (e.g., Nivolumab or Pembrolizumab); or the PD-L1 inhibitor, e.g., the anti-PD-L1 antibody (e.g., MSB0010718C) (alone or in combination with other immunomodulators) is used in combination with one or more of the agents listed in Table 1; e.g., 1) an Inhibitor of Apoptosis (IAP) inhibitor; 2) an inhibitor of a Target of Rapamycin (TOR) kinase; 3) an inhibitor of a human homolog of mouse double minute 2 E3 ubiquitin ligase (HDM2); 4) a PIM kinase inhibitor; 5) an inhibitor of Human epidermal growth factor 3 (HER3) kinas
- IAP Inhibi
- one or more of the aforesaid combinations is used to treat a disorder, e.g., a disorder described herein (e.g., a disorder disclosed in Table 1). In one embodiment, one or more of the aforesaid combinations is used to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- one or more of the immunomodulators described herein are used in combination with:
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with an IAP inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- a cancer e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the IAP inhibitor is disclosed in Table 1, e.g., LCL161, or in a publication recited in Table 1, e.g., International Patent Publication No. WO2008/016893 (e.g., Formula (I), Example 1, and Compound A), European Patent No.2051990, and U.S. Patent No.8,546,336.
- the IAP inhibitor is disclosed, e.g., in International Patent Publication No. WO2008/016893 (e.g., Formula (I), Example 1, and Compound A), European Patent No. 2051990, and U.S. Patent No.8,546,336.
- the IAP inhibitor e.g., LCL161
- the structure e.g., LCL161
- the publication recited in Table 1 e.g., International Patent Publication No. WO2008/016893 (e.g., Formula (I), Example 1, and Compound A), European Patent No.2051990, and U.S. Patent No.8,546,336.
- the inhibitor of the immune checkpoint molecule (e.g., one of Nivolumab, Pembrolizumab or MSB0010718C) is used in combination with LCL161 to treat a cancer or disorder described in Table 1, e.g., a solid tumor, e.g., a breast cancer or a pancreatic cancer; or a hematological malignancy, e.g., multiple myeloma or a hematopoeisis disorder.
- a cancer or disorder described in Table 1 e.g., a solid tumor, e.g., a breast cancer or a pancreatic cancer
- a hematological malignancy e.g., multiple myeloma or a hematopoeisis disorder.
- R 1 is H, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl or C 3 -C 10 cycloalkyl, which R 1 may be unsubstituted or substituted;
- R 2 is H, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 10 cycloalkyl which R 2 may be unsubstituted or substituted;
- R 3 is H, CF 3 , C 2 F 6 , C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, CH 2 -Z, or
- R 2 and R 3 taken together with the nitrogen atom to which they are attached, form a heterocyclic ring, which alkyl, alkenyl, alkynyl or het ring may be unsubstituted or substituted;
- Z is H, OH, F, Cl, CH 3 , CH 2 CI, CH 2 F or CH 2 OH;
- R 4 is C 0-10 alkyl, C 0-10 alkenyl, C 0-10 alkynyl, C 3 -C 10 cycloalkyl, wherein the C 0-10 alkyl, or cycloalkyl group is unsubstituted or substituted;
- A is het, which may be substituted or unsubstituted
- D is C 1 -C 7 alkylene or C 2 -C 9 alkenylene, C(O), O, NR 7 , S(O)r, C(O)-C 1 -C 10 alkyl, 0-C 1 - C 10 alkyl, S(O)r-C r C 10 alkyl, C (O) C 0 -C 10 arylalkyl, OC 0 -C 10 arylalkyl, or S(O)r C 0 -C 10 arylalkyl, which alkyl and aryl groups may be unsubstituted or substituted;
- r is O, 1 or 2;
- a 1 is a substituted or unsubstituted aryl or unsubstituted or substituted het which substituents on aryl and het are halo, alkyl, lower alkoxy, NR 5 R 6 , CN, NO 2 or SR 5 ;
- each Q is independently H, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, aryl C 1 -C 10 alkoxy, OH, O-C 1 - C 10 alkyl, (CH 2 ) 0 - 6 -C 3 -C 7 cycloalkyl, aryl, aryl C 1 -C 10 alkyl, O-(CH 2 ) 0 - 6 aryl, (CH 2 ) 1 - 6 het, het, O-(CH 2 ) 1-6 het, -OR 11 , C(O)R 11 , -C(O)N(R 11 )(R 12 ), N(R 11 )(R 12 J 1 SR 11 , S(O)R 111 S(O) 2 R 11 , S(O) 2 - N(R 11 )(R 12 ), or NR 11 -S(O) 2 -(R 12 ), wherein alkyl, cycloalkyl and
- n 0, 1 , 2 or 3, 4, 5, 6 or 7;
- het is a 5- to 7-membered monocyclic heterocyclic ring containing 1-4 heteroring atoms selected from N, O and S or an 8- to 12-membered fused ring system that includes one 5- to 7- membered monocyclic heterocyclic ring containing 1 , 2 or 3 heteroring atoms selected from N, O and S, which het is unsubstituted or substituted;
- R 11 and R 12 are independently H, C 1 -C 10 alkyl, (CH 2 ) 0 - 6 -C 3 -C 7 cycloalkyl, (CH 2 ) 0 - 6 - (CH) 0 - 1 (aryl) 1 .
- alkyl substituents of R 11 and R 12 may be unsubstituted or substituted by one or more substituents selected from C 1 -C 10 alkyl, halogen, OH, O-C 1 -C 6 alkyl, -S-C 1 -C 6 alkyl, CF 3 or NR 11 R 12 ;
- substituted cycloalkyl substituents of R 11 and R 12 are substituted by one or more substituents selected from a C 2 -C 10 alkene; C 1 -C 6 alkyl; halogen; OH; 0-C 1 - C 6 alkyl; S-C 1 -C 6 alkyl,CF 3 ; or NR 11 R 12 ;
- substituted het or substituted aryl of R 11 and R 12 are substituted by one or more substituents selected from halogen, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, nitro, CNO-C(O)- C r C 4 alkyl and C(O)-O-C r C 4 -alkyl;
- R 5 , R 6 and R 7 are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, cycloalkyl, or cycloalkyl lower alkyl, C(O)R 5 ; S(O)R 5 C(O)OR 5 C(O)N R 5 R 6 , and
- R 1 , R 2 , R 3 , R 4 , Q, and A and A 1 groups are independently halo, hydroxy, lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower alkoxy, aryl, aryl lower alkyl, amino, amino lower alkyl, diloweralkylamino, lower alkanoyl, amino lower alkoxy, nitro, cyano, cyano lower alkyl, carboxy, lower carbalkoxy, lower alkanoyl, aryloyl, lower arylalkanoyl, carbamoyl, N-mono- or N,N-di lower alkyl carbamoyl, lower alkyl carbamic acid ester, amidino, guanidine, ureido, mercapto, sulfo, lower alkylthio, sulfoamino, sulfonamide, benzosulfonamide,
- R 8 and R 14 can be the same or different and are independently H or lower alkyl, or R 8 and R 14 , together with the N atom, form a 3- to 8-membered heterocyclic ring containing a nitrogen heteroring atoms and may optionally contain one or two additional heteroring atoms selected from nitrogen, oxygen and sulfur, which heterocyclic ring may be unsubstituted or substituted with lower alkyl, halo, lower alkenyl, lower alkynyl, hydroxy, lower alkoxy, nitro, amino, lower alkyl, amino, diloweralkyl amino, cyano, carboxy, lower carbalkoxy, formyl, lower alkanoyl, oxo, carbarmoyl, ⁇ /-lower or ⁇ /, ⁇ /- dilower alkyl carbamoyl, mercapto, or lower alkylthio; and
- R 9 , R 10 and R 13 are independently hydrogen, lower alkyl, halogen substituted lower alkyl, aryl, aryl lower alkyl, halogen substituted aryl, halogen substituted aryl lower alkyl.
- LCL161 has the following structure:
- LCL161 is (S)-N-((S)-1-cyclohexyl-2-((S)-2-(4-(4- fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a TOR kinase inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the TOR kinase inhibitor is disclosed in Table 1, e.g., Rad-001, or in a publication recited in Table 1, e.g., in International Patent Publication No. WO 2014/085318 (e.g.,
- the TOR kinase inhibitor e.g., Rad-001
- the TOR kinase inhibitor has the structure (compound or generic structure) provided in Table 1, or as disclosed in the publication recited in Table 1, e.g., International Patent Publication No. WO 2014/085318 (e.g., Compound B).
- the inhibitor of the immune checkpoint molecule e.g., one of Nivolumab,
- Pembrolizumab or MSB0010718C is used in combination with Rad-001 to treat a cancer or disorder described in Table 1, e.g., a solid tumor, e.g., a sarcoma, a lung cancer (e.g., a non-small cell lung cancer (NSCLC) (e.g., a NSCLC with squamous and/or non-squamous histology)), a melanoma (e.g., an advanced melanoma), a digestive/gastrointestinal cancer, a gastric cancer, a neurologic cancer, a prostate cancer, a bladder cancer, a breast cancer; or a hematological malignancy, e.g., a lymphoma or leukemia.
- a solid tumor e.g., a sarcoma
- a lung cancer e.g., a non-small cell lung cancer (NSCLC) (e.g., a NSCLC with squam
- Rad-001 has the following structure:
- Rad-001 is ((1R, 9S, 12S, 15R, 16E, 18R, 19R, 21R, 23S, 24E, 26E, 28E, 30S, 32S, 35R)-1,18-dihydroxy-12- ⁇ (1R)-2-[(1S, 3R, 4R)-4-(2-hydroxyethoxy)-3- methoxycyclohexyl]-1-methylethyl ⁇ -19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36- dioxa-4-aza-tricyclo[30.3.1.04,9] hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone).
- the inhibitor of the immune checkpoint molecule is used in combination with a HDM2 ligase inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- a cancer e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the HDM2 ligase inhibitor is disclosed in Table 1, e.g., CGM097, or in a publication recited in Table 1, e.g., International Patent Publication No. WO2011/076786 (e.g., Formula (I) or Example 106).
- the HDM2 ligase inhibitor is disclosed, e.g., in International Patent Publication No.
- the HDM2 ligase inhibitor e.g., CGM097
- the HDM2 ligase inhibitor has the structure provided in Table 1 (compound or generic structure), or as disclosed in the publication recited in Table 1, e.g., International Patent Publication No. WO2011/076786 (e.g., Formula (I) or Example 106).
- the inhibitor of the immune checkpoint molecule e.g., one of Nivolumab, Pembrolizumab or MSB0010718C
- the HDM2 ligase inhibitor is a compound of formula (I), or a tautomer or N-oxide or pharmaceutically acceptable salt or solvate thereof,
- Z is CH 2 or N-R 4 ;
- X is halogen
- R 4 is selected from the group consisting of H and C 1 -C 7 -alkyl
- R 6 is independently selected from the group consisting of H, R'O, and (R') 2 N;
- R 7 is independently selected from the group consisting of R'O and (R') 2 N;
- each R' is independently selected from the group consisting of H, C 1 -C 7 -alkyl, C 1 -C 7 - alkenyl, halo- C 1 -C 7 -alkyl, halo-C 1 -C 7 -alkenyl, C 3 -C 12 -cycloalkyl, heterocyclyl, aryl, hydroxy- C 1 -C 7 -alkyl, C 1 -C 7 -alkoxy-C 1 -C 7 alkyl, amino-C 1 -C 7 -alkyl, N- C 1 -C 7 -alkyl-amino- C 1 -C 7 -alkyl, N,N-di- C 1 -C 7 -alkyl-amino- C 1 -C 7 -alkyl, C 3 -C 12 -cycloalkyl- C 1 -C 7 -alkyl, heterocyclyl- C 1 -C 7 - alkyl,
- heterocyclyl-carbonyl- C 1 -C 7 -alkyl aryl-carbonyl- C 1 -C 7 -alkyl, C 1 -C 7 -alkyl-carbonyl-amino- C 1 - C 7 -alkyl, C 1 -C 7 -alkyl-carbonyl-N- C 1 -C 7 -alkyl-amino- C 1 -C 7 -alkyl, halo- C 1 -C 7 -alkyl–carbonyl- amino- C 1 -C 7 -alkyl, halo- C 1 -C 7 -alkyl-carbonyl-N- C 1 -C 7 -alkyl-amino- C 1 -C 7 -alkyl, wherein aryl, heterocyclyl and C 3 -C 12 -cycloalkyl are unsubstituted or substituted by 1-4 substituents selected from C 1 -C 7 -alky
- each R 1 is independently selected from the group consisting of halogen, cyano, nitro, C d- alkyl, C 1 -C 7 -alkenyl, halo- C 1 -C 7 -alkyl, hydroxyl, C 1 -C 7 -alkoxy, amino, N- C 1 -C 7 -alkyl-amino, N,N-di- C 1 -C 7 -alkyl-amino, amino-carbonyl-amino, N- C 1 -C 7 -alkyl-amino-carbonyl-amino, N.N-di- C 1 -C 7 -alkyl-amino-carbonyl-amino, C 1 -C 7 -alkyl-carbonyl-amino, amino-carbonyl, N- C 1 -C 7 -alkyl-amino-carbonyl, ⁇ , ⁇ -di- C 1 -C 7 -alkyl-
- R 2 is selected from
- phenyl, 2-pyridyl or 3-pyridyl being optionally substituted by 1-2 additional substituents selected from halogen, cyano, C 1 -C 7 -alkyl, halo- C 1 -C 7 -alkyl, hydroxyl, C 1 -C 7 -alkoxy, or hydroxy- C 1 -C 7 -alkyl;
- Z is a 4-6 membered heterocyclic ring, annulated to phenyl in para and meta position, containing 1-3 heteroatoms selected from N,O, S,which is optionally substituted by 1-2 additional substituents selected from halogen, cyano, C 1 -C 7 -alkyl, halo- C 1 -C 7 -alkyl, hydroxyl, C 1 -C 7 -alkoxy, hydroxyl- C 1 -C 7 -alkyl;
- each R 3 is independently selected from H, C 1 -C 7 -alkyl, hydroxy- C 1 -C 7 -alkyl, C 3 -C 12 - cycloalkyl, C 1 -C 7 -alkoxy- C 1 -C 7 -alkyl-carbonyl, amino-C 1 -C 7 -alkyl-carbonyl, N- C 1 -C 7 -alkyl- amino- C 1 -C 7 -alkyl-carbonyl, N, N-di-C 1 -C 7 -alkyl-amino- C 1 -C 7 -alkyl-carbonyl, (R 5 ) 2 N-C 3 -C 12 - cycloalkyl, (R 5 ) 2 N- C 1 -C 7 -alkyl, (R 5 ) 2 N-C 3 -C 12 -cycloalkyl-C 1 -C 7 -alkyl, (R 5 ) 2 N-C
- C 1 -C 7 -alkoxy amino, N- C 1 -C 7 -alkyl-amino, N,N-di- C 1 -C 7 -alkyl-amino, hydroxy-carbonyl, C 1 -C 7 -alkoxy-carbonyl, amino-carbonyl, N- C 1 -C 7 -alkyl-amino-carbonyl, N,N-di- C 1 -C 7 -alkyl-amino-carbonyl, C 1 -C 7 - alkyl-carbonyl, C 1 -C 7 -alkyl-sulphonyl, heterocyclyl, C 1 -C 7 -alkyl-carbonyl-amino, C 1 -C 7 -alkyl- carbonyl-N- C 1 -C 7 -alkyl-amino, and
- each R 5 is independently selected from H, C 1 -C 7 -alkyl, hydroxy- C 1 -C 7 -alkyl, C 1 -C 7 - alkyl-carbonyl, C 1 -C 7 -alkyl-carbonyl, C 1 -C 7 -alkyl-carbonyl- C 1 -C 7 -alkyl, amino-carbonyl- C 1 - C 7 -alkyl, N- C 1 -C 7 -alkyl-amino-carbonyl- C 1 -C 7 -alkyl, N,N-di- C 1 -C 7 -alkyl-amino-carbonyl- C 1 - C 7 -alkyl, C 1 -C 7 -alkyl-sulfonyl, amino-sulfonyl, N- C 1 -C 7 -alkyl-amino-sulfonyl, N,N-di- C 1 -C 7
- R 1 is ortho-chloro
- R 2 is selected from para- C 1 -C 7 -alkyl-phenyl, para-(halo- C 1 -C 7 -alkyl)-phenyl, para- C 1 -C 7 -alkoxy- phenyl, para-halo-phenyl, para-nitro-phenyl, para-(C 1 -C 7 -alkoxy-carbonyl)-phenyl, para- (hydroxy-carbonyl)-phenyl, wherein the phenyl is optionally substituted by 1-2 additional substituents, said substituents being independently selected from halo and methyl,
- R 6 and R 7 are not both ethoxy or methoxy.
- CGM097 has the following structure:
- CGM097 is (S)-1-(4-chlorophenyl)-7-isopropoxy-6-methoxy-2-(4- ⁇ methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino ⁇ phenyl)-1,4- dihydro-2H-isoquinolin-3one.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a PIM kinase inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the PIM kinase inhibitor is disclosed in Table 1, or in a publication recited in Table 1, e.g., International Patent Publication No. WO2010/026124 (e.g., Formula I or Example 70), European Patent Application No. EP2344474, and U.S. Patent Publication No.2010/0056576.
- the PIM kinase inhibitor is disclosed, e.g., in International Patent Publication No. WO2010/026124 (e.g., Formula I or Example 70), European Patent Application No. EP2344474, and U.S. Patent Publication No.2010/0056576.
- the PIM kinase inhibitor e.g., LGH447, has the structure (compound or generic structure) provided in Table 1, or as disclosed in the publication recited in Table 1, e.g.. International Patent
- the inhibitor of the immune checkpoint molecule e.g., one of Nivolumab, Pembrolizumab or MSB0010718C
- the PIM kinase inhibitor is used in combination with the PIM kinase inhibitor to treat a cancer or disorder described in Table 1, e.g., hematological malignancy, e.g., multiple myeloma, myelodysplastic syndrome, myeloid leukemia, or non-Hodgkin lymphoma.
- the PIM kinase inhibitor is a compound of formula (I),
- X l , X 2 , X 3 and X 4 are independently selected from CR2 and N; provided that at least one but not more than two of X 1 , X 2 , X 3 and X 4 are N;
- Y is selected from a group consisting of cycloalkyl, partially unsaturated cycloalkyl, andiieterocycloalkyl, wherein each member of said group may be substituted with up to four substituents;
- Z 2 and Z 3 are independently selected from CR 12 and N; provided that not more than one of Z 2 and Z 3 can be N;
- R 1 is selected from the group consisting of hydrogen, -NHR 3 halo, hydroxyl, alkyl, cyano, and nitro;
- R 2 and R 12 independently at each occurrence are selected from the group consisting of hydrogen, halo, hydroxyl, nitro, cyano, SO 3 H and substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, amino, cycloalkyl, hetero cycloalkyl, and partially saturated cycloalkyl;
- R 3 is selected from the group consisting of hydrogen, -CO-R 4 and substituted or unsubstituted alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
- R 4 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, and alkylamino; and R 5 represents a group selected from substituted or unsubstituted aryl, C 3 -C 7 cycloalkyl, heteroaryl, partially unsaturated cycloalkyl and alkyl, wherein each said substituted R 5 group may be substituted with up to four substituents selected from halo, cyano, amino, C 1-4 alkyl, C 3-6 cycloalkyl, alkoxy, nitro, carboxy, carbonyl, carboalkoxy, aminocarboxy, substituted
- aminocarbonyl aminosulfonyl, substituted aminosulfonyl and alkoxy alkyl.
- LGH447 has the following structure:
- LGH447 is N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridine- 3-yl)-6-(2,6-difluorophenyl)-3-fluoropicolinamide.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a HER3 kinase inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the HER3 kinase inhibitor is disclosed in Table 1, e.g., LJM716, or in a publication recited in Table 1.
- the HER3 kinase inhibitor is disclosed, e.g., in International Patent Publication No.2012/022814 and U.S. Patent No.8,735,551.
- LJM716 is a monoclonal antibody provided in Table 1, or as disclosed in the publication recited in Table 1.
- the inhibitor of the immune checkpoint molecule e.g., one of Nivolumab, Pembrolizumab or MSB0010718C
- a cancer or disorder described in Table 1 e.g., a solid tumor, e.g. a gastric cancer, an esophageal cancer, a breast cancer, a head and neck cancer, a stomach cancer, or a digestive/gastrointestinal cancer therapy.
- the HER3 kinase inhibitor e.g., LJM716, is an anti-HER3 monoclonal antibody or antigen binding fragment thereof, that comprises a VH of SEQ ID NO: 141 and VL of SEQ ID NO: 140, as described in U.S.8,735,551.
- the HER3 kinase inhibitor, e.g., LJM716, is an anti-HER3 monoclonal antibody or antigen binding fragment thereof, that comprises a heavy chain variable region CDR1 of SEQ ID NO: 128;
- the HER3 kinase inhibitor e.g., LJM716, is an anti-HER3 monoclonal antibody or antigen binding fragment thereof, that recognizes a conformational epitope of a HER3 receptor, e.g., the conformational epitope comprises amino acid residues 265-277, and 315 within domain 2 and amino acid residues 571, 582-584, 596-597, 600-602, and 609-615 within domain 4 of the HER3 receptor of SEQ ID NO: 1 of U.S.
- the amino acid sequences of the heavy and light chain variable regions of LJM716 include at least the following: Heavy chain variable region (SEQ ID NO: 141 as disclosed in U.S.8,735,551) (SEQ ID NO: 8) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINSQGKSTYYADSV KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGDEGFDIWGQGTLVTVSS Light chain variable region (SEQ ID NO: 140 as disclosed in U.S.8,735,551) (SEQ ID NO: 9) DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIYGASSLQSGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQYSSFPTTFGQGTKVEIK
- the inhibitor of the immune checkpoint molecule is used in combination with a
- the HDAC inhibitor is disclosed in Table 1, e.g., LBH589, or in a publication recited in Table 1, e.g., in International Patent Publication Nos.2014/072493 and 2002/022577 (e.g., formula (I) and Example 200) and European Patent Application No. EP1870399.
- the HDAC inhibitor is disclosed, e.g., in International Patent Publication Nos. 2014/072493 and 2002/022577 (e.g., formula (I) and Example 200) and European Patent Application No. EP1870399.
- LBH589 has the structure (compound or generic) provided in Table 1, or as disclosed in the publication recited in Table 1, e.g., in
- the inhibitor of the immune checkpoint molecule (e.g., one of Nivolumab, Pembrolizumab or MSB0010718C) is used in combination with LBH589 to treat a cancer or disorder described in Table 1, e.g., a solid tumor,e.g., a bone cancer, a small cell lung cancer, a respiratory/thoracic cancer a prostate cancer, a non-small cell lung cancer (NSCLC), a nerologic cancer, a gastric cancer, a melanoma, a breast cancer, a pancreatic cancer, a colorectal cancer, a renal cancer, or a head and neck cancer, or a liver cancer; or a hematological malignancy, e.g., multiple myeloma, a hematopoeisis disorder,
- a solid tumor e.g., a bone cancer, a small cell lung cancer, a respiratory/thoracic cancer a prostate cancer, a non-small cell lung cancer (
- the HDAC inhibitor is a compound of formula (I):
- R 1 is H, halo, or a straight chain C 1 -C 6 alkyl (especially methyl, ethyl or n-propyl, which methyl, ethyl and n-propyl substituents are unsubstituted or substituted by one or more substituents described below for alkyl substituents);
- R 2 is selected from H, C 1 -C 10 alkyl, (e.g. methyl, ethyl or -CH 2 CH 2 -OH), C 4 - C 9 cycloalkyl, C 4 -C 9 heterocycloalkyl, C 4 -C 9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), aryl, heteroaryl, arylalkyl (e.g. benzyl), heteroarylalkyl (e.g.
- R 5 is selected from H, C 1 -C 6 alkyl, C 4 -C 9 cycloalkyl, C 4 -C 9 heterocycloalkyl, acyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), heteroarylalkyl (e.g., pyridylmethyl), aromatic polycycles, non
- n, n 1 , n 2 , and n 3 are the same or different and independently selected from 0 - 6, when n1 is 1-6, each carbon atom can be optionally and independently substituted with R 3 and/or R 4 ;
- X and Y are the same or different and independently selected from H, halo, C 1 -C 4 alkyl, such as CH 3 and CF 3, NO 2 , C(O)R 1 , OR 9 , SR 9 , CN, and NR 10 R 11 ;
- R 6 is selected from H, C 1 -C 6 alkyl, C 4 - C 9 cycloalkyl, C 4 - C 9 heterocycloalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), aryl, heteroaryl, arylalkyl (e.g., benzyl, 2- phenylethenyl), heteroarylalkyl (e.g., pyridylmethyl), OR 12 , and NR 13 R 14 ;
- R 7 is selected from OR 15 , SR ⁇ 5 , S(O)R 16 , SO 2 R 17 , NR 13 R ⁇ 4 , and NR 12 SO 2 R 6 ;
- R 8 is selected from H, OR 15 , NR 13 R 14 , C 1 -C 6 alkyl, C 4 - C 9 cycloalkyl, C 4 -C 9
- heterocycloalkyl aryl, heteroaryl, arylalkyl (e.g., benzyl), and heteroarylalkyl (e.g.,
- R 9 is selected from C 1 -C 6 alkyl, for example, CH 3 and CF 3 , C(O)-alkyl, for example C(O)CH 3 , and C(O)CF 3 ;
- R 10 and R 11 are the same or different and independently selected from H, C 1 -C 4 alkyl, and -C(O)-alkyl;
- R 12 is selected from H, C 1 -C 6 alkyl, C 4 - C 9 cycloalkyl, C 4 - C 9 heterocycloalkyl, C 4 - C 9 heterocycloalkylalkyl, aryl, mixed aryl and non-aryl polycycle, heteroaryl, arylalkyl (e.g., benzyl), and heteroarylalkyl (e.g., pyridylmethyl);
- R 13 and R 14 are the same or different and independently selected from H, C 1 -C 6 alkyl, C 4 -C 9 cycloalkyl, C 4 - C 9 heterocycloalkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), heteroarylalkyl (e.g., pyridylmethyl), amino acyl, or R 13 and R 14 together with the nitrogen to which they are bound are C 4 - C 9 heterocycloalkyl, heteroaryl, polyheteroaryl, non-aromatic polyheterocycle or mixed aryl and non-aryl polyheterocycle;
- R 15 is selected from H, Ci-Ce alkyl, C 4 - C 9 cycloalkyl, C 4 - C 9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and (CH 2 ) m ZR 12 ;
- R 16 is selected from C 1 -C 6 alkyl, C 4 -C 9 cycloalkyl, C 4 -C 9 heterocycloalkyl, aryl, heteroaryl, polyheteroaryl, arylalkyl, heteroarylalkyl and (CH 2 ) m ZR ⁇ 2 ;
- R 17 is selected from C 1 -C 6 alkyl, C 4 - C 9 cycloalkyl, C 4 - C 9 heterocycloalkyl, aryl, aromatic polycycles, heteroaryl, arylalkyl, heteroarylalkyl, polyheteroaryl and
- n is an integer selected from 0 to 6;
- LBH589 has the following structure:
- LBH589 is (E)-N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3- yl)ethyl)amino)methyl)phenyl)acrylamide.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a Janus kinase inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the Janus kinase inhibitor is disclosed in Table 1, e.g., INC424, or in a publication recited in Table 1, e.g., in International Patent Publication Nos.
- WO2007/070514 e.g., Formula (I) or Example 67
- WO2014/018632 European Patent Application No. EP2474545, and U.S. Patent No.7,598,257
- the Janus kinase inhibitor is disclosed, e.g., in International Patent Publication Nos.2007/070514 (e.g., Formula (I) or Example 67) and 2014/018632, European Patent Application No. EP2474545, and U.S. Patent No.7,598,257.
- the Janus kinase inhibitor e.g., INC424, has the structure (compound or generic) provided in Table 1, or as disclosed in the publication recited in Table 1, e.g., in
- the inhibitor of the immune checkpoint molecule (e.g., one of Nivolumab, Pembrolizumab or MSB0010718C) is used in combination with INC424 to treat a cancer or disorder described in Table 1, e.g., a solid tumor,e.g., a prostate cancer, a lung cancer, a breast cancer, a pancreatic cancer, a colorectal cancer; or a hematological malignancy, e.g., multiple myeloma, lymphoma (e.g., non-Hodgkin's lymphoma), or leukemia (e.g., myeloid leukemia, lymphocytic leukemia).
- the cancer has, or is identified as having, a JAK mutation.
- the JAK mutation is a JAK2 V617F mutation.
- the Janus kinase inhibitor is a compound of Formula (I):
- a 1 and A 2 are independently selected from C and N;
- T, U, and V are independently selected from O, S, N, CR 5 , and NR 6 ; wherein the 5- membered ring formed by A 1 , A 2 , U, T, and V is aromatic;
- X is N or CR 4 ;
- Y is C 1-8 alkylene, C 2-8 alkenylene, C 2-8 alkynylene, (CR 11 R 12 )p-(C 3-10 cycloalkylene)- (CR 11 R I2 ) q , (CR l I R 12 ) p -(arylene)-(CR 11 R 12 ) q , (CR 11 R 12 ) p -(C 1-10 heterocycloalkylene)-(CR 11 R 12 ) q , (CR 11 R 12 )p-(heteroarylene)-(CR 11 'R 12 ) q , (CR 11 R 12 )pO(CR 11 R 12 ), (CR 11 R 12 ) p S(CR 11 R 12 ), (CR 11 R 12 ) p C(O)(CR 11 R 12 ) q , (CR 1 (CR 1 I R 12 ) p C(O)NR c (CR I 1 R 12 ) q , (CR 11 R I2 ) p C(
- W is C 1-8 alkylenyl, C 2-8 alkenylenyl, C 2-8 alkynylenyl, O, S , C(O), C(O)NR c' , C(O)O, OC(O), OC(O)NR c’ , NR c’ , NR c’ C(O)NR d’ , S(O), S(O)NR c' , S(O) 2 , or S(O) 2 NR c" ;
- Q is H, halo, CN, NO 2 , Ci -8 alkyl, C 2- S alkenyl, C 2-8 alkynyl, d. 8 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, Ci -8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from halo, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, halosulfanyl, C 1-4 hydroxyalkyl, C 1-4 cyanoalkyl, Cy 2 , CN, NO 2 , OR 3' , SR a' , C(O)R b" , C
- Cy 1 and Cy 2 are independently selected from aryl, heteroaryl, cycloalkyl, and
- heterocycloalkyl each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, halosulfanyl, C 1-4 hydroxyalkyl, C 1-4 cyanoalkyl, CN, NO 2 , 0R a" , SR a" , C(O)R b" , C(O)NR c" R d" , C(O)OR 3" ,
- R 1 , R 2 , R 3 , and R 4 are independently selected from H, halo, C 1-6 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-6 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO 2 , OR 7 , SR 7 , C(O)R 8 , C(O)NR 9 R 10 , C(O)OR 7 OC(O)R 8 , OC(O)NR 9 R 10 , NR 9 R 10 , NR 9 C(O)R 8 , NR 0 C(O)OR 7 , S(O)R 8 , S(O)NR 9 R 10 , S(O) 2 R 8 , NR 9 S(O) 2 R 8 , and S(O) 2 NR 9 R 10 ;
- R 5 is H, halo, C )-4 alkyl, C 2-4 alken
- R 6 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, OR 7 , C(O)R 8 , C(O)NR 9 R 10 , C(O)OR 7 , S(O)R 8 , S(O)NR 9 R 10 , S(O) 2 R 8 , or S(O) 2 NR 9 R 10 ;
- R 7 is H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
- R 8 is H, C 1-6 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2 . 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
- R 9 and R 10 are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2 . 6 alkynyl, C 1-6 alkylcarbonyl, arylcarbonyl, C 1-6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and
- R 9 and R 10 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group
- R 11 and R 12 are independently selected from H and - ⁇ ⁇ - ⁇ 2 - ⁇ 3 - ⁇ 4 ;
- D 1 and E 1 are independently absent or independently selected from C 1-6 alkylene, C 2-6 alkenylene, C 2 . 6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the Ci -6 alkylene, C 2-6 alkenylene, C 2 . 6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO 2 , N 3 , SCN, OH, Ci. 6 alkyl, C 1-6 haloalkyl, C 2 . 8 alkoxyalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, amino, C 1-6 alkylamino, and C 2-8 dialkylamino;
- D 2 and E 2 are independently absent or independently selected from C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, (C 1-6 alkylene) r -O-(C 1-6 alkylene) s , (C 1-6 alkylene) r -S-( C 1-6 alkylene) s , (C 1-6 alkylene) r -NR e -(C 1-6 alkylene) s , (C , .
- D 3 and E 3 are independently absent or independently selected from C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the C )-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO 2 , N 3 , SCN, OH, C 1-6 alkyl, C 1-6 haloalkyl, C 2-8 alkoxyalkyl, C 1-6 alkoxy, C 1-6 haloalkyl, amino, C 1-6 alkylamino, and C 2-8 dialkylamino;
- R a is H, Cy 1 , -(C 1-6 alkyl)-Cy 1 , C -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, or C 2 . 6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
- R b is H, Cy 1 , -(C 1-6 alkyl)-Cy', C 1-6 alkyl, C 1-6 haloalkyl, C 2 . 6 alkenyl, C 2-6 alkynyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2 . 6 alkenyl, or C 2 . 6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and
- R a’ and R a" are independently selected from H, Ci -6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, halosulfanyl, aryl
- R b’ and R b” are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2- 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl,
- cycloalkylalkyl and heterocycloalkylalkyl wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl,
- cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
- R c and R d are independently selected from H, Cy 1 , -(C 1-6 alkyl)-Cy', C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, or C 2-6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from Cy 1 , - (C 1-6 alkyl)-Cy', OH, CN, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, and halosulfanyl;
- R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents
- R c’ and R d’ are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2- 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,
- cycloalkylalkyl and heterocycloalkylalkyl wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
- R c’ and R d’ together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents
- R c” and R d are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2- 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,
- cycloalkylalkyl and heterocycloalkylalkyl wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2 - 6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
- R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents
- R independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
- R j is H, CN, NO 2 , or C 1-6 alkyl
- R e and R f are independently selected from H and C 1-6 alkyl
- R i is H, CN, or NO 2 ;
- n 0 or 1 ;
- n 0 or 1
- p 0, 1, 2, 3, 4, 5, or 6;
- q 0, 1, 2, 3, 4, 5 or 6;
- r is 0 or 1;
- INC424 has the following structure:
- INC424 is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo-[2,3-d]pyrimidin-4- yl)-1H-pyrazol-1-yl]propanenitrile.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with an FGF receptor inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the FGF receptor inhibitor is disclosed in Table 1, e.g., BUW078, or in a publication recited in Table 1, e.g., International Patent Publication No.
- the FGF receptor inhibitor e.g., BUW078, has the structure (compound or generic structure) provided in Table 1, or as disclosed in the publication recited in Table 1, e.g.,
- the FGF receptor inhibitor is disclosed in Table 1, e.g., BGJ398, or in a publication recited in Table 1, e.g., U.S.8,552,002 (e.g., Example 145 or Formula (I) in column 6).
- the FGF receptor inhibitor e.g., BGJ398, has the structure (compound or generic structure) provided in Table 1, or as disclosed in the publication recited in Table 1, e.g., U.S.8,552,002 (e.g., Example 145 or Formula (I) in column 6).
- MSB0010718C is used in combination with BUW078 or BGJ398 to treat a cancer described in Table 1, e.g., a solid tumor, e.g., a digestive/gastrointestinal cancer; or a hematological cancer.
- a cancer described in Table 1 e.g., a solid tumor, e.g., a digestive/gastrointestinal cancer; or a hematological cancer.
- the FGF receptor inhibitor is a compound of Formula (I):
- X represents N or CH
- R 1 represents hydrogen, halogen, alkyl, alkyl substituted with saturated heterocyclyl which is unsubstituted or substituted by alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, di-substituted amino wherein the substituents are selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, substituted alkoxy wherein the substituents are selected from the group consisting of halo and alkoxy;
- R 2 represents hydrogen, halogen, alkyl, alkyl substituted with saturated heterocyclyl which is unsubstituted or substituted by alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, di-substituted amino wherein the substituents are selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, substituted alkoxy wherein the substituents are selected from the group consisting of halo and alkoxy;
- A represents aryl or heteroaryl;
- B represents aryl or heteroaryl
- R A1 represents hydrogen or a substituent different from hydrogen
- R A2 represents a direct bond or an alkanediyl
- R B1 represents hydrogen or a substituent different from hydrogen
- R represents a direct bond or aminocarbonyl
- n represents an integer selected from 0 to 3;
- n an integer selected from 0 to 5;
- BUW078 has the following structure:
- BUW078 is 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5- carboxylic acid (4-dimethylaminomethyl-1H-imidazol-2-yl)-amide.
- the FGF receptor inhibitor has the following structure:
- n 0, 1, 2, 3, 4 or 5;
- X, Y and Z are each independently selected from N or C-R 5 , wherein at least two of X, Y and Z are N;
- X 1 is oxygen
- hydroxyguanidino formamidino; isothioureido; ureido; mercapto; C(O)H or other acyl; acyloxy; substituted hydroxy; carboxy; sulfo; sulfamoyl; carbamoyl; a substituted or unsubstituted cyclic group, for example the cyclic group (whether substituted or unsubstituted) may be cycloalkyl, e.g.
- cyclohexyl phenyl, pyrrole, imidazole, pyrazole, isoxazole, oxazole, thiazole, pyridazine, pyrimidine, pyrazine, pyridyl, indole, isoindole, indazole, purine, indolizidine, quinoline, isoquinoline, quinazoline, pteridine, quinolizidine, piperidyl, piperazinyl, pyrollidine, morpholinyl or thiomorpholinyl and, for example, substituted lower aliphatic or substituted hydroxy may be substituted by such substituted or unsubstituted cyclic groups;
- -L 1 - having 1, 2, 3, 4 or 5 in-chain atoms (e.g. selected from C, N, O and S) and optionally being selected from (i) C 1 , C 2 , C 3 or C 4 alkyl, such an alkyl group optionally being interrupted and/or terminated by
- R a is hydrogen, hydroxy, hydrocarbyloxy or hydrocarbyl, wherein hydrocarbyl is optionally interrupted by an -O- or -NH- linkage and may be, for example, selected from an aliphatic group (e.g., having 1 to 7 carbon atoms, for example 1, 2, 3, or 4), cycloalkyl, especially cyclohexyl, cycloalkenyl, especially cyclohexenyl, or another carbocyclic group, for example phenyl; where the hydrocarbyl moiety is substituted or unsubstituted;
- each R 4 is the same or different and selected from an organic or inorganic moiety, for example, each R 4 is the same or different and selected from halogen; hydroxy; protected hydroxy for example trialkylsilylhydroxy; amino; amidino; guanidino; hydroxyguanidino; formamidino; isothioureido; ureido; mercapto; C(O)H or other acyl; acyloxy; carboxy; sulfo; sulfamoyl;
- X is CR 5 , wherein R 5 is H; X1 is oxygen; Y is N; Z is N; R 1 is a substituted organic moiety is a cyclic group (e.g., phenyl) substituted with 4-ethylpiperazinyl and –L 1 - is N Ra , wherein N Ra is H; R 2 is an organic moiety (e.g., H); R 3 is an organic moiety (e.g., lower aliphatic, e.g., methyl); R 4 is chloro or methoxy; and n is 4.
- R 5 is H
- X1 is oxygen
- Y is N
- Z is N
- R 1 is a substituted organic moiety is a cyclic group (e.g., phenyl) substituted with 4-ethylpiperazinyl and –L 1 - is N Ra , wherein N Ra is H;
- R 2 is an organic moiety (e.g., H);
- BGJ398 has the following structure:
- BGJ398 is 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4- ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with an EGF receptor inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the EGF receptor inhibitor is disclosed in Table 1, e.g., EGF816, or in a publication recited in Table 1, e.g., in WO 2013/184757 (e.g., Formula (5), in claims 7, 10, 11 and 12, or in Example 5).
- the EGF receptor inhibitor, e.g., EGF816, has the structure (compound or generic structure) provided in Table 1, or as disclosed in the publication recited in Table 1, e.g., in WO 2013/184757 (e.g., Formula (5), in claims 7, 10, 11 and 12, or in Example 5).
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with EGF816 to treat a cancer described in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)).
- a cancer described in Table 1 e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)).
- NSCLC non-small cell lung cancer
- EGF816 is administered at an oral dose of about 50 to 500 mg, e.g., about 100 mg to 400 mg, about 150 mg to 350 mg, or about 200 mg to 300 mg, e.g., about 100 mg, 150 mg or 200 mg.
- the dosing schedule can vary from e.g., every other day to daily, twice or three times a day.
- EGF816 is administered at an oral dose from about 100 to 200 mg, e.g., about 150 mg, once a day.
- the EGF receptor inhibitor is of formula:
- W 1 and W 2 are independently CR 1 or N;
- R 1 , R 1’ and R 2 are independently hydrogen; halo; cyano; C 1-6 alkyl; C 1-6 haloalkyl; 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; phenyl, 5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O, S and P, and optionally substituted by oxo; - X 1 -C(O)OR 3 ; -X 1 -O-C(O)R 3 ; -X 1 -C(O)R 3 ; -X 1 -C(O)NR 4 R 5 ; -X 1 -C(O)NR 4 - X 3 -C(O)OR 3 ; -X 1 -C(O)NR 4 -X 3 -S(O) 0 - 2 R 6 ; -X 1 -NR 4 R 5 ; -X 1 -NR 4 -X 2 -C(O)R
- R 3 , R 4 and R 5 are independently hydrogen, C 1-6 alkyl or C 1-6 haloalkyl; or wherein R 4 and R 5 together with N in NR 4 R 5 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R 7 ;
- R 6 is C 1-6 alkyl or C 1-6 haloalkyl
- R 6a and R 6b are independently hydroxy, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 4-12 membered monocyclic or bicyclic heterocyclyl comprising 1-4 heteroatoms selected from N, O and S, and optionally substituted with oxo; R 8 is
- X 1 and X 2 are independently a bond or C 1-6 alkyl
- X 3 is C 1-6 alkyl
- X 4 is C 2-6 alkyl
- R 12 , R 13 , R 16 and R 17 are independently hydrogen or C 1-6 alkyl
- R 14 and R 15 are independently hydrogen; C 1-6 alkyl; -C(O)O-(C 1-6 alkyl); C 3-7 cycloalkyl unsubstituted or substituted with C 1-6 alkyl; or R 14 and R 15 together with N in NR 14 R 15 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S, and P, and optionally substituted with 1-4 R 18 groups;
- R 7 and R 18 are independently oxo, halo, hydroxyl, C 1-6 alkyl or C 1-6 alkoxy; and m and q are independently 1-2;
- R 1 and R 1’ are independently hydrogen; methyl; t-butyl;
- R 2 is hydrogen; chloro; methyl; trifluoromethyl; methoxy;
- piperidinylmethyl ((4-methyl-3-oxo-piperazin-lyl)methyl); ((4-acetylpiperazin-1-yl)methyl); (1,1-dioxidothiomorpholine-4-carbonyl); pyrrolidinyl carbonyl unsubstituted or substituted by 1- 2 hydroxy; pyrrolidinylethoxy; (l,l-dioxidothiomorpholino)methyl; or 1,2,4-oxadiazolyl unsubstituted or substituted by C 1-6 alkyl;
- R 2 is -CH 2 -N(CH 3 )-C(O)-CH 3 ; -CH 2 -O-(CH 2 ) 2 -OCH 3 ; -CH 2 -N(CH 3 )- (CH 2 ) 2 -SO 2 (CH 3 ); -C(O)NH-(CH 2 ) 1 . 2 -C(O)-OCH 3 ; -C(O)NH-(CH 2 ) 1 . 2 -C(O)OH; or -C(O)NH- (CH 2 ) 2 -SO 2 (CH 3 ).
- R 8 is
- R 14 and R 15 are independently hydrogen, C 1-6 alkyl or C 3-7 cycloalkyl; or R 14 and R 15 together with N in NR 14 R 15 may form an azetidinyl, piperidyl, pyrrolidinyl or morpholinyl; where said azetidinyl or pyrrolidinyl can be optionally substituted with 1-2 halo, methoxy or hydroxyl; and
- R 12 and R 13 are independently hydrogen, halo, cyano, C 1-6 alkyl or C 1-6 haloalkyl;
- R 16 and R 17 are independently hydrogen or C 1-6 alkyl; or R 16 and R 17 together with the carbon to which they are attached may form a C 3-6 cycloalkyl.
- the EGF receptor inhibitor has the following structure: or
- EGF816 has the followin structure:
- EGF816 is (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2- enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a c-MET inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the c-MET inhibitor is disclosed in Table 1, e.g., INC280, or in a publication recited in Table 1, e.g., in EP 2099447 (e.g., in claim 1 or 53) or US 7,767,675 (e.g., in claim 4).
- the c-MET inhibitor e.g., INC280, has the structure (compound or generic structure) provided in Table 1, or as disclosed in the publication recited in Table 1.
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with INC280 to treat a cancer described in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non- small cell lung cancer (NSCLC)), glioblastoma multiforme (GBM), a renal cancer, a liver cancer or a gastric cancer.
- a cancer described in Table 1 e.g., a solid tumor, e.g., a lung cancer (e.g., non- small cell lung cancer (NSCLC)), glioblastoma multiforme (GBM), a renal cancer, a liver cancer or a gastric cancer.
- the cancer has, or is identified as having, a c-MET mutation (e.g., a c-MET mutation or a c-MET amplification).
- INC280 is administered at an oral dose of about 100 to 1000 mg, e.g., about 200 mg to 900 mg, about 300 mg to 800 mg, or about 400 mg to 700 mg, e.g., about 400 mg, 500 mg or 600 mg.
- the dosing schedule can vary from e.g., every other day to daily, twice or three times a day.
- INC280 is administered at an oral dose from about 400 to 600 mg twice a day.
- the c-MET inhibitor has the following structure:
- A is N or CR 3 ;
- Cy 1 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 ⁇ W-X-Y-Z;
- Cy 2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 -W'-X'-Y'-Z';
- L 1 is (CR 4 R 5 ) m , (CR 4 R 5 ) p -(cycloalkylene)-(CR 4 R 5 ) q , (CR 4 R 5 ) p -(arylene)-(CR 4 R 5 ) q , (CR 4 R 5 ) p -(heterocycloalkylene)-(CR 4 R 5 ) q , (CR 4 R 5 ) p -(heteroarylene)-(CR 4 R 5 ) q ,
- R 1 is H or ⁇ W"-X"-Y"-Z"
- R 2 is H, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, NO 2 , OR A , SR A , C(O)R B , C(O)NR C R D , C(O)OR A , OC(O)R B , OC(O)NR C R D , NR C R D , NR C C(O)R B
- R 3 is H, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, , CN, NO 2 , OR A , SR A , C(O)R B , C(O)NR C R D , C(O)OR A , OC(O)R B , OC(O)NR C R D , NR C R D , NR C C(O)R B , NR C C(O)NR C R D , NR C C(O)OR A , S(O)R B , S(O)NR C R D , S(O) 2 R B , NR C S(O) 2 R B , and S(O) 2 NR C R D ; wherein said cycloalkyl, aryl, heterocycloalkyl, heteroaryl, or C 1-6 alky
- R 2 and ⁇ L 2 -Cy 2 are linked together to form a group of formula:
- ring B is a fused aryl or fused heteroaryl ring, each optionally substituted with 1, 2, or 3 -W'-X'-Y'-Z';
- R 4 and R 5 are independently selected from H, halo, OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C 1-6 haloalkyl, CN, and NO 2 ;
- R 7 and R 8 are independently selected from H, halo, OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, CN, and NO 2 ;
- R 7 and R 8 together with the C atom to which they are attached form a 3, 4, 5, 6, or 7 - membered cycloalkyl or heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituent independently selected from halo, OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, CN, and NO 2 ;
- R 9 is H, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl;
- W, W', and W" are independently absent or independently selected from C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, O, S, NR h , CO, COO, CONR h , SO, SO 2 , SONR h and
- each of the C 1-6 alkylene, C 2-6 alkenylene, and C 2-6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, OH, C 1-6 alkoxy, C 1-6 haloalkoxy, amino, C 1-6 alkylamino, and C 2-8 dialkylamino;
- X, X', and X" are independently absent or independently selected from C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO 2 , OH, C 1-6 alkyl, C 1-6 haloalkyl, C 2-8 alkoxyalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 2-8 alkoxyalkoxy, cycloalkyl, heterocycloalkyl, C(O)OR j , C(O)NR h R i , amino, C 1-6 alkylamino, and C 2-8 dialkylamin
- Y, Y', and Y" are independently absent or independently selected from C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, O, S, NR h , CO, COO, CONR h , SO, SO 2 , SONR h , and NR h CONR i , wherein each of the C 1-6 alkylene, C 2-6 alkenylene, and C 2-6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, OH, C 1-6 alkoxy, C 1-6 haloalkoxy, amino, C 1-6 alkylamino, and C 2-8 dialkylamino;
- heterocycloalkyl ring each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, halosulfanyl, CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , NR c3 R d3 ,
- heterocycloalkyl ring each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, halosulfanyl, CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , NR c3 R d3 ,
- Cy 4 , and Cy 5 are independently selected from aryl, cycloalkyl, heteroaryl, and
- R A is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl wherein said C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, and C 1-4 alkyl;
- R B is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl wherein said C 1-4 alkyl, C 2-4 alkenyl, or C 2-4 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, and C 1-4 alkyl;
- R C and R D are independently selected from H, C 1-4 alkyl, C 2-4 alkenyl, or C 2-4 alkynyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, or C 2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, and C 1-4 alkyl;
- R C and R D together with the N atom to which they are attached form a 4-, 5-, 6- or 7 - membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, and C 1-4 alkyl;
- R a , R a1 , R a2 , R a3 , and R a4 are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,
- heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2 - 6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;
- R b , R b1 , R b2 , R b3 , and R b4 are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,
- heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy; R c and R d are independently selected from H, C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, ary
- heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkyl;
- R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;
- R c1 and R d1 are independently selected from H, C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,
- cycloalkylalkyl or heterocycloalkylalkyl wherein said C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,
- cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1- 6 haloalkoxy;
- R c1 and R d1 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;
- R c2 and R d2 are independently selected from H, C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,
- cycloalkylalkyl heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroarylaryl, and biheteroaryl, wherein said C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkylalkyl, heterocycloalkylalkyl, wherein said C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalky
- arylcycloalkyl arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl
- heteroarylheterocycloalkyl, heteroarylaryl, and biheteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)OR a4 , C(O)R b4 , S(O) 2 R b3 , alkoxyalkyl, and alkoxyalkoxy;
- R c2 and R d2 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 baloalkyl, C 1-6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)OR a4 , C(O)R b4 , S(O) 2 R b3 , alkoxyalkyl, and alkoxyalkoxy;
- R c3 and R d3 are independently selected from H, C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,
- cycloalkylalkyl or heterocycloalkylalkyl wherein said C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,
- cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1- 6 haloatkoxy;
- R c3 and R d3 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;
- R c4 and R d4 are independently selected from H, C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2- 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,
- cycloalkylalkyl or heterocycloalkylalkyl wherein said C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,
- cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1- 6 haloalkoxy;
- R c4 and R d4 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;
- R e , R e1 , R e2 , and R e4 are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, (C 1-6 alkoxy)-C 1-6 alkyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocycloalkylalkyl;
- R f , R f1 , R f2 , and R f4 are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl;
- R g is H, CN, and NO 2 ;
- R h and R i are independently selected from H and C 1-6 alkyl
- R j is H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl;
- n 0, 1, 2, 3, 4, 5, or 6;
- p 0, 1, 2, 3, or 4;
- q 0, 1, 2, 3, or 4;
- r is 0, 1, 2, 3, 4, 5, or 6;
- s 0, 1, 2, 3, or 4;
- t 0, 1, 2, 3, or 4;
- L 1 is (CR 4 R 5 ) m , wherein R 4 and R 5 are independently H and m is 1; Cy 1 is heteroaryl; R 1 is H; A is N; R 2 is H; L 2 is (CR 7 R 8 ) r ,wherein r is 0; and Cy 2 is aryl substituted with 2 W'-X'-Y'-Z'.
- INC280 has the following structure:
- INC280 is 2-fluoro-N-methyl-4-[7-(quinolin-6- ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, or a pharmaceutically acceptable salt thereof.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with an Alk inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the Alk inhibitor is disclosed in Table 1, e.g., LDK378, or in a publication recited in Table 1, e.g., in WO 2008/073687 (e.g., Example 7/Compound 66) or US 8,039,479 (e.g., claim 1 or 5) (also known as ceritinib (Zykadia®).
- the Alk inhibitor, e.g., LDK378, has the structure (compound or generic structure) provided in Table 1, or as disclosed in the publication recited in Table 1, e.g., in WO 2008/073687 (e.g., Example 7/Compound 66) or US 8,039,479 (e.g., claim 1 or 5).
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with LDK378 to treat a cancer described in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a lymphoma (e.g., an anaplastic large-cell lymphoma or non-Hodgkin lymphoma), an inflammatory myofibroblastic tumor (IMT), or a neuroblastoma.
- the NSCLC is a stage IIIB or IV NSCLC, or a relapsed locally advanced or metastic NSCLC.
- the cancer e.g., the lung cancer, lymphoma, inflammatory myofibroblastic tumor, or neuroblastoma
- the ALK fusion has, or is identified as having, an ALK rearrangement or translocation, e.g., an ALK fusion.
- the ALK fusion is an EML4-ALK fusion, e.g., an EML4-ALK fusion described herein.
- the ALK fusion is an ALK-ROS1 fusion.
- the cancer has progressed on, or is resistant or tolerant to, a ROS1 inhibitor, or an ALK inhibitor, e.g., an ALK inhibitor other than LDK378.
- the cancer has progressed on, or is resistant or tolerant to, crizotinib.
- the subject is an ALK-na ⁇ ve patient, e.g., a human patient.
- the subject is a patient, e.g., a human patient, that has been pretreated with an ALK inhibitor.
- the subject is a patient, e.g., a human patient, that has been pretreated with LDK378.
- LDK378 and Nivolumab are administered to an ALK-na ⁇ ve patient. In another embodiment, LDK378 and Nivolumab are administered to a patient that has been pretreated with an ALK inhibitor. In yet another embodiment, LDK378 and Nivolumab are administered to a patient that has been pretreated with LDK378.
- LDK378 is administered at an oral dose of about 100 to 1000 mg, e.g., about 150 mg to 900 mg, about 200 mg to 800 mg, about 300 mg to 700 mg, or about 400 mg to 600 mg, e.g., about 150 mg, 300 mg, 450 mg, 600 mg or 750 mg. In certain embodiment, LDK378 is administered at an oral dose of about 750 mg or lower, e.g., about 600 mg or lower, e.g., about 450 mg or lower. In certain embodiments, LDK378 is administered with food. In other embodiments, the dose is under fasting condition. The dosing schedule can vary from e.g., every other day to daily, twice or three times a day.
- LDK378 is administered daily. In one embodiment, LDK378 is administered at an oral dose from about 150 mg to 750 mg daily, either with food or in a fasting condition. In one embodiment, LDK378 is administered at an oral dose of about 750 mg daily, in a fasting condition. In one embodiment, LDK378 is administered at an oral dose of about 750 mg daily, via capsule or tablet. In another embodiment, LDK378 is administered at an oral dose of about 600 mg daily, via capsule or tablet. In one embodiment, LDK378 is administered at an oral dose of about 450 mg daily, via capsule or tablet.
- LDK378 is administered at a dose of about 450 mg and nivolumab is administered at a dose of about 3 mg/kg. In another embodiment, the LDK378 dose is 600 mg and the nivolumab dose is 3 mg/kg. In one embodiment, LDK378 is administered with a low fat meal.
- the Alk inhibitor has the following structure:
- R 1 is halo or C 1-6 alkyl
- R 2 is H
- R 3 is (CR 2 ) 0-2 SO 2 R 12 ;
- R 4 is C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; OR 12 , NR(R 12 ), halo, nitro, SO 2 R 12 ,
- R 6 is isopropoxy or methoxy
- R 8 and R 9 is (CR 2 ) q Y and the other is C 1-6 alkyl, cyano, C(O)O 0-1 R 12 , CONR(R 12 ) or CONR(CR 2 ) p NR(R 12 );
- X is (CR 2 ) q Y, cyano, C(O)O 0-1 R 12 , CONR(R 12 ), CONR(CR 2 ) p NR(R 12 ),
- CONR(CR 2 ) p OR 12 CONR(CR 2 ) p SR 12 , CONR(CR 2 ) p S(O) 1-2 R 12 or (CR 2 ) 1-6 NR(CR 2 ) p OR 12 ;
- Y is pyrrolidinyl, piperidinyl or azetidinyl, each of which is attached to the phenyl ring via a carbon atom;
- R 12 and R 13 are independently 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 5-7 membered heterocyclic ring comprising N, O and/or S; aryl or heteroaryl; or R 12 is H or C 1-6 alkyl;
- R is H or C 1-6 alkyl
- n 0-1;
- p 0-4;
- LDK378 has the following structure:
- LDK378 is 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)- phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a CDK4/6 inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the CDK4/6 inhibitor is disclosed in Table 1, e.g., LEE011, or in a publication recited in Table 1, e.g., in US 8,685,980 or US 8,415,355 (e.g., Formula (I) in columns 3-4 or in Example 74 at column 66).
- the CDK4/6 inhibitor e.g., LEE011
- MSB0010718C is used in combination with LEE011 to treat a cancer described in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a neurologic cancer, melanoma or a breast cancer, or a hematological malignancy, e.g., lymphoma.
- a cancer described in Table 1 e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a neurologic cancer, melanoma or a breast cancer, or a hematological malignancy, e.g., lymphoma.
- a cancer described in Table 1 e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a neurologic cancer, melanoma or a breast cancer,
- the CDK4/6 inhibitor has the following structure:
- X is CR 9 or N
- R 1 is C 1-8 alkyl, CN, C(O)OR 4 or CONR 5 R 6 , a 5-14 membered heteroaryl group, or a 3-14 membered cycloheteroalkyl group;
- R 2 is C 1-8 alkyl, C 3-14 cycloalkyl, or a 5-14 membered heteroaryl group, and wherein R 2 may be substituted with one or more C 1-8 alkyl, or OH;
- L is a bond, C 1-8 alkylene, C(O), or C(O)NR 10 , and wherein L may be substituted or unsubstituted;
- Y is H, R 11 , NR 12 R 13 , OH, or Y is part of the following group
- Y is CR 9 or N; where 0-3 R 8 may be present, and R 8 is C 1-8 alkyl, oxo, halogen, or two or more R 8 may form a bridged alkyl group;
- W is CR 9 , or N, or O (where W is O, R 3 is absent); R 3 is H, C 1-8 alkyl, C 1-8 alkylR 14 , C 3-14 cycloalkyl, C(O)C 1-8 alkyl, C 1-8 haloalkyl, C 1-8 alkylOH, C(O)NR 14 R 15 , C 1-8 cyanoalkyl, C(O)R 14 , C 0-8 alkylC(O)C 0-8 alkylNR 14 R 15 , C 0-8 alkylC(O)OR 14 , NR 14 R 15 , SO 2 C 1-8 alkyl, C 1-8 alkylC 3-14 cycloalkyl, C(O)C 1-8 alkylC 3-14 cycloalkyl, C 1-8 alkoxy, or OH which may be substituted or unsubstituted when R 3 is not H.
- R 9 is H or halogen
- R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , and R 15 are each independently selected from H, C 1- 8 alkyl, C 3-14 cycloalkyl, a 3-14 membered cycloheteroalkyl group, a C 6-14 aryl group, a 5-14 membered heteroaryl group, alkoxy, C(O)H, C(N)OH, C(N)OCH 3 , C(O)C 1-3 alkyl, C 1-8 alkylNH 2 , C 1-6 alkylOH, and wherein R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , and R 13 , R 14 , and R 15 when not H may be substituted or unsubstituted;
- n and n are independently 0-2;
- L, R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , and R 13 , R 14 , and R 15 may be substituted with one or more of C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-14 cycloalkyl, 5-14 membered heteroaryl group, C 6-14 aryl group, a 3-14 membered cycloheteroalkyl group, OH, (O), CN, alkoxy, halogen, or NH 2 .
- X is CR 9 , wherein R 9 is H; R 1 is CONR 5 R 6 , wherein R 5 and R 6 are both C 1-8 alkyl, specifically methyl; R 2 is C 3-14 cycloalkyl, specifically cyclopentyl; L is a bond;
- Y is N, zero R 8 are present, W is N, m and n are both 1, and R 3 is H.
- LEE011 has the following structure:
- LEE011 is 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)- 7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide or a pharmaceutically acceptable salt thereof.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a PI3K-inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- a cancer described herein e.g., a cancer disclosed in Table 1
- the PI3K-inhibitor is disclosed in Table 1, e.g., BKM120 or BYL719, or in a publications recited in Table 1, e.g., in WO2007/084786 (e.g., Example 10 in [0389] or Formula (I) in [0048]) or WO2010/029082 (e.g., Example 15 or Formula (I)).
- the PI3K-inhibitor e.g., BKM120 or BYL719, has the structure (compound or generic structure) provided in Table 1, or as disclosed in the publications recited in Table 1 e.g., in
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with BKM120 or BYL719 to treat a cancer or disorder described in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a prostate cancer, an endocrine cancer, an ovarian cancer, a melanoma, a bladder cancer, a female reproductive system cancer, a digestive/gastrointestinal cancer, a colorectal cancer, glioblastoma multiforme (GBM), a head and neck cancer, a gastric cancer, a pancreatic cancer or a breast cancer; or a hematological malignancy, e.g., leukemia, NSCLC)
- GBM glioblastoma multiforme
- the PI3K-inhibitor has the following structure:
- W is CRWor N, wherein Rw is selected from the group consisting of (1) hydrogen, (2) cyano, (3) halogen, (4) methyl, (5) trifluoromethyl, and (6) sulfonamido; R 1 is selected from the group consisting of (1) hydrogen, (2) cyano, (3) nitro, (4) halogen, (5) substituted and unsubstituted alkyl, (6) substituted and unsubstituted alkenyl, (7) substituted and unsubstituted alkynyl, (8) substituted and unsubstituted aryl, (9) substituted and unsubstituted heteroaryl, (10) substituted and unsubstituted heterocyclyl, (11) substituted and unsubstituted cycloalkyl, (12) -COR 1a , (13) -CO 2 R 1a (14)–CONR 1a R 1b , (15)–NR 1a R 1b ,, (16)–NR 1a COR 1b
- W is CRw and Rw is hydrogen
- R 1 is unsubstituted heterocyclyl
- R 2 is hydrogen
- R 3 is substituted alkyl
- R 4 is hydrogen
- BKM120 has the following structure:
- BKM120 is 4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4- yl)pyridine-2-amine or a pharmaceutically acceptable salt thereof.
- the PI3K-inhibitor has the following structure:
- R 1 represents one of the following substituents: (1) unsubstituted or substituted, preferably substituted C 1 -C 7 alkyl, wherein said substituents are independently selected from one or more, preferably one to nine of the following moieties: deuterium, fluoro, or one to two of the following moietiesC 3 -C 5 cycloalkyl; (2) optionally substituted C 3 -C 5 cycloalkyl wherein said substituents are independently substituted C 3 -C 5 cycloalkyl wherein said substituents are independently selected from one or more, preferably one to four of the following moieties: deuterium, C 1 -C 4 alkyl (preferably methyl), fluoro, cyano, aminocarbonyl; (3) optionally substituted phenyl wherein said substituents are independently selected from one or more, preferably one to two of the following moieties: deuterium, halo, cyano, C 1 -C 7 alkyl, C 1 -C 7 alky
- A is ;
- R 1 is substituted C 1 -C 7 alkyl, wherein said substituents are independently selected from one or more, preferably one to nine of deuterium, fluoro, or C 3 -C 5 cycloalkyl;
- R 2 is hydrogen, and
- R 3 is methyl.
- BYL719 has the following structure:
- BYL719 is (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-( ⁇ 4- methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl ⁇ -amide) or a pharmaceutically acceptable salt thereof.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a BRAF inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the BRAF inhibitor is disclosed in Table 1, e.g., LGX818, or in a publication recited in Table 1, e.g., WO2011/025927 (e.g., Example 6/Compound 6 or Formula (Ia) in
- the BRAF inhibitor e.g., LGX818, has the structure (compound or generic structure) provided in Table 1, or as disclosed in the publication recited in Table 1.
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with LGX818 to treat a cancer described in Table 1, e.g., a solid tumor, e.g., a lung cancer (e.g., non-small cell lung cancer (NSCLC)), a melanoma, e.g., advanced melanoma, a thyroid cancer, e.g, papillary thyroid cancer, or a colorectal cancer.
- the cancer has, or is identified as having, a BRAF mutation (e.g., a BRAF V600E mutation), a BRAF wildtype, a KRAS wildtype or an activating KRAS mutation.
- the cancer may be at an early, intermediate or late stage.
- the BRAF inhibitor has the following structure:
- R 2 , R 3 , R 5 , and R 6 are independently selected from hydrogen, halo, cyano, C 1-4 alkyl, halo-substituted C 1-4 alkyl, C 1-4 alkoxy and halo-substituted C 1- 4 alkoxy; with the proviso that when R 5 is fluoro and R 1 is selected from hydrogen, -X1R8a, - X 1 C(O)NR 8a R 8b , -XNR 8a X 2 R 8b , -X 1 NR 8a C(O)X 2 OR 8b and–X 1 NR 8a S(O) 0-2 R 8b , R 3 and R 6 are not both hydrogen; R 4 is selected from–R 9 and–NR 10 R 11 ; wherein R 9 is selected from C 1-6 alkyl, C 3- 8 cycloalkyl, C 3-8 heterocycloalkyl, aryl, and heteroaryl; where
- R 3 is halo (e.g., chloro); R 4 is R 9 ; R 9 is C 1-6 alkyl (e.g., methyl), R 5 is halo (e.g., fluoro), R 7 is C 1-4 alkyl (e.g., isopropyl); Y is CR 6 ; and R 6 is H.
- LGX818 has the following structure:
- LGX818 is methyl (S)-(1-((4-(3-(5-chloro-2-fluoro-3- (methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2- yl)carbamate or a pharmaceutically acceptable salt thereof.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a CAR T cell targeting CD19 to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the CAR T cell targeting CD19 is disclosed in Table 1, e.g., CTL019, or in a publication recited in Table 1, e.g., WO 2012/079000, e.g., SEQ ID NO: 12 (e.g., full-length CAR) or SEQ ID NO: 14 (e.g., CD19 scFv).
- the CAR T cell targeting CD19 e.g., CTL019, has the structure (compound or generic structure) provided in Table 1, or as disclosed in the publication recited in Table 1.
- one of Nivolumab is disclosed in Table 1, e.g., CTL019, or in a publication recited in Table 1, e.g., WO 2012/079000, e.g., SEQ ID NO: 12 (e.g., full-length CAR) or SEQ ID NO: 14 (e.g., CD19 scFv).
- the CAR T cell targeting CD19 e.g., CTL
- Pembrolizumab or MSB0010718C is used in combination with CTL019 to treat a cancer described in Table 1, e.g., a solid tumor, or a hematological malignancy, e.g., a lymphocytic leukemia or a non-Hodgkin lymphoma.
- the CAR T cell targeting CD19 has the USAN designation
- CTL019 is made by a gene modification of T cells is mediated by stable insertion via transduction with a self-inactivating, replicationdeficient Lentiviral (LV) vector containing the CTL019 transgene under the control of the EF-1 alpha promoter.
- CTL019 is a mixture of transgene positive and negative T cells that are delivered to the subject on the basis of percent transgene positive T cells.
- the inhibitor of the immune checkpoint molecule is used in combination with a MEK inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- a cancer described herein e.g., a cancer disclosed in Table 1.
- the MEK inhibitor is disclosed in Table 1, e.g., MEK162, or in a publication recited in Table 1, e.g., WO2003/077914 (e.g., Example 18/Compound 29lll or Formula II).
- the MEK inhibitor e.g., MEK162
- WO2003/077914 e.g., Example 18/Compound 29lll or Formula II.
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with MEK162 to treat a cancer described in Table 1.
- the cancer or disorder treated with the combination is chosen from a melanoma, a colorectal cancer, a non-small cell lung cancer, an ovarian cancer, a breast cancer, a prostate cancer, a pancreatic cancer, a hematological malignancy or a renal cell carcinoma, a multisystem genetic disorder, a digestive/gastrointestinal cancer, a gastric cancer, or a colorectal cancer; or rheumatoid arthritis.
- the cancer has, or is identified as having, a KRAS mutation.
- the MEK inhibitor has the following structure:
- R 1 , R 2 , R 9 and R 10 are independently selected from hydrogen, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR 3 , -C(O)R 3 , -C(O)OR 3 ,
- R 3 is selected from hydrogen, trifluoromethyl, and
- R', R" and R'" independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl;
- R" is selected from lower alkyl, lower alkenyl, aryl and arylalkyl; or
- any two of R', R", R'" or R"" can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or
- R 3 and R 4 can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, - NR SO 2 R “" , -SO 2 NR ' R “ , -C(O)R , -C(O)OR , - OC(O)R , -NR ' C(0)0R "” , - NR C(O)R “ , -C(O)NRR “ , -SO 2 R "” , -NR ' R “ , -NR ' C(O)NR “ R '” , - NR ' C(NCN)NR “ R '” , -OR , aryl, heteroaryl, arylalkyl
- R 4 and R 5 independently represent hydrogen or C 1 -C 6 alkyl
- R 4 and R 5 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl,
- R 6 is selected from trifluoromethyl
- R 7 is selected from hydrogen
- W is selected from heteroaryl, heterocyclyl, -C(O)OR 3 , -C(O)NR 3 R 4 , -C(O)NR 4 OR 3 , - C(O)R 4 OR 3 , -C(O)(C 3 -C 10 cycloalkyl), -C(O)(C 1 -C 10 alkyl), -C(O)(aryl), -C(O)(heteroaryl) and - C(O)(heterocyclyl), each of which is optionally substituted with 1-5 groups independently selected from -NR 3 R 4 , -OR 3 , -R 2 , and C 1 - C 10 alkyl, C 2 -C 10 alkenyl, and C 2 -C 10 alkynyl, each of which is optionally substituted with 1 or 2 groups independently selected from-NR 3 R 4 and-OR 3 ;
- R 8 is selected from hydrogen, -SCF 3 , -Cl, -Br, -F, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR 3 , -C(O)R 3 , -C(O)OR 3 ,-NR 4 C(O)OR 6 , -OC(O)R 3 , -NR 4 SO 2 R 6 , -SO 2 NR 3 R 4 , -NR 4 C(O)R 3 , -C(O)NR 3 R 4 ,-NR 5 C(O)NR 3 R 4 , -NR 3 R 4 , and
- n 0, 1, 2, 3, 4 or 5;
- R 7 is C ⁇ - C 10 alkyl, C 3 -C 7 cycloalkyl or C 3 -C 7 cycloalkylalkyl, each of which can be optionally substituted with 1 - 3 groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR 4 SO 2 R 6 , - SO 2 NR 3 R 4 , -C(O)R 3 , -C(O)OR 3 , -OC(O)R 3 , -SO 2 R 3 , -NR 4 C(O)OR 6 , -NR 4 C(O)R 3 , -C(O)NR 3 R 4 , - NR 3 R 4 , -NR 5 C(O)NR 3 R 4 , -NR 5 C(NCN)NR 3 R 4 , -OR 3 , aryl, heteroaryl, aryl
- heteroarylalkyl heterocyclyl, and heterocyclylalkyl.
- R 1 is halogen
- R 2 is hydrogen
- R 3 is C 1 - C 10 alkyl substituted with OR’ and R’ is hydrogen
- R 4 is hydrogen
- R 7 is C 1 - C 10 alkyl
- R 8 is bromo
- R 9 is halogen
- R 10 is hydrogen
- W is–C(O)NR 4 OR 3 .
- MEK162 has the following structure:
- MEK162 is 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2- hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide or a pharmaceutically acceptable salt thereof.
- the inhibitor of the immune checkpoint molecule (alone or in combination with other immunomodulators) is used in combination with a BCR-ABL inhibitor to treat a cancer, e.g., a cancer described herein (e.g., a cancer disclosed in Table 1).
- the BCR-ABL inhibitor is disclosed in Table 1, e.g., AMN-107, or in a publication recited in Table 1, e.g., in WO 2004/005281 (e.g., in Example 92 or Formula (I) in claim 1) or US 7,169,791 (e.g., in claim 8).
- AMN-107 has the structure (compound or generic structure) provided in Table 1, or as disclosed in the publication recited in Table 1, e.g., in WO 2004/005281 (e.g., in Example 92 or Formula (I) in claim 1) or US 7,169,791 (e.g., in claim 8).
- one of Nivolumab, Pembrolizumab or MSB0010718C is used in combination with AMN-107 to treat a cancer or disorder described in Table 1, e.g., a solid tumor, e.g., a neurologic cancer, a melanoma, a digestive/gastrointestinal cancer, a colorectal cancer, a head and neck cancer; or a hematological malignancy, e.g., chronic myelogenous leukemia (CML), a lymphocytic leukemia, a myeloid leukemia; Parkinson's disease; or pulmonary hypertension.
- CML chronic myelogenous leukemia
- a lymphocytic leukemia a myeloid leukemia
- Parkinson's disease Parkinson's disease
- pulmonary hypertension e.g., chronic myelogenous leukemia (CML), a lymphocytic leukemia, a myeloid leukemia; Parkinson's disease; or pulmonary hypertension.
- the BCR-ABL inhibitor has the following structure:
- R 1 represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy- lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
- R 2 represents hydrogen, lower alkyl, optionally substituted by one or more identical or different radicals R 3 , cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; and
- R 3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N- mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; or wherein
- R 1 and R 2 together represent alkylene with four, five or six carbon atoms optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, oxo, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms; oxaalkylene with one oxygen and three or four carbon atoms; or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy- lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N-disubstituted carbamoyl- lower alkyl, cycloalkyl, lower alkoxy
- R 4 represents hydrogen, lower alkyl, or halogen
- R 1 is hydrogen
- R 2 is phenyl substituted with CF 3 and
- R4 is CH 3
- AMN-107 has the followin structure:
- AMN-107 is 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N- [5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or pharmaceutically acceptable salt thereof.
- SMAC mimetic LCL161 also known as SMAC mimetic LCL161 is an orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with antineoplastic activity.
- SMAC mimetic LCL161 binds to IAPs, such as X chromosome-linked IAP (XIAP) and cellular IAPs 1 and 2. Since IAPs shield cancer cells from the apoptosis process, this agent can be used to restore and promote the induction of apoptosis through apoptotic signaling pathways in cancer cells.
- IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding and inhibiting active caspases-3, -7 and -9, which play essential roles in apoptosis (programmed cell death), necrosis and inflammation.
- LCL161 has the structure provided in Table 1, or as disclosed in the publication recited in Table 1, e.g., International Patent Publication No. WO2008/016893 (e.g., Formula (I), Example 1, and Compound A), European Patent No.2051990, and U.S. Patent No. 8,546,336.
- LCL161 has the following structure:
- LCL161 is (S)-N-((S)-1-cyclohexyl-2-((S)-2-(4-(4- fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide.
- an immunomodulatory e.g., an inhibitor of the immune checkpoint molecule (e.g., a PD-1 inhibitor, e.g., Nivolumab or Pembrolizumab, a PD-L1 inhibitor, e.g., MSB0010718C, or a TIM-3 inhibitor, e.g., an anti-TIM-3 antibody molecule) is used in combination with LCL161 to treat a cancer or disorder described in Table 1, e.g., a solid tumor, e.g., a breast cancer or a pancreatic cancer; or a hematological malignancy, e.g., multiple myeloma or a hematopoeisis disorder.
- a PD-1 inhibitor e.g., Nivolumab or Pembrolizumab
- a PD-L1 inhibitor e.g., MSB0010718C
- a TIM-3 inhibitor e.g., an anti-TIM-3 antibody molecule
- the inhibitor of the immune checkpoint molecule (e.g., an anti-PD-1 antibody molecule or an anti-TIM-3 antibody molecule) is administered intravenously.
- LCL161 is administered orally.
- the inhibitor of the immune checkpoint molecule (e.g., the anti-PD-1 antibody molecule or anti- TIM-3 antibody molecule) is administered, e.g., intravenously, at least one, two, three, four, five, six, or seven days, e.g., three days, after LCL161 is administered, e.g., orally.
- LCL161 is administered orally.
- the inhibitor of the immune checkpoint molecule (e.g., the anti-PD-1 antibody molecule or anti-TIM-3 antibody molecule) is administered, e.g., intravenously, at least one, two, three, four, five, six, or seven days, e.g., three days, before LCL161 is administered, e.g., orally.
- the inhibitor of the immune checkpoint molecule (e.g., the anti-PD-1 antibody molecule or anti-TIM-3 antibody molecule) is administered, e.g., intravenously, on the same day, as LCL161 is administered, e.g., orally.
- the administration of the inhibitor of the immune checkpoint molecule e.g., the anti-PD-1 antibody molecule or anti-TIM-3 antibody molecule
- LCL161 results in a synergistic effect.
- the inhibitor of the immune checkpoint molecule e.g., the anti-PD-1 antibody molecule or anti-TIM-3 antibody molecule
- LCL161 results in a synergistic effect.
- concentration LCL161 that is required to achieve inhibition, e.g., growth inhibition, is lower than the therapeutic dose of LCL161 as a monotherapy, e.g., 10-20%, 20-30%, 30-40%, 40-50%, 50- 60%, 60-70%, 70-80%, or 80-90% lower.
- the concentration of the inhibitor of the immune checkpoint molecule e.g., the anti-PD-1 antibody molecule or anti-TIM-3 antibody molecule
- the concentration of the inhibitor of the immune checkpoint molecule is lower than the therapeutic dose of the inhibitor of the immune checkpoint molecule (e.g., the anti-PD-1 antibody molecule or anti-TIM-3 antibody molecule) as a monotherapy, e.g., 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, or 80-90% lower.
- administration of LCL161, alone or in combination with an anti-PD-1 antibody molecule increases the expression of an immune-active cytokine, e.g., IFN-gamma, in the cancer or the subject.
- administration of LCL161, alone or in combination with an anti-PD-1 antibody molecule reduces the expression of an immune-suppressive cytokine, e.g., IL-10, in the cancer or the subject.
- the LCL161 is administered at a dose (e.g., oral dose) of about 10- 3000 mg, e.g., about 20-2400 mg, about 50-1800 mg, about 100-1500 mg, about 200-1200 mg, about 300-900 mg, e.g., about 600 mg, about 900 mg, about 1200 mg, about 1500 mg, about 1800 mg, about 2100 mg, or about 2400 mg.
- a dose e.g., oral dose
- a dose e.g., oral dose of about 10- 3000 mg, e.g., about 20-2400 mg, about 50-1800 mg, about 100-1500 mg, about 200-1200 mg, about 300-900 mg, e.g., about 600 mg, about 900 mg, about 1200 mg, about 1500 mg, about 1800 mg, about 2100 mg, or about 2400 mg.
- LCL161 is administered once a week or once every two weeks.
- LDK378 (ceritinib) is an Anaplastic Lymphoma Kinase (ALK) inhibitor. Its chemical formula is 5-chloro-N 2 -(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N 4 -[2-(propane-2- sulfonyl)-phenyl]-pyrimidine-2,4-diamine.
- a process for preparing LDK378 was disclosed in WO2008/073687.
- the compound has been approved by the US FDA as ZYKADIA® for the treatment of patients with Anaplastic Lymphoma Kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or are intolerant to crizotinib.
- ALK Anaplastic Lymphoma Kinase
- NSCLC metastatic non-small cell lung cancer
- the currently approved daily dose for use of LDK378 (alone) in NSCLC is 750 mg orally on an empty stomach (i.e., is not to be administered within 2 hours of a meal).
- LDK378 demonstrated a high rate of rapid and durable responses in 246 ALK-positive NSCLC patients treated in the 750 mg dose group (RD). In these patients the overall response rate (ORR) was 58.5%. Among the 144 ALK-positive NSCLC patients with a confirmed complete response (CR) or partial response (PR), 86.1% of those patients achieved a response within 12 weeks, with a median time to response of 6.1 weeks. The estimated median duration of response (DOR) based on investigator assessment was long at 9.69 months. The median progression-free survival (PFS) was 8.21 months with 53.3% of the patients censored.
- ORR overall response rate
- ceritinib showed this level of high anti-cancer activity regardless of prior ALK inhibitor status (i.e., whether or not the patient received previous treatment with an ALK inhibitor).
- a high ORR of 54.6% and 66.3% was observed in patients treated with a prior ALK inhibitor and in ALK inhibitor-na ⁇ ve patients, respectively.
- metastatic ALK-positive NSCLC remains a difficult disease to treat.
- Harnessing the immune system to treat patients with NSCLC represents a novel and new treatment approach, and nivolumab can be safely combined with LDK378.
- Combination therapy involving targeted agent LDK378 and immunotherapy can improve progression- free survival and ultimately overall survival in NSCLC patients.
- the present disclosure relates to a pharmaceutical combination, especially a pharmaceutical combination product, comprising the combination of an immunomodulator and an agent disclosed herein.
- the compounds in the pharmaceutical combination can be administered separately or together.
- LDK378 and the Nivolumab can be administered independently at the same time or separately within time intervals, wherein time intervals allow that the combination partners are jointly active.
- pharmaceutical combination refers to a product obtained from mixing or combining in a non-fixed combination the active ingredients, e.g. (i) LDK378, or a pharmaceutically acceptable salt thereof, and (ii) Nivolumab or a pharmaceutically acceptable salt thereof separately or together.
- non-fixed combination means that the active ingredients, e.g. LDK378 and Nivolumab, are both administered separately or together, independently at the same time or separately within time intervals, wherein such administration provides therapeutically effective levels of the active ingredient in the subject in need.
- cocktail therapy e.g. the administration of three or more active ingredients.
- This term defines especially a“kit of parts” in the sense that the combination partners (i) LDK378 and (ii) Nivolumab (and if present further one or more co-agents) as defined herein can be dosed independently of each other.
- joint therapeutically effective means that the compounds show synergistic interaction when administered separately or together, independently at the same time or separately within time intervals, to treat a subject in need, such as a warm-blooded animal in particular a human.
- the combination of the present disclosure possesses beneficial therapeutic properties, e.g. synergistic interaction, strong in-vivo and in-vitro antitumor response, which can be used as a medicine. Its characteristics render it particularly useful for the treatment of cancer.
- Suitable cancers that can be treated with the combination of the present disclosure include but are not limited to anaplastic large cell lymphoma (ALCL), neuroblastoma, lung cancer, non-small cell lung cancer (NSCLC).
- the cancer is NSCLC.
- the combination according to the present disclosure can besides or in addition be administered especially for cancer therapy in combination with chemotherapy, radiotherapy, immunotherapy, surgical intervention, or in combination of these.
- Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above.
- Other possible treatments are therapy to maintain the patient’s status after tumor regression, or even chemo-preventive therapy, for example in patients at risk.
- the combination of LDK378 and Nivolumab can be used to manufacture a medicament for an ALK mediated disease as described above.
- the combination can be used in a method for the treatment of an ALK, as described above, said method comprising administering an effective amount of a combination of (i) LDK378, or a pharmaceutically acceptable salt thereof, and (ii) Nivolumab or a pharmaceutically acceptable salt thereof separately or together, to a subject in need thereof, according to the present disclosure.
- jointly (therapeutically) active may mean that the compounds may be given separately or sequentially (in a chronically staggered manner, especially a sequence specific manner) in such time intervals that they preferably, in the warm-blooded animal, especially human, to be treated, and still show a (preferably synergistic) interaction (joint therapeutic effect).
- a joint therapeutic effect can, inter alia, be determined by following the blood levels, showing that both compounds are present in the blood of the human to be treated at least during certain time intervals, but this is not to exclude the case where the compounds are jointly active although they are not present in blood simultaneously.
- the present disclosure also describes the method for the treatment of an ALK mediated disease, wherein the combination of (i) LDK378, or a pharmaceutically acceptable salt thereof, and (ii) Nivolumab or a pharmaceutically acceptable salt thereof separately or together.
- the present disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising effective amounts of (i) LDK378, or a pharmaceutically acceptable salt thereof, and (ii) Nivolumab, or a pharmaceutically acceptable salt thereof.
- the present disclosure also describes the pharmaceutical combination according to the present disclosure in the form of a“kit of parts” for the combined administration.
- the independent formulations or the parts of the formulation, product, or composition can then, e.g. be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts.
- the compounds useful according to the disclosure may be manufactured and/or formulated by the same or different manufacturers.
- the combination partners may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising LDK378 and the Nivolumab); (ii) by the physician themselves (or under the guidance of a physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the disclosure and the other therapeutic agent.
- the effect of the combination is synergistic.
- composition is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated, and can be determined by standard clinical techniques.
- in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges.
- the precise dose to be employed can also depend on the route of administration, and the seriousness of the condition being treated and can be decided according to the judgment of the practitioner and each subject's circumstances in view of, e.g., published clinical studies. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from 150 mg to 750 mg of LDK378 orally. In most cases, the daily dose for LDK378 can be between 300 mg and 750 mg.
- LDK378 When administered in combination with Nivolumab, LDK378 can be administered at 450 mg with 3 mg/kg nivolumab, 600 mg LDK378 with 3 mg/kg Nivolumab, or 300 mg LDK378 with 3 mg/kg nivolumab.
- the most preferred dose of both compounds for combination therapy is 600 mg of LDK378 with 3 mg/kg Nivolumab.
- Particularly 600 mg LDK378 with 3 mg/kg Nivolumab is the most preferred dosing regimen for treating ALK-positive (e.g., EML4-ALK) NSCLC.
- Nivolumab can be administered as the fixed dose infusion every two weeks. Ceritinib is to be taken together with a low fat meal.
- ceritinib is administered within 30 minutes after consuming a low fat meal.
- a patient should refrain from eating for at least an hour after intake of ceritinib and the low fat meal.
- administration of ceritinib with daily meal intake can reduce the incidence and/or severity of gastrointestinal events. It is estimated that the steady state exposure of ceritinib at 450 mg and 600 mg with daily low-fat meal intake is within 20% relative to that of ceritinib at the recommended phase II dose of 750 mg administered fasted, as predicted by model-based clinical trial simulation, using a population pharmacokinetic model established for ALK-positive cancer patients in one clinical study in conjunction with absorption parameters estimated from another clinical study.
- The“low-fat meal” denotes herein a meal that contains approximately 1.5 to 15 grams of fat and approximately 100 to 500 total calories.
- ceritinib does not have a mechanism of action that would be expected to antagonize an immune response. Furthermore, immune-related adverse events have not been frequently reported in ceritinib trials. Potential overlapping toxicities between ceritinib and Nivolumab include diarrhea, nausea, AST and ALT elevations, pneumonitis, and hyperglycemia. The mechanisms of these toxicities are not expected to be similar, given the mechanisms of action of the two compounds and thus the safety profile can be managed.
- LDK378 for use as a medicine, wherein LDK378, or a pharmaceutically acceptable salt thereof, is to be administered in combination with Nivolumab, or a pharmaceutically acceptable salt thereof, for the treatment of an ALK mediated disease, e.g. cancer.
- ALK mediated disease refers to a disease in which activity of the kinase leads to abnormal activity of the regulatory pathways including overexpression, mutation or relative lack of activity of other regulatory pathways in the cell that result in excessive cell proliferation, e.g. cancer.
- the ALK mediated disease can be non-small cell lung cancer (NSCLC) that is driven by the echinoderm microtubule-associated protein-like 4 (EML4) - anaplastic lymphoma kinase (ALK) translocation.
- NSCLC non-small cell lung cancer
- EML4 echinoderm microtubule-associated protein-like 4
- ALK anaplastic lymphoma kinase
- ALK is translocated, mutated, and/or amplified in several tumor types, and thus ALK mediated disease include, in addition to NSCLC, neuroblastoma, and anaplastic large cell lymphoma (ALCL). Alterations in ALK play a key role in the pathogenesis of these tumors.
- Other fusion partners of ALK besides EML4 that can be relevant in an ALK mediated disease are KIF5B, TFG, KLC1 and PTPN3, but are expected to be less common than EML4. Preclinical experiments have shown that the various ALK fusion partners mediate ligand-independent
- a pharmaceutical combination comprising (i) LDK378, or a pharmaceutically acceptable salt thereof, and (ii) nivolumab, or a pharmaceutically acceptable salt thereof.
- LDK378 in combination with Nivolumab for the manufacture of a medicament for an ALK mediated disease.
- LDK378 in combination with Nivolumab for the manufacture of a medicament according to item 13, wherein the cancer is non-small cell lung cancer.
- a pharmaceutical composition comprising LDK378 or a pharmaceutically acceptable salt thereof and Nivolumab or a pharmaceutically acceptable salt thereof for simultaneous or separate administration for the treatment of cancer.
- composition according to items 22 or 23, wherein the composition comprises effective amounts of LDK378 and nivolumab.
- composition according to any one of items 15 to 18, wherein the composition further comprises a pharmaceutical acceptable carrier.
- LDK378 for use as a medicine, wherein LDK378, or a pharmaceutically acceptable salt thereof, is to be administered in combination with Nivolumab, or a
- LDK378 for use as a medicine according to item 19, for the treatment of cancer.
- a method for treating cancer in a subject in need thereof comprising
- LDK378, or a pharmaceutically acceptable salt thereof a therapeutically effective amount of i) LDK378, or a pharmaceutically acceptable salt thereof, and (ii) nivolumab, or a pharmaceutically acceptable salt thereof.
- Lung cancer is the most common cancer worldwide and the sub-type non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases.
- NSCLC sub-type non-small cell lung cancer
- EGFR epidermal growth factor receptor
- L858R and exon 19 deletion (Ex19del) activating EGFR oncogenic mutations predominate in NSCLC patients and account for 38% and 46% of EGFR NSCLC mutations respectively.
- EGFR Exon 20 insertion mutations (Ex20ins) are also relatively frequent, accounting for 9% of all EGFR mutations in NSCLC patients.
- TKIs reversible EGFR Tyrosine Kinase Inhibitors
- erlotinib and gefitinib reversible EGFR Tyrosine Kinase Inhibitors
- TKIs EGFR Tyrosine Kinase Inhibitors
- Second-generation EGFR TKIs have been developed to try to overcome the mechanism of acquired resistance.
- third- generation EGFR TKIs have been developed which are WT EGFR sparing but also have relative equal potency for activating EGFR (L858R and ex19del) and acquired (T790M) mutations.
- Third generation EFGR TKIs such as AZD9291 (mereletinib) and CO-1686 (rociletinib) are beginning to enter clinical development and are showing significant initial promise (e.g., see “AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer”, Hanne et al., N Engl J Med, 2015; 372; 1689-99 and“Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer”, Sequist et al, J Med, 2015; 372; 1700-9).
- ASP8273 a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations”, Sakagami et al., AACR; Cancer Res 2014; 74; 1728.
- the present invention relates to the surprising finding that a combination treatment comprising the selective mutated-EGFR inhibitor EGF816 and the anti-PD-1 antagonist Nivolumab are safe and tolerated when administered as a combination therapy to treat patients with NSCLC that have mutated-EGFR.
- EGF816 is an EGFR inhibitor.
- EGF816 is also known as (R,E)-N-(7-chloro-1-(1-(4- (dimethylamino)but-2-enoyl)azepan-3-yl)-1Hbenzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), or a pharmaceutically acceptable salt thereof.
- a particularly useful salt is the mesylate salt thereof.
- WO2013/184757 the contents of which are hereby incorporated by reference, describes EGF816, its method of preparation and pharmaceutical compositions comprising EGF816.
- EGF816 has the following structure:
- EGF816 is a targeted covalent irreversible EGFR inhibitor that selectively inhibits activating and acquired resistance mutants (L858R, ex19del and T790M), while sparing WT EGFR. (see Jia et al., Cancer Res October 1, 201474; 1734). EGF816 has shown significant efficacy in EGFR mutant (L858R, ex19del and T790M) cancer models (in vitro and in vivo) with no indication of WT EGFR inhibition at clinically relevant efficacious concentrations.
- the disclosure relates to a pharmaceutical combination, comprising (a) a compound of formula I:
- the disclosure provides a combination for use in a method of treating a cancer, especially an EGFR mutated cancer wherein:
- the combined administration has clinical efficacy, e.g., as measured by
- the progression of cancer may be monitored by methods known to those in the art.
- the progression may be monitored by way of visual inspection of the cancer, such as, by means of X-ray, CT scan or MRI or by tumor biomarker detection.
- an increased growth of the cancer indicates progression of the cancer.
- Progression of cancer such as NSCLC or tumors may be indicated by detection of new tumors or detection of metastasis or cessation of tumor shrinkage.
- Tumor evaluations can be made based on RECIST criteria (Therasse et al. 2000), New Guidelines to Evaluate the Response to Treatment in Solid Tumors, Journal of National Cancer Institute, Vol.92; 205-16 and revised RECIST guidelines (version 1.1)
- Tumor progression may be determined by comparison of tumor status between time points after treatment has commenced or by comparison of tumor status between a time point after treatment has commenced to a time point prior to initiation of the relevant treatment.
- the lymphoma e.g., an anaplastic large-cell lymphoma or non- Hodgkin lymphoma
- the lymphoma has, or is identified as having, an ALK translocation, e.g., an EML4-ALK fusion.
- the combination is for use in the treatment of NSCLC.
- the combination is for use in the treatment of NSCLC, wherein the NSCLC is characterized by one or more of: aberrant activation, or amplification, or mutations of epidermal growth factor receptor.
- the combination is for use in the treatment of NSCLC, wherein the NSCLC is characterized by harboring an EGFR exon 20 insertion, an EGFR exon 19 deletion, EGFR L858R mutation, EGFR T790M, or any combination thereof.
- the combination is for use in the treatment of NSCLC, wherein the NSCLC is characterized by harboring L858R and T790M mutations of EGFR. In some embodiments, the combination is for use in the treatment of NSCLC, wherein the NSCLC is characterized by harboring an EGFR exon 20 insertion and T790M mutations of EGFR.
- the combination is for use in the treatment of NSCLC, wherein the NSCLC is characterized by harboring an EGFR exon 19 deletion and T790M mutations of EGFR.
- the combination is for use in the treatment of NSCLC, wherein the NSCLC is characterized by harboring EGFR mutation selected from the group consisting of an exon 20 insertion, an exon 19 deletion, L858R mutation, T790M mutation, and any combination thereof.
- the cancer is an inflammatory myofibroblastic tumor (IMT).
- IMT inflammatory myofibroblastic tumor
- the inflammatory myofibroblastic tumor has, or is identified as having, an ALK rearrangement or translocation, e.g., an ALK fusion, e.g., an EML4-ALK fusion.
- the cancer is a neuroblastoma.
- the neuroblastoma has, or is identified as having, an ALK rearrangement or translocation, e.g., an ALK fusion, e.g., an EML4-ALK fusion.
- an ALK rearrangement or translocation e.g., an ALK fusion, e.g., an EML4-ALK fusion.
- EGF816 may be administered at a dose of 75, 100, 150, 225, 150, 200, 225, 300 or 350 mg. These doses may be administered once daily. E.g. EGF816 may be administered at a dose of 100 or 150 mg once daily.
- Nivolumab may be administered in an amount from about 1 mg/kg to 5 mg/kg, e.g., 3 mg/kg, and may be administered over a period of 60 minutes, ca. once a week to once every 2, 3 or 4 weeks.
- the combination of EGF816 and Nivolumab is administered as a combination therapy wherein the administration protocol is:
- Nivolumab is administered intravenously over a period of 60 minutes at least one hour after administration of (i), every 2 weeks.
- the administration protocol is repeated for the duration of a 28 day cycle.
- the term“pharmaceutical combination” as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non- fixed combinations of the active ingredients.
- the term“fixed combination” means that the active ingredients, e.g., a compound of formula (I) and one or more combination partners, are both administered to a patient simultaneously in the form of a single entity or dosage.
- the term“non- fixed combination” means that the active ingredients, e.g., a compound of the present invention and one or more combination partners, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient.
- cocktail therapy e.g., the administration of three or more active ingredients.
- a pharmaceutical combination comprising:
- a kit comprising the pharmaceutical combinations according to any one of Enumerated Embodiments 1 to 3 and information about using the constituents of the
- Embodiments 1 to 3 simultaneously, separately or sequentially.
- a method of treating or preventing cancer in a subject in need thereof comprising sequential, simultaneous or separate administration of (R,E)-N-(7-chloro-1-(1-(4- (dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide, or a pharmaceutically acceptable salt thereof and Nivolumab according to any one of
- Embodiments 1 to 3 in a jointly therapeutically effective amount to treat or prevent said cancer.
- Embodiments 1 to 3 in the form of a kit for combined administration comprising (a) one or more dosage units of (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H- benzo[d]imidazol-2-yl)-2-methylisonicotinamide, or a pharmaceutically acceptable salt thereof, and (b) one or more dosage units of Nivolumab.
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19206634.8A EP3662903A3 (fr) | 2014-10-03 | 2015-10-02 | Polythérapies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462059832P | 2014-10-03 | 2014-10-03 | |
PCT/US2015/053799 WO2016054555A2 (fr) | 2014-10-03 | 2015-10-02 | Polythérapies |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19206634.8A Division EP3662903A3 (fr) | 2014-10-03 | 2015-10-02 | Polythérapies |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3200775A2 true EP3200775A2 (fr) | 2017-08-09 |
EP3200775B1 EP3200775B1 (fr) | 2019-11-20 |
Family
ID=54337395
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15782164.6A Active EP3200775B1 (fr) | 2014-10-03 | 2015-10-02 | Polythérapies |
EP19206634.8A Withdrawn EP3662903A3 (fr) | 2014-10-03 | 2015-10-02 | Polythérapies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19206634.8A Withdrawn EP3662903A3 (fr) | 2014-10-03 | 2015-10-02 | Polythérapies |
Country Status (12)
Country | Link |
---|---|
US (2) | US20170209574A1 (fr) |
EP (2) | EP3200775B1 (fr) |
JP (2) | JP2017535528A (fr) |
KR (1) | KR20170066546A (fr) |
CN (1) | CN107106687A (fr) |
AU (2) | AU2015327868A1 (fr) |
BR (1) | BR112017006664A2 (fr) |
CA (1) | CA2963281A1 (fr) |
EA (1) | EA201790737A1 (fr) |
ES (1) | ES2774448T3 (fr) |
MX (2) | MX2017004360A (fr) |
WO (1) | WO2016054555A2 (fr) |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101386494B1 (ko) | 2005-05-10 | 2014-04-24 | 인사이트 코포레이션 | 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법 |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
MX364200B (es) | 2008-04-09 | 2019-04-16 | Genentech Inc | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. |
KR101649548B1 (ko) | 2008-07-08 | 2016-08-19 | 인사이트 홀딩스 코포레이션 | 인돌아민 2,3-디옥시게나아제의 억제제로서의 1,2,5-옥사디아졸 |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
IL300955A (en) | 2010-06-03 | 2023-04-01 | Pharmacyclics Llc | (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-H1-pyrazolo[4,3-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1- Indicated for use as a drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma |
CN103648499B (zh) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | 用于制备异喹啉酮的方法及异喹啉酮的固体形式 |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
EP2992017B1 (fr) | 2013-05-02 | 2020-11-18 | AnaptysBio, Inc. | Anticorps dirigés contre la protéine de mort programmée 1 (pd-1) |
PL3021869T3 (pl) | 2013-07-16 | 2020-11-16 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT |
WO2015048312A1 (fr) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Méthodes de traitement de cancers hématologiques |
CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2015109391A1 (fr) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Polythérapie anticancéreuse à base de smc |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
ES2899457T3 (es) | 2014-02-04 | 2022-03-11 | Pfizer | Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer |
ME03558B (fr) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molécules d'anticorps anti-lag-3 et leurs utilisations |
CN106132439A (zh) | 2014-03-31 | 2016-11-16 | 豪夫迈·罗氏有限公司 | 包含抗血管发生剂和ox40结合激动剂的组合疗法 |
EP3191126B1 (fr) * | 2014-09-13 | 2020-05-13 | Novartis AG | Thérapies combinées d'inhibiteurs d'alk |
CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
CN112263677A (zh) | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
KR20180015650A (ko) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | 항-ox40 항체 및 이의 사용 방법 |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
MY188049A (en) | 2015-05-29 | 2021-11-12 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
WO2017007658A1 (fr) * | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | Combinaison à médiation immunitaire pour le traitement du cancer |
CA2992298A1 (fr) | 2015-07-23 | 2017-01-26 | Inhibrx Lp | Proteines hybrides multivalentes et multispecifiques se liant a gitr |
MA48579A (fr) | 2015-09-01 | 2020-03-18 | Agenus Inc | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
JP7034066B2 (ja) | 2015-10-02 | 2022-03-11 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激tnf受容体に対する二重特異性抗体 |
JP2018532756A (ja) * | 2015-11-04 | 2018-11-08 | インサイト・コーポレイションIncyte Corporation | インドールアミン2,3−ジオキシゲナーゼを阻害するための医薬組成物と方法、及びその適応 |
CA3007233A1 (fr) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anticorps et leurs methodes d'utilisation |
SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
WO2017106810A2 (fr) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Combinaison d'un inhibiteur de c-met avec une molécule d'anticorps dirigée contre pd-1 et ses utilisations |
JP2018538321A (ja) * | 2015-12-28 | 2018-12-27 | シンダックス ファーマシューティカルズ,インコーポレイティド | 卵巣がんの処置のためのhdac阻害剤および抗pd−l1抗体の組合せ |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
KR20240014585A (ko) | 2016-03-04 | 2024-02-01 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
WO2017175200A1 (fr) * | 2016-04-08 | 2017-10-12 | The Regents Of The University Of California | Hydrogels et protéines d'acide hyaluronique modifié pour la libération contrôlée dans le temps d'agents biologiques |
WO2017192924A1 (fr) * | 2016-05-04 | 2017-11-09 | Fred Hutchinson Cancer Research Center | Vaccins à base de néoantigènes à base cellulaire et leurs utilisations |
KR102375327B1 (ko) * | 2016-05-05 | 2022-03-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 관문 분자를 표적으로 하는 dna 단클론성 항체 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
SG11201810023QA (en) | 2016-05-27 | 2018-12-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
EP3463456A1 (fr) * | 2016-06-03 | 2019-04-10 | ImClone LLC | Combinaison de ramucirumab et de pembrolizumab pour le traitement de certains cancers |
WO2017223422A1 (fr) * | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Polythérapies |
WO2018009916A1 (fr) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugués d'adjuvant d'anticorps |
EP3490548A4 (fr) * | 2016-08-01 | 2020-04-15 | Molecular Templates, Inc. | Administration de promédicaments activés par l'hypoxie en combinaison à des agents immunomodulateurs pour le traitement du cancer |
CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
CA3034266A1 (fr) * | 2016-08-19 | 2018-02-22 | Brooklyn Immunotherapeutics Llc | Utilisations d'inhibiteurs de pd-1/pd-l1 et/ou d'inhibiteurs de ctla-4 avec un agent biologique contenant de multiples composants de cytokine pour traiter le cancer |
WO2018039275A1 (fr) | 2016-08-24 | 2018-03-01 | Ignyta, Inc. | Combinaisons pour le traitement du cancer |
CN106350488B (zh) * | 2016-09-19 | 2019-09-27 | 大连大学 | 用于治疗肿瘤的pd-1封闭cik的制备方法 |
JP2019530704A (ja) | 2016-10-06 | 2019-10-24 | ファイザー・インコーポレイテッド | がんの処置のためのアベルマブの投与レジメン |
TWI764943B (zh) * | 2016-10-10 | 2022-05-21 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 |
CN117586403A (zh) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
AU2017354070A1 (en) | 2016-11-01 | 2019-05-16 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (PD-1) |
EP3534965A4 (fr) | 2016-11-03 | 2020-06-24 | Trillium Therapeutics Inc. | Améliorations de la thérapie de blocage de cd47 par des inhibiteurs de hdac |
EP3534964A4 (fr) | 2016-11-03 | 2020-07-15 | Trillium Therapeutics Inc. | Amélioration de la thérapie de blocage des cd47 par des inhibiteurs du protéasome |
MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
MX2019006072A (es) | 2016-11-30 | 2019-08-14 | Oncomed Pharm Inc | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). |
KR20240023677A (ko) | 2016-12-05 | 2024-02-22 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
EA201991383A1 (ru) | 2016-12-07 | 2019-12-30 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
DK3600419T5 (en) * | 2017-03-20 | 2023-11-13 | Vaccinex Inc | Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent |
CN111148518A (zh) * | 2017-03-30 | 2020-05-12 | 丹娜法伯癌症研究院 | 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法 |
CN110475567A (zh) * | 2017-03-31 | 2019-11-19 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
EP3606518A4 (fr) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | Méthodes et compositions de détection et de modulation d'une signature génique de résistance à l'immunothérapie d'un cancer |
WO2018195386A1 (fr) | 2017-04-20 | 2018-10-25 | The University Of Chicago | Procédés et compositions de traitement du cancer avec des peptides à affinité mec liés à des anticorps immunothérapeutiques |
BR112019025478A8 (pt) * | 2017-06-02 | 2022-12-06 | Bayer Ag | Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer |
CN111491661A (zh) | 2017-07-27 | 2020-08-04 | 诺莫坎制药有限责任公司 | M(h)dm2/4的抗体及其在诊断和治疗癌症中的用途 |
WO2020159504A1 (fr) * | 2019-01-30 | 2020-08-06 | Nomocan Pharmaceuticals Llc | Anticorps dirigés contre m(h)dm2/4 et leur utilisation dans le diagnostic et le traitement du cancer |
WO2019023786A1 (fr) * | 2017-08-01 | 2019-02-07 | University Health Network | Thérapies combinées pour l'inhibition de la protéine kinase ttk |
EP3678669A4 (fr) * | 2017-09-08 | 2021-06-09 | University Health Network | Polythérapies visant à inhiber la kinase 4 de type polo |
EP3695408A4 (fr) * | 2017-10-02 | 2021-12-15 | The Broad Institute, Inc. | Procédés et compositions pour détecter et moduler une signature génétique de résistance à l'immunothérapie dans un cancer |
AU2018353432A1 (en) | 2017-10-19 | 2020-04-23 | Debiopharm International S.A. | Combination product for the treatment of cancer |
JP7378394B2 (ja) | 2017-11-03 | 2023-11-13 | オーリジーン オンコロジー リミテッド | Tim-3およびpd-1経路の二重阻害剤 |
EP3706798A1 (fr) | 2017-11-06 | 2020-09-16 | Aurigene Discovery Technologies Limited | Thérapies conjointes à des fins d'immunomodulation |
CN116392497A (zh) * | 2017-11-28 | 2023-07-07 | 深圳艾欣达伟医药科技有限公司 | 葡磷酰胺的抗癌医药用途 |
US20200377599A1 (en) * | 2017-11-30 | 2020-12-03 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
WO2019122941A1 (fr) | 2017-12-21 | 2019-06-27 | Debiopharm International Sa | Polythérapie contre le cancer faisant intervenir un antagoniste d'iap et une molécule anti pd-1 |
US20200385478A1 (en) * | 2018-01-05 | 2020-12-10 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
RU2020123665A (ru) | 2018-01-08 | 2022-02-10 | Г1 Терапьютикс, Инк. | Преимущественные режимы дозирования g1т38 |
EP3737373A4 (fr) * | 2018-01-10 | 2021-09-08 | Array Biopharma, Inc. | Méthodes et polythérapie pour traiter le cancer |
WO2019161320A1 (fr) * | 2018-02-17 | 2019-08-22 | Apollomics Inc. | Traitement du cancer à l'aide d'une combinaison d'un modulateur de neutrophiles avec un modulateur de point de contrôle immunitaire |
US20200376035A1 (en) * | 2018-02-26 | 2020-12-03 | The Trustees Of The University Of Pennsylvania | Methods and compositions comprising cart and a smac mimetic |
AU2018412532A1 (en) * | 2018-03-08 | 2020-10-22 | Astrazeneca Ab | Compositions and methods for treating late stage lung cancer |
US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
CN112218634A (zh) * | 2018-04-09 | 2021-01-12 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
JP2021524446A (ja) * | 2018-05-16 | 2021-09-13 | デューク ユニバーシティ | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
WO2020024932A1 (fr) * | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Méthode de traitement du cancer par combinaison d'un inhibiteur d'iap et d'un modulateur de molécule de point de contrôle immunitaire |
WO2020038397A1 (fr) * | 2018-08-21 | 2020-02-27 | I-Mab | Anticorps bispécifiques anti-pd-l1/anti-lag3 et leurs utilisations |
BR112021007448A2 (pt) * | 2018-11-14 | 2021-10-26 | Bayer Aktiengesellschaft | Combinação farmacêutica de anticorpos anti-ceacam6 e anti-pd-1 ou anti-pd-l1 para o tratamento de câncer |
JP2022511437A (ja) | 2018-11-26 | 2022-01-31 | デバイオファーム インターナショナル エス.エー. | Hiv感染の組み合わせ治療 |
JP2022522994A (ja) | 2019-01-17 | 2022-04-21 | デビオファーム・インターナショナル・エス・アー | がんの処置のための組合せ物 |
EP3696191A1 (fr) | 2019-02-14 | 2020-08-19 | Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) | Cellules car-t pour le traitement du cancer positif cd1a |
EP3928793A4 (fr) * | 2019-02-20 | 2022-12-07 | Saitama Medical University | Procédé et composition pour prédire une survie à long terme dans une immunothérapie anticancéreuse |
WO2020172233A1 (fr) * | 2019-02-22 | 2020-08-27 | The Trustees Of Columbia University In The City Of New York | Traitement du cancer de la prostate par ablation d'androgènes et blocage d'il-8 |
MA55088A (fr) * | 2019-02-28 | 2022-01-05 | Taiho Pharmaceutical Co Ltd | Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire |
WO2020190725A1 (fr) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugués ciblant le her2 |
US20200319163A1 (en) * | 2019-03-29 | 2020-10-08 | Georgetown University | Methods and compositions overcoming cancer cell immune resistance |
CN110179977A (zh) * | 2019-05-22 | 2019-08-30 | 华中科技大学同济医学院附属同济医院 | 用于治疗黑色素瘤、肺癌或结直肠癌的组合药物制剂 |
EP3996750A4 (fr) * | 2019-07-12 | 2024-01-03 | Univ Oregon Health & Science | Constructions thérapeutiques pour la co-administration d'un inhibiteur de la kinase mitotique et d'un inhibiteur des points de contrôle immunitaire |
FI4007777T3 (fi) | 2019-08-02 | 2024-01-11 | Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer Frcb Idibap | CAR-T-soluja B-solujen kypsymisantigeeniä (BCMA) vastaan multippelin myelooman hoitoon |
MX2022001732A (es) | 2019-08-12 | 2022-05-06 | Purinomia Biotech Inc | Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39. |
KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
US20220265698A1 (en) * | 2019-09-11 | 2022-08-25 | Aureo Co., Ltd. | Composition for enhancing effect of antibody drug |
JP2022550037A (ja) | 2019-09-25 | 2022-11-30 | デバイオファーム インターナショナル エス.エー. | 局所進行性扁平上皮癌を有する患者の治療のための投与レジメン |
CA3157042A1 (fr) * | 2019-11-21 | 2021-05-27 | Beibei JIANG | Procedes de traitement du cancer utilisant des anticorps anti-ox40 en combinaison avec des anticorps anti-tigit |
BR112022009794A2 (pt) * | 2019-11-21 | 2022-08-09 | Univ Texas | Método para tratar câncer no pulmão |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
CN112972688A (zh) * | 2021-02-08 | 2021-06-18 | 吉林大学第一医院 | PPARδ抑制剂联合免疫治疗药物在制备抗肿瘤药物中的应用 |
US20220251218A1 (en) * | 2021-02-10 | 2022-08-11 | Gnt Biotech & Medicals Corporation | Pharmaceutical combination and method for overcoming immune suppression or stimulating immune response against cancer |
WO2023005992A1 (fr) * | 2021-07-27 | 2023-02-02 | 广州嘉越医药科技有限公司 | Combinaison pharmaceutique et application associée |
CN115671289B (zh) * | 2021-07-27 | 2024-04-26 | 广州嘉越医药科技有限公司 | 药物组合及其应用 |
WO2023043958A1 (fr) * | 2021-09-16 | 2023-03-23 | Gt Biopharma, Inc. | Protéines de fusion ciblant pd-l1 et méthodes d'utilisation y afférant |
WO2023161530A1 (fr) | 2022-02-28 | 2023-08-31 | Onechain Immunotherapeutics S.L | Fraction de ciblage cd1a humanisée pour traiter le cancer positif au cd1a |
EP4234582A1 (fr) | 2022-02-28 | 2023-08-30 | Onechain Immunotherapeutics SL | Fraction de ciblage de cd1a humanisé pour le traitement du cancer positif à cd1a |
CN117604110B (zh) * | 2024-01-23 | 2024-04-19 | 杭州华得森生物技术有限公司 | 用于乳腺癌诊断和预后判断的生物标志物及其应用 |
Family Cites Families (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (fr) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Récepteurs chimériques par liaison et expression de l'ADN |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1988007089A1 (fr) | 1987-03-18 | 1988-09-22 | Medical Research Council | Anticorps alteres |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JP3771253B2 (ja) | 1988-09-02 | 2006-04-26 | ダイアックス コープ. | 新規な結合タンパク質の生成と選択 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
WO1991000906A1 (fr) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Animaux chimeriques et transgeniques pouvant produire des anticorps humains |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
WO1991010741A1 (fr) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation d'anticorps xenogeniques |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1992020791A1 (fr) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methode de production de chainons de paires de liaison specifique |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
EP0564531B1 (fr) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees |
ES2330052T3 (es) | 1991-03-01 | 2009-12-03 | Dyax Corporation | Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas. |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
EP0580737B1 (fr) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Banques de recepteurs heterodimeres utilisant des phagemides |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
CA2076465C (fr) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065 |
DK1087013T3 (da) | 1992-08-21 | 2009-05-11 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
WO1998006842A1 (fr) | 1996-08-16 | 1998-02-19 | Schering Corporation | Antigenes de surface de cellules mammaliennes et reactifs qui y sont lies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
PT1787999E (pt) | 1997-04-07 | 2010-11-11 | Genentech Inc | Anticorpos anti-vegf |
DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
WO1999020758A1 (fr) | 1997-10-21 | 1999-04-29 | Human Genome Sciences, Inc. | Proteines tr11, tr11sv1 et tr11sv2 de type recepteur du facteur de necrose tumorale humain |
US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
JP2002502607A (ja) | 1998-02-09 | 2002-01-29 | ジェネンテク・インコーポレイテッド | 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸 |
EP1073465B1 (fr) | 1998-04-15 | 2005-06-22 | The Brigham And Women's Hospital, Inc. | Compositions pour recepteurs inhibiteurs des lymphocytes t et utilisation de telles compositions |
EP1143957A3 (fr) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Traitement de l'arthrite a l'aide d'inhibiteurs de la mek |
IL145134A0 (en) * | 1999-03-25 | 2002-06-30 | Knoll Gmbh | Human antibodies that bind human il-12 and methods for producing |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
CA2378179A1 (fr) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation avec des homologues de ligands et de recepteurs du facteur de necrose tumorale |
SI1301472T1 (sl) | 2000-07-19 | 2014-05-30 | Warner-Lambert Company Llc | Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7596459B2 (en) | 2001-02-28 | 2009-09-29 | Quadlogic Controls Corporation | Apparatus and methods for multi-channel electric metering |
CN100522967C (zh) | 2002-02-01 | 2009-08-05 | 阿里亚德基因治疗公司 | 含磷化合物及其应用 |
EP2308861B1 (fr) | 2002-03-08 | 2017-03-01 | Eisai R&D Management Co., Ltd. | Composes macrocycliques utiles en tant qu'agents pharmaceutiques |
PT2275102E (pt) | 2002-03-13 | 2015-10-27 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
US20040047858A1 (en) | 2002-09-11 | 2004-03-11 | Blumberg Richard S. | Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof |
CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
EP1578419A4 (fr) | 2002-12-30 | 2008-11-12 | 3M Innovative Properties Co | Complexes immunostimulants |
CA2525717A1 (fr) | 2003-05-23 | 2004-12-09 | Wyeth | Ligand du gitr et molecules et anticorps lies au ligand du gitr et leurs utilisations |
ME00425B (me) | 2003-05-30 | 2011-10-10 | Genentech Inc | Liječenje sa anti-vegf antitijelima |
EP1660126A1 (fr) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005044853A2 (fr) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anticorps anti-vegf |
WO2005055808A2 (fr) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions et methodes pour le diagnostic et le traitement du cancer du poumon |
GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
US7932260B2 (en) | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
WO2006083289A2 (fr) | 2004-06-04 | 2006-08-10 | Duke University | Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive |
RS52670B (en) | 2004-06-11 | 2013-06-28 | Japan Tobacco Inc. | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PIRIDO (2,3-D) PYRIMIDINE DERIVATIVES AND SIMILAR COMPOUNDS FOR CANCER TREATMENT |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
EA201890903A9 (ru) | 2004-09-02 | 2021-11-10 | Дженентек, Инк. | Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе |
ES2432091T5 (es) | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
CA2970873C (fr) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
WO2007004415A1 (fr) | 2005-07-01 | 2007-01-11 | Murata Manufacturing Co., Ltd. | Substrat céramique à couches multiples, procédé pour le fabriquer et feuille verte composite pour la fabrication dudit substrat |
CA2618218C (fr) | 2005-07-21 | 2015-06-30 | Ardea Biosciences, Inc. | Inhibiteurs n-(arylamino)-sulfonamide de mek |
FR2888850B1 (fr) * | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
TWI468162B (zh) | 2005-12-13 | 2015-01-11 | 英塞特公司 | 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并〔2,3-b〕吡啶及吡咯并〔2,3-b〕嘧啶 |
EP1981969A4 (fr) | 2006-01-19 | 2009-06-03 | Genzyme Corp | Anticorps anti-gitr destines au traitement du cancer |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CA2647282A1 (fr) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Polytherapie a base d'un anticorps anti-ctla4 |
PE20110224A1 (es) | 2006-08-02 | 2011-04-05 | Novartis Ag | PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO |
MX2009001878A (es) | 2006-08-21 | 2009-03-03 | Genentech Inc | Compuestos de aza-benzofuranilo y metodos de uso. |
ES2689444T3 (es) | 2006-11-22 | 2018-11-14 | Incyte Holdings Corporation | Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa |
BRPI0722384A2 (pt) | 2006-12-08 | 2012-06-12 | Irm Llc | compostos inibidores de proteÍna quinase, composiÇÕes contendo os mesmos bem como seus usos |
EP2091918B1 (fr) | 2006-12-08 | 2014-08-27 | Irm Llc | Composés et compositions inhibant la protéine kinase |
EP3222634A1 (fr) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Anticorps dirigés contre le récepteur humain de mort programmée pd-1 |
ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
PE20140100A1 (es) | 2007-09-12 | 2014-02-12 | Genentech Inc | Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos |
US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
PT2690101E (pt) | 2007-12-19 | 2015-10-08 | Genentech Inc | 5-anilinoimidazopiridinas e métodos de utilização |
US8747847B2 (en) | 2008-02-11 | 2014-06-10 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
EP2282995B1 (fr) | 2008-05-23 | 2015-08-26 | Novartis AG | Dérivés de quinoléines et de quinoxalines en tant qu' inhibiteurs de protéine tyrosine kinases |
MX2011000039A (es) | 2008-07-02 | 2011-05-31 | Emergent Product Dev Seattle | Proteinas antagonistas del factor-beta de crecimiento transformante (tgf-beta), que se unen a multiples objetivos. |
BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
PL2331547T3 (pl) | 2008-08-22 | 2015-01-30 | Novartis Ag | Związki pirolopirymidynowe jako inhibitory CDK |
KR20110074850A (ko) | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Pd-1 길항제 및 그의 사용 방법 |
WO2010027423A2 (fr) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions d'antagonistes de pd-1 et methodes d'utilisation associees |
CN103333157A (zh) | 2008-09-02 | 2013-10-02 | 诺瓦提斯公司 | 作为激酶抑制剂的吡啶甲酰胺衍生物 |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
WO2010030002A1 (fr) | 2008-09-12 | 2010-03-18 | 国立大学法人三重大学 | Cellule capable d'exprimer un ligand gitr exogène |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
AU2009308707A1 (en) * | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | LIGHT targeting molecules and uses thereof |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
WO2010089411A2 (fr) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Anticorps pd-1 et anticorps pd-l1 et leurs utilisations |
EP2990421B1 (fr) | 2009-04-30 | 2018-02-21 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Anticorps anti-ceacam1 et leurs procédés d'utilisation |
WO2010136508A2 (fr) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Ciblage de cellules souches |
DK2769737T3 (en) * | 2009-07-20 | 2017-07-24 | Bristol Myers Squibb Co | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
WO2011066342A2 (fr) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Inhibition simultanée de pd-l1/pd-l2 |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
KR101846590B1 (ko) | 2010-06-11 | 2018-04-09 | 교와 핫꼬 기린 가부시키가이샤 | 항 tim-3 항체 |
EA036314B1 (ru) | 2010-08-20 | 2020-10-26 | Новартис Аг | Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака |
CN106220739A (zh) | 2010-12-09 | 2016-12-14 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
WO2012177624A2 (fr) | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Rayonnement focalisé pour améliorer les thérapies basées sur l'immunité contre les néoplasmes |
MY193562A (en) | 2011-08-01 | 2022-10-19 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
WO2013039954A1 (fr) | 2011-09-14 | 2013-03-21 | Sanofi | Anticorps anti-gitr |
WO2013054320A1 (fr) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcino-embryonnaire (ceacam) |
LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
CA2892371C (fr) | 2011-12-01 | 2021-01-19 | The Brigham And Women's Hospital, Inc. | Anticorps recombinants anti-ceacam1 pour la therapie de cancer |
WO2013179174A1 (fr) | 2012-05-29 | 2013-12-05 | Koninklijke Philips N.V. | Système d'éclairage |
JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
KR101566538B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Th17 세포 전환용 에피토프 및 이의 용도 |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
AU2013295855A1 (en) | 2012-07-27 | 2015-02-12 | Novartis Ag | Prediction of treatment response to JAK/STAT inhibitor |
CA2916638C (fr) | 2012-07-31 | 2021-01-12 | The Brigham And Women's Hospital, Inc. | Modulation de la reponse immunitaire |
JP6356134B2 (ja) | 2012-10-12 | 2018-07-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 免疫応答の増強 |
CA2890663A1 (fr) | 2012-11-08 | 2014-05-15 | Novartis Ag | Combinaison pharmaceutique comprenant un inhibiteur de b-raf et un inhibiteur d'histone desacetylase et leur utilisation dans le traitement de maladies proliferatives |
JP2016501221A (ja) | 2012-11-28 | 2016-01-18 | ノバルティス アーゲー | 併用療法 |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
AU2014364606A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
CA2934073A1 (fr) * | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Polytherapie comprenant un vaccin a base de neoantigenes |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
ME03558B (fr) * | 2014-03-14 | 2020-07-20 | Novartis Ag | Molécules d'anticorps anti-lag-3 et leurs utilisations |
JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
EP3191126B1 (fr) * | 2014-09-13 | 2020-05-13 | Novartis AG | Thérapies combinées d'inhibiteurs d'alk |
-
2015
- 2015-10-02 AU AU2015327868A patent/AU2015327868A1/en not_active Abandoned
- 2015-10-02 MX MX2017004360A patent/MX2017004360A/es unknown
- 2015-10-02 ES ES15782164T patent/ES2774448T3/es active Active
- 2015-10-02 CA CA2963281A patent/CA2963281A1/fr not_active Abandoned
- 2015-10-02 EA EA201790737A patent/EA201790737A1/ru unknown
- 2015-10-02 EP EP15782164.6A patent/EP3200775B1/fr active Active
- 2015-10-02 WO PCT/US2015/053799 patent/WO2016054555A2/fr active Application Filing
- 2015-10-02 EP EP19206634.8A patent/EP3662903A3/fr not_active Withdrawn
- 2015-10-02 KR KR1020177012013A patent/KR20170066546A/ko not_active Application Discontinuation
- 2015-10-02 CN CN201580066100.7A patent/CN107106687A/zh active Pending
- 2015-10-02 US US15/515,469 patent/US20170209574A1/en not_active Abandoned
- 2015-10-02 JP JP2017517730A patent/JP2017535528A/ja not_active Ceased
- 2015-10-02 BR BR112017006664A patent/BR112017006664A2/pt not_active Application Discontinuation
-
2017
- 2017-04-03 MX MX2020005894A patent/MX2020005894A/es unknown
-
2020
- 2020-05-19 US US16/878,155 patent/US20210000951A1/en not_active Abandoned
-
2021
- 2021-07-05 AU AU2021204687A patent/AU2021204687A1/en not_active Abandoned
- 2021-11-26 JP JP2021191659A patent/JP2022043060A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2016054555A3 (fr) | 2016-06-30 |
CA2963281A1 (fr) | 2016-04-07 |
US20210000951A1 (en) | 2021-01-07 |
JP2017535528A (ja) | 2017-11-30 |
EP3662903A3 (fr) | 2020-10-14 |
EA201790737A1 (ru) | 2017-08-31 |
ES2774448T3 (es) | 2020-07-21 |
KR20170066546A (ko) | 2017-06-14 |
EP3200775B1 (fr) | 2019-11-20 |
MX2020005894A (es) | 2020-08-13 |
US20170209574A1 (en) | 2017-07-27 |
CN107106687A (zh) | 2017-08-29 |
EP3662903A2 (fr) | 2020-06-10 |
AU2015327868A1 (en) | 2017-04-20 |
WO2016054555A2 (fr) | 2016-04-07 |
MX2017004360A (es) | 2017-06-26 |
AU2021204687A1 (en) | 2021-08-19 |
BR112017006664A2 (pt) | 2017-12-26 |
JP2022043060A (ja) | 2022-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210000951A1 (en) | Combination therapies | |
US20240075136A1 (en) | Combination therapies | |
US20200030442A1 (en) | Combination therapies | |
CN108025051B (zh) | 包含抗pd-1抗体分子的联合疗法 | |
TWI692484B (zh) | 針對pd-1之抗體分子及其用途 | |
EP3964528A1 (fr) | Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3 | |
CA2936962A1 (fr) | Molecules d'anticorps anti-lag-3 et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170411 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180129 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1242582 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602015042142 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031000000 Ipc: A61K0039395000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/28 20060101ALI20190507BHEP Ipc: A61K 31/506 20060101ALI20190507BHEP Ipc: A61K 39/395 20060101AFI20190507BHEP Ipc: A61P 35/00 20060101ALI20190507BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20190617 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015042142 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1203433 Country of ref document: AT Kind code of ref document: T Effective date: 20191215 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20191120 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200221 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200220 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200220 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200320 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2774448 Country of ref document: ES Kind code of ref document: T3 Effective date: 20200721 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200412 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1203433 Country of ref document: AT Kind code of ref document: T Effective date: 20191120 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015042142 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20200821 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20200924 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20200924 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20201009 Year of fee payment: 6 Ref country code: CH Payment date: 20201015 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20210929 Year of fee payment: 7 Ref country code: FR Payment date: 20210930 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20210922 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20211108 Year of fee payment: 7 Ref country code: DE Payment date: 20210923 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20211031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211002 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211002 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602015042142 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20221002 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221031 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221002 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221002 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20231124 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221003 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221003 |